1 00:00:05,960 --> 00:00:23,040 WELCOME TO NHLBI COUNCIL 2 00:00:23,040 --> 00:00:26,600 I THINK THAT'S THE THING YOU HAD 3 00:00:26,600 --> 00:00:28,720 TO SAY. 4 00:00:28,720 --> 00:00:33,400 AS A REMINDER WE ARE BEINGNG 5 00:00:33,400 --> 00:00:36,120 RECORDED AND SOMEONE WILL GET 6 00:00:36,120 --> 00:00:38,120 RID OF THE NOTICE AND I'LL MAKE 7 00:00:38,120 --> 00:00:41,120 A FEW ADMINISTRATIVE UNCEMENTS 8 00:00:41,120 --> 00:00:44,640 STARTED. 9 00:00:44,640 --> 00:00:48,160 I WANT TO WELCOME OUR PUBLIC 10 00:00:48,160 --> 00:00:49,120 VISITORS AS WELL AS STAFF TO 11 00:00:49,120 --> 00:00:49,760 OPEN SESSION. 12 00:00:49,760 --> 00:00:53,000 THE NOTICE OF THE SCHEDULE MEET 13 00:00:53,000 --> 00:00:54,160 WAS PUBLISHED IN THE FEDERAL 14 00:00:54,160 --> 00:00:58,200 REGISTER AS REQUIRED. 15 00:00:58,200 --> 00:00:59,560 AND I WISH SOMEBODY WOULD PLEASE 16 00:00:59,560 --> 00:01:01,360 TURN OFF WHATEVER IS MAKING THE 17 00:01:01,360 --> 00:01:04,120 NOISE THAT IS NOT SUPPOSED TO. 18 00:01:04,120 --> 00:01:05,200 RECORDING, PLEASE REMEMBER THE 19 00:01:05,200 --> 00:01:06,480 OPEN SESSION OF TODAY'S MEETING 20 00:01:06,480 --> 00:01:08,320 IS BEING WEBCAST AND RECORDED. 21 00:01:08,320 --> 00:01:10,440 THE VIDEO WILL BE ARCHIVED AND 22 00:01:10,440 --> 00:01:13,400 AVAILABLE TO THE PUBLIC AND OUR 23 00:01:13,400 --> 00:01:14,760 NIH COLLEAGUES FOR AN INDEFINITE 24 00:01:14,760 --> 00:01:15,440 PERIOD MUCH TIME. 25 00:01:15,440 --> 00:01:18,160 THEN I'M GOING TO GIVE YOU A 26 00:01:18,160 --> 00:01:20,160 BRIEF OVERVIEW OF THIS 27 00:01:20,160 --> 00:01:21,440 AFTERNOON'S AGENDA AND THE 28 00:01:21,440 --> 00:01:23,320 MEETING WILL START WITH A REPORT 29 00:01:23,320 --> 00:01:26,280 FROM THE DIRECTOR, DR. GIBBONS. 30 00:01:26,280 --> 00:01:29,880 WE'LL HAVE A PRESENTATION FROM 31 00:01:29,880 --> 00:01:33,280 DIR'S AND LASTLY REVIEW THE 32 00:01:33,280 --> 00:01:35,400 CONCEPTS DISCUSSED AT THE APRIL 33 00:01:35,400 --> 00:01:36,880 BOARD OF EXTERNAL EXPERTS 34 00:01:36,880 --> 00:01:40,280 MEETING BEFORE WE END THE OPEN 35 00:01:40,280 --> 00:01:40,520 SESSION. 36 00:01:40,520 --> 00:01:42,280 I DON'T THINK WE WANT TO DELAY 37 00:01:42,280 --> 00:01:43,200 ANY MORE. 38 00:01:43,200 --> 00:01:47,000 WE'LL HAVE A REPORT FROM 39 00:01:47,000 --> 00:01:48,960 DR. GIBBONS AND BREAK QUICKLY TO 40 00:01:48,960 --> 00:01:51,040 PICK UP OUR LUNCHES AND HAVE A 41 00:01:51,040 --> 00:01:54,160 WORKING LUNCH. 42 00:01:54,160 --> 00:02:22,560 DR. GIBBONS. 43 00:02:22,560 --> 00:02:24,960 YOU CAN SEE NIH HAS HAD A PRETTY 44 00:02:24,960 --> 00:02:26,720 GOOD RUN OVER THE LAST FIVE TO 45 00:02:26,720 --> 00:02:33,440 SIX YEARS WITH A NUMBER OF 46 00:02:33,440 --> 00:02:37,160 INCREASES AND YOU SEE WHERE WE 47 00:02:37,160 --> 00:02:39,680 LANDED IN FY23 WITH A 48 00:02:39,680 --> 00:02:42,920 SIGNIFICANT INCREASE OF 4.2% ANA 49 00:02:42,920 --> 00:02:45,200 PARTICULAR ELEMENTS PUT INTO 50 00:02:45,200 --> 00:02:55,640 NHLBI'S BASE NOTABLY THE 51 00:02:57,200 --> 00:02:58,240 COVID-19 DISPARITIES OR SEAL 52 00:02:58,240 --> 00:03:01,640 PROGRAM AND THERE WERE A NUMBER 53 00:03:01,640 --> 00:03:02,280 OF TOPICS RAISED. 54 00:03:02,280 --> 00:03:07,600 IT'S A LITTLE DIFFERENT FROM THE 55 00:03:07,600 --> 00:03:09,120 PREVIOUS ONES WHERE THE NIH 56 00:03:09,120 --> 00:03:14,120 DIRECTOR SHARED IT WITH CDC AND 57 00:03:14,120 --> 00:03:15,480 OTHER AGENCIES AND TOP OF THE 58 00:03:15,480 --> 00:03:16,520 TOPICS INCLUDE THE NEXT 59 00:03:16,520 --> 00:03:21,920 GENERATION, HEALTH DISPARITIES, 60 00:03:21,920 --> 00:03:25,560 INCLUSIVE EXCELLENCE IN OUR 61 00:03:25,560 --> 00:03:28,480 WORKFORCE AS WELL AS RURAL 62 00:03:28,480 --> 00:03:30,960 HEALTH AND DIABETES AND DOWN 63 00:03:30,960 --> 00:03:32,600 SYNDROME AND THEY'RE RELEVANT TO 64 00:03:32,600 --> 00:03:34,760 NHLBI PORTFOLIO AND PRIORITIES 65 00:03:34,760 --> 00:03:44,120 AS WELL. 66 00:03:44,120 --> 00:03:45,800 EVERYONE READS THE NEWSPAPERS 67 00:03:45,800 --> 00:03:48,360 AND SO IT WON'T SHOCK YOU SOME 68 00:03:48,360 --> 00:03:50,040 US HAD TREPIDATION ABOUT SOME OF 69 00:03:50,040 --> 00:03:52,560 THE CUTS THAT WERE BEING 70 00:03:52,560 --> 00:03:53,960 CONTEMPLATED THAT WERE GOING TO 71 00:03:53,960 --> 00:03:59,840 AFFECT A NUMBER OF AGENCIES 72 00:03:59,840 --> 00:04:08,280 INCLUDING HHS THAT APPEAR TO 73 00:04:08,280 --> 00:04:10,880 HAVE BEEN AVERTED IN THE 74 00:04:10,880 --> 00:04:13,080 GREATEST SEVERITY BUT THERE'S 75 00:04:13,080 --> 00:04:14,600 QUESTIONS WHERE WE LAND NOW THE 76 00:04:14,600 --> 00:04:16,120 DEBT LIMIT HAS BEEN INCREASED. 77 00:04:16,120 --> 00:04:22,360 WE ANTICIPATED FY24 WOULD BE A 78 00:04:22,360 --> 00:04:26,000 TIGHT YEAR AND THE DEBT CRISIS 79 00:04:26,000 --> 00:04:27,800 RELIEF STILL SUGGESTS IT WILL BE 80 00:04:27,800 --> 00:04:29,600 TIGHT AND THE LAME DUCK YEAR OFF 81 00:04:29,600 --> 00:04:31,720 A PRESIDENT OFTEN IS FAIRLY 82 00:04:31,720 --> 00:04:34,640 TIGHT AS WELL AS WE GET WOUND UP 83 00:04:34,640 --> 00:04:38,840 FOR NEW CONGRESS. 84 00:04:38,840 --> 00:04:41,520 SO THIS WILL BE A LEANER PERIOD 85 00:04:41,520 --> 00:04:44,600 IN THE NEXT YEAR OR TWO THAN THE 86 00:04:44,600 --> 00:04:46,600 FOUR OR FIVE WE ENJOYED 87 00:04:46,600 --> 00:04:50,480 PREVIOUSLY. 88 00:04:50,480 --> 00:04:54,800 OBVIOUSLY THAT PUTS SOME TENSION 89 00:04:54,800 --> 00:04:56,920 ON WHAT WE'RE ABLE TO DO AND 90 00:04:56,920 --> 00:04:58,600 GOES TO THE 91 00:04:58,600 --> 00:05:02,200 INVESTIGATOR-INITIATED PROGRAMS 92 00:05:02,200 --> 00:05:05,160 AND PROJECTS IN SCIENCE AS OUR 93 00:05:05,160 --> 00:05:06,440 BED ROCK INVESTMENT AND THERE'S 94 00:05:06,440 --> 00:05:07,840 TRENDS TOWARDS INCREASED 95 00:05:07,840 --> 00:05:10,440 APPLICATIONS. 96 00:05:10,440 --> 00:05:13,520 SO A NUMBER OF APPLICATIONS HAVE 97 00:05:13,520 --> 00:05:15,240 BEEN GOING UP AND THE COST OF 98 00:05:15,240 --> 00:05:17,120 EACH GRANT IS PROBABLY GOING UP 99 00:05:17,120 --> 00:05:22,600 OVER 30% OVER THE LAST FIVE 100 00:05:22,600 --> 00:05:25,720 YEARS IT'S BECOMING MORE AND 101 00:05:25,720 --> 00:05:28,000 MORE CHALLENGING TO MAINTAIN THE 102 00:05:28,000 --> 00:05:30,360 SUCCESS RATES HOVERING AROUND 103 00:05:30,360 --> 00:05:32,560 20% OR SO. 104 00:05:32,560 --> 00:05:36,400 BUT AGAIN THOSE TWOVERS MORE 105 00:05:36,400 --> 00:05:38,760 APPLICATIONS, MORE EXPENSIVE 106 00:05:38,760 --> 00:05:40,320 GRANTS IT'S INCREASINGLY 107 00:05:40,320 --> 00:05:42,320 DIFFICULT TO HIT THE AWARD 108 00:05:42,320 --> 00:05:45,600 TARGETS THAT WE'D LIKE TO AND 109 00:05:45,600 --> 00:05:46,200 MAINTAIN THE SUCCESS RATE AS 110 00:05:46,200 --> 00:05:47,000 HIGH AS WE CAN. 111 00:05:47,000 --> 00:05:48,880 WE STILL ENDEAVOR TO DO THAT FOR 112 00:05:48,880 --> 00:05:50,640 THE NEXT GENERATION OF EARLY 113 00:05:50,640 --> 00:05:52,640 STAGE INVESTIGATORS IN 114 00:05:52,640 --> 00:05:54,520 PARTICULAR AND THIS YEAR WE HAD 115 00:05:54,520 --> 00:05:58,240 TO HAVE A PAY LINE OF 14 116 00:05:58,240 --> 00:06:02,600 PERCENTILE AND THE BONUS ESIs TO 117 00:06:02,600 --> 00:06:06,520 24th PERCENTILE AND WE ARE USING 118 00:06:06,520 --> 00:06:08,480 THE SELECTIVE PAY MECHANISM WE 119 00:06:08,480 --> 00:06:17,240 ALWAYS HAD FOR MERITORIOUS ERGRE 120 00:06:17,240 --> 00:06:18,320 PROGRAMMATIC BALANCE FOR THOSE 121 00:06:18,320 --> 00:06:19,320 ABOVE THE PAY LINE. 122 00:06:19,320 --> 00:06:22,200 ALSO AS PART OF OUR STEWARDSHIP 123 00:06:22,200 --> 00:06:26,480 I WANT TO RELAY OUR WELCOME AND 124 00:06:26,480 --> 00:06:30,480 TRANSITIONS PARTICULARLY IN 125 00:06:30,480 --> 00:06:33,760 LEADERSHIP IN PARTICULAR A NEWER 126 00:06:33,760 --> 00:06:36,560 DEPUTY, DR. CAROL LEWIS FROM THE 127 00:06:36,560 --> 00:06:41,040 DEPUTY DIRECTOR IN TRANSITIONAL 128 00:06:41,040 --> 00:06:42,720 RESEARCH AND INFORMATION SCIENCE 129 00:06:42,720 --> 00:06:48,720 AND A BELATED WELCOME TO CINDY 130 00:06:48,720 --> 00:06:53,760 COUGHMAN DEPUTY OF OSPEEC OFFICE 131 00:06:53,760 --> 00:06:55,600 OF SCIENCE POLICY, EDUCATION AND 132 00:06:55,600 --> 00:06:56,720 COMMUNICATION. 133 00:06:56,720 --> 00:07:01,960 WE WELCOME THESE TWO NEW 134 00:07:01,960 --> 00:07:02,360 LEADERS. 135 00:07:02,360 --> 00:07:10,960 AND THIS IS A SHOUT OUT DLD WHO 136 00:07:10,960 --> 00:07:12,920 WILL TAKE OVER THE ENTIRE 137 00:07:12,920 --> 00:07:18,040 INSTITUTE NOW THAT THEY HAVE THE 138 00:07:18,040 --> 00:07:25,280 FRONT LINE COUNCIL MEMBERS AND 139 00:07:25,280 --> 00:07:28,400 HIS ARRIVAL AS WE APPRECIATE GUS 140 00:07:28,400 --> 00:07:30,880 JOINING US AS WELL AS I WANTED 141 00:07:30,880 --> 00:07:35,520 TO INTRODUCE TO COUNCIL AND THE 142 00:07:35,520 --> 00:07:36,120 EXTRAMURAL COMMUNITY A MOVE 143 00:07:36,120 --> 00:07:38,760 WE'RE MAKING THAT IS PART OF OUR 144 00:07:38,760 --> 00:07:42,320 CLINICAL TRIAL AND CLINICAL 145 00:07:42,320 --> 00:07:45,560 STUDIES STEWARDSHIP AND 146 00:07:45,560 --> 00:07:47,520 PARTICULARLY ENSURING WE'RE 147 00:07:47,520 --> 00:07:52,040 ALWAYS LEADING INVESTIGATORS TO 148 00:07:52,040 --> 00:07:54,280 JOIN US IN THE INSTITUTE TO HELP 149 00:07:54,280 --> 00:07:56,760 US WITH THAT STEWARDSHIP AND 150 00:07:56,760 --> 00:07:58,480 MANAGEMENT AND TYPICALLY 151 00:07:58,480 --> 00:07:59,440 INVESTIGATORS THAT HAD BEEN AT 152 00:07:59,440 --> 00:08:01,280 THE FRONT LINES AND BRING THAT 153 00:08:01,280 --> 00:08:05,400 PERSPECTIVE IN AND WE CREATED 154 00:08:05,400 --> 00:08:08,520 THIS POSITION AND OF CHIEF 155 00:08:08,520 --> 00:08:10,080 MEDICAL RESEARCH OFFICER AND 156 00:08:10,080 --> 00:08:13,400 THAT'S NOW A COMMON ELEMENT 157 00:08:13,400 --> 00:08:18,000 ACROSS MOST OF OUR CENTERS AND 158 00:08:18,000 --> 00:08:19,640 DIVISIONS AND THE MOST RECENT 159 00:08:19,640 --> 00:08:25,600 ADDITION ON THE DOD SIDE AND 160 00:08:25,600 --> 00:08:36,080 ALSO A HINT OF AND DR. KILEY 161 00:08:42,320 --> 00:08:44,000 WILL EXPAND ON SUBSEQUENTLY 162 00:08:44,000 --> 00:08:49,880 WHERE WE'RE ALWAYS AS PART OF 163 00:08:49,880 --> 00:08:51,720 THE STRATEGIC VISIONING REFRESH 164 00:08:51,720 --> 00:08:53,080 AND EVERGREENING LOOKING TO 165 00:08:53,080 --> 00:08:54,120 ADAPT WHERE THE SCIENCE IS GOING 166 00:08:54,120 --> 00:08:56,280 AND WHERE WE NEED TO ADAPT 167 00:08:56,280 --> 00:08:57,360 ORGANIZATIONALLY TO MAKE SURE 168 00:08:57,360 --> 00:08:58,720 WE'RE STILL AT THE LEADING EDGE 169 00:08:58,720 --> 00:09:03,760 OF IT. 170 00:09:03,760 --> 00:09:06,160 IF NOT, AHEAD OF IT AND 171 00:09:06,160 --> 00:09:09,000 APPRECIATE THE LONG DIVISION 172 00:09:09,000 --> 00:09:10,120 TAKING THE STEP BACK. 173 00:09:10,120 --> 00:09:13,680 IT HAD BEEN A STRUCTURE AT A 174 00:09:13,680 --> 00:09:16,760 DECADE OR TWO AND FRANKLY THE 175 00:09:16,760 --> 00:09:21,120 DIVISION ITSELF HAS PROBABLY 176 00:09:21,120 --> 00:09:23,400 INCREASED MAYBE 40% AND 177 00:09:23,400 --> 00:09:25,520 PARTICULAR NUMBERS BUT IT'S A 178 00:09:25,520 --> 00:09:26,880 HARD WORKING GROUP AND THERE'S A 179 00:09:26,880 --> 00:09:33,200 LOT OF NEW SCIENCE THAT'S COME 180 00:09:33,200 --> 00:09:34,960 IN AND WANTED TO BE ALIGNED WIT 181 00:09:34,960 --> 00:09:35,840 THE SCIENTIFIC OPPORTUNITIES 182 00:09:35,840 --> 00:09:38,040 GOING FORWARD EGO WE HAVE 183 00:09:38,040 --> 00:09:42,680 ATRUCTURE THAT WASNG TO 184 00:09:42,680 --> 00:09:44,440 MEET THE SCIENTIFIC 185 00:09:44,440 --> 00:09:45,920 OPPORTUNITIES WITH AFFECTIVE 186 00:09:45,920 --> 00:09:48,200 LEADERSHIP A BETTER BALANCE OF 187 00:09:48,200 --> 00:09:51,600 WORK LOAD AND BETTER BALANCE OF 188 00:09:51,600 --> 00:09:55,160 SUCCESSION PLANNING, OPERATIONS 189 00:09:55,160 --> 00:09:58,480 AND DEVELOPMENT OF NEW 190 00:09:58,480 --> 00:09:59,160 LEADERSHIP. 191 00:09:59,160 --> 00:10:01,440 THIS WILL RESULT IN THE 192 00:10:01,440 --> 00:10:04,560 EXPANSION FROM THOSE TWO 193 00:10:04,560 --> 00:10:08,240 BRANCHES TO FOUR AND EOB ALSO IS 194 00:10:08,240 --> 00:10:11,280 THE HOME OF THE NATIONAL CENTER 195 00:10:11,280 --> 00:10:12,640 FOR SLEEP DISORDER RESEARCH 196 00:10:12,640 --> 00:10:13,480 PROGRAM AS WELL. 197 00:10:13,480 --> 00:10:15,920 SO JUST WANTED TO GIVE THE 198 00:10:15,920 --> 00:10:17,400 EXTRAMURAL COMMUNITY A HEADS UP 199 00:10:17,400 --> 00:10:19,680 OF THE TRANSITIONS AND AGAIN 200 00:10:19,680 --> 00:10:21,720 DR. KILEY WILL EXPLAIN THAT IN 201 00:10:21,720 --> 00:10:32,200 GREATER DETAIL SUBSEQUENTLY. 202 00:10:38,760 --> 00:10:41,440 AND WE TURN TO THE INTRAMURAL 203 00:10:41,440 --> 00:10:42,840 PROGRAM AS PART OF TRANSPARENCY 204 00:10:42,840 --> 00:10:44,680 TO ENSURE COUNCIL IS AWARE OF 205 00:10:44,680 --> 00:10:47,360 PERFORMANCE REVIEWS OF THOSE 206 00:10:47,360 --> 00:10:48,960 RESEARCH PROGRAMS PERFORMED BY 207 00:10:48,960 --> 00:10:51,240 OUR BOARD OF SCIENTIFIC 208 00:10:51,240 --> 00:10:52,840 COUNSELORS THAT GOES THROUGH AND 209 00:10:52,840 --> 00:10:57,800 REVIEWS OF ALL OF OUR 210 00:10:57,800 --> 00:11:05,800 INVESTIGAT 211 00:11:05,800 --> 00:11:09,440 INVESTIGATORS AND THERE'S T 212 00:11:09,440 --> 00:11:11,760 EXCEPTIONAL RESEARCH THAT 213 00:11:11,760 --> 00:11:12,760 COMPLEMENTS AND EXTENDS OUR 214 00:11:12,760 --> 00:11:17,440 RESEARCH PORTFOLIO. 215 00:11:17,440 --> 00:11:21,480 THIS IS A SNAPSHOT OF THE NEXT 216 00:11:21,480 --> 00:11:25,680 GENERATION OF NHLBI DIVISION OF 217 00:11:25,680 --> 00:11:29,000 INTRAMURAL RESEARCH WITH A FOCUS 218 00:11:29,000 --> 00:11:31,720 ON THE TENURE-TRAND I 219 00:11:31,720 --> 00:11:32,920 WON'T BELABOR IT BUT YOU CAN SEE 220 00:11:32,920 --> 00:11:39,240 FROM THE PHOTOS THE FACE OF THE 221 00:11:39,240 --> 00:11:47,840 DIR IS CHANGING AND DIVERSE IN 222 00:11:47,840 --> 00:11:49,680 MANY WAYS ACROSS THE INSTITUTE 223 00:11:49,680 --> 00:11:55,160 AND DELIGHTED WE'LL BE ABLE TO 224 00:11:55,160 --> 00:11:56,880 HIGHLIGHT ONE PARTICULAR PROGRAM 225 00:11:56,880 --> 00:11:59,280 DR. AGBOR-ENOH WILL BE 226 00:11:59,280 --> 00:12:00,240 PRESENTING LATER AND WANTED TO 227 00:12:00,240 --> 00:12:09,360 GIVE HIM A PARTICULAR SHOUT OUT. 228 00:12:09,360 --> 00:12:11,200 LET ME CLOSE WITH THE OTHER KEY 229 00:12:11,200 --> 00:12:13,360 FEATURE OF OUR UPDATE TODAY AND 230 00:12:13,360 --> 00:12:15,400 IT'S AN EXPRESSION OF APPRECIATE 231 00:12:15,400 --> 00:12:21,240 TO ALL OF YOU TO BE PART OF THE 232 00:12:21,240 --> 00:12:23,520 NHLBI 75th ANNIVERSARY AS AN 233 00:12:23,520 --> 00:12:28,480 OPPORTUNITY TO DO A STRATEGIC 234 00:12:28,480 --> 00:12:31,440 REFRESH OF OUR STRATEGIC VISION 235 00:12:31,440 --> 00:12:33,080 DOCUMENT TO KEEP IT EVER GREEN I 236 00:12:33,080 --> 00:12:37,720 BELIEVE BACK IN 2016 WHEN THAT 237 00:12:37,720 --> 00:12:38,040 WAS RELEASED. 238 00:12:38,040 --> 00:12:44,960 SO WE'RE DUE FOR THAT REFRESH 239 00:12:44,960 --> 00:12:46,560 AND WE LOOK FORWARD TO A SESSION 240 00:12:46,560 --> 00:12:47,760 WITH OUR ADVISORY COUNCIL AND 241 00:12:47,760 --> 00:12:50,480 BOARD OF EXPERTS TO DO THAT 242 00:12:50,480 --> 00:12:52,320 ACTIVITY THIS FALL BEFORE WE 243 00:12:52,320 --> 00:12:55,120 HOPE TO REFLECT SOME OF THE 244 00:12:55,120 --> 00:12:59,040 PROGRESS THAT HAS BEEN MADE AS 245 00:12:59,040 --> 00:13:00,240 WE IMPLEMENTED THE STRATEGIC 246 00:13:00,240 --> 00:13:03,280 VISION OF 2016 BUT ALSO TO PIVOT 247 00:13:03,280 --> 00:13:07,280 AND LOOK FORWARD TO EMERGING 248 00:13:07,280 --> 00:13:09,120 OPPORTUNITIES ORRT EXTENSIONS O 249 00:13:09,120 --> 00:13:13,520 NEW DIRECTIONS WE MAY TAKE AS A 250 00:13:13,520 --> 00:13:15,360 RESULT OF THAT AND INVOLVES 251 00:13:15,360 --> 00:13:20,080 RECONVENING THE STAKEHOLDERS AND 252 00:13:20,080 --> 00:13:23,760 ADVISORS SUCH AS ALL IN HELPINGT 253 00:13:23,760 --> 00:13:27,160 PATH FORWARD IN WAYS THAT WILL 254 00:13:27,160 --> 00:13:30,840 ENHANCE AND ADVANCE OUR SCIENCE 255 00:13:30,840 --> 00:13:34,680 OF HLBS PORTFOLIO. 256 00:13:34,680 --> 00:13:36,680 DON'T NEED TOEMIND OF YOU ALL 257 00:13:36,680 --> 00:13:39,080 MUCH THE FOUR MAJOR GOALS OF 258 00:13:39,080 --> 00:13:42,320 UNDERSTANDING HUMAN BIOLOGY, 259 00:13:42,320 --> 00:13:45,240 REDUCING HUMAN DISEASE AND IT'S 260 00:13:45,240 --> 00:13:46,760 ELEMENT OF TRANSLATION AS WELL 261 00:13:46,760 --> 00:13:49,280 AS WORKFORCE WITH THE VARIOUS 262 00:13:49,280 --> 00:13:53,200 OBJECTIVES THAT HAVE BEEN OUT I 263 00:13:53,200 --> 00:13:56,360 WON'T BELABOR HERE BUT WE SEE 264 00:13:56,360 --> 00:13:58,400 THE STRATEGIC REFRESH FOR THE 265 00:13:58,400 --> 00:14:01,840 MOST PART PROBABLY CAN LEAF THE 266 00:14:01,840 --> 00:14:03,320 BASIC GOALS THE OVER ARCHING 267 00:14:03,320 --> 00:14:05,800 GOALS AND MANY STRATEGIC 268 00:14:05,800 --> 00:14:09,280 OBJECTIVES I SUSPECT ARE ALREADY 269 00:14:09,280 --> 00:14:17,360 SORTING OUT AND ESTABLISHING THE 270 00:14:17,360 --> 00:14:19,400 REAL STRATEGIC INITIATIVES AND 271 00:14:19,400 --> 00:14:22,640 CHALLENGES WE NEED TO TAKE ON IN 272 00:14:22,640 --> 00:14:24,360 THE NEXT 5 TO 10 YEARS THAT WILL 273 00:14:24,360 --> 00:14:25,480 OUR EVER 274 00:14:25,480 --> 00:14:31,360 GREENING PROCESS THIS FAGR 275 00:14:31,360 --> 00:14:34,800 TOWARD THAT END, I THINK ONE OF 276 00:14:34,800 --> 00:14:43,560 THE ILLUSTRATIVE PRIORITIES WE 277 00:14:43,560 --> 00:14:45,880 HAVE HAD UNTIL WE HAVE AN 278 00:14:45,880 --> 00:14:47,280 EVIDENCE-BASED ELIMINATION OF 279 00:14:47,280 --> 00:14:54,680 HEALTH DISPARITIES AND ADDRESS 280 00:14:54,680 --> 00:14:56,920 HEALTH EQUITY THIS WILL BE AN 281 00:14:56,920 --> 00:14:58,760 IMPORTANT PART OF OUR STRATEGIC 282 00:14:58,760 --> 00:15:00,200 VISIONING AND IMPLEMENTATION THE 283 00:15:00,200 --> 00:15:01,600 DIVISIONS AND CENTERS AND STAFF 284 00:15:01,600 --> 00:15:04,880 HAVE ALREADY BEEN ENGAGED IN. 285 00:15:04,880 --> 00:15:09,360 CLEARLY WE RECOGNIZE THE 286 00:15:09,360 --> 00:15:11,600 PROBLEMS PERSIST AND RECOGNIZING 287 00:15:11,600 --> 00:15:14,320 IN MANY WAYS THESE COMPLEX 288 00:15:14,320 --> 00:15:16,280 PROBLEMS REPRESENT GOOD 289 00:15:16,280 --> 00:15:18,960 OPPORTUNITIES PARTICULARLY TO 290 00:15:18,960 --> 00:15:20,680 THE EXTENT THAT THEY'RE VEXING 291 00:15:20,680 --> 00:15:25,520 AND PERSISTENT BECAUSE OF THE 292 00:15:25,520 --> 00:15:27,240 COMPLEXITY AND ALSO PROBABLY 293 00:15:27,240 --> 00:15:29,760 NECESSITATES SOME NOVEL 294 00:15:29,760 --> 00:15:31,640 APPROACHES PERHAPS THE MAN IN 295 00:15:31,640 --> 00:15:38,320 THE BOX APPROACHES AND CERTAINLY 296 00:15:38,320 --> 00:15:41,160 MULTI-LEVEL, MULTI-DIMENSIONAL 297 00:15:41,160 --> 00:15:42,680 ADDRESS THE DRIVERS OF THE 298 00:15:42,680 --> 00:15:48,480 DISPARITY AND RELEVANT TO OUR 299 00:15:48,480 --> 00:15:51,080 PORTFOLIO OF THE KEY ONES AND 300 00:15:51,080 --> 00:15:54,480 THIS ILLUSTRATES THE GEOGRAPHIC 301 00:15:54,480 --> 00:15:57,800 DISPARITIES UNDER PINNING THIS 302 00:15:57,800 --> 00:16:00,800 WHETHER IT'S HYPERTENSION OR 303 00:16:00,800 --> 00:16:06,160 COPD OR OBESITY AND A PUT IN 304 00:16:06,160 --> 00:16:09,920 DIABETES AND I DON'T THIS 305 00:16:09,920 --> 00:16:11,520 NOT LOST ON ANYONE THERE'S 306 00:16:11,520 --> 00:16:13,160 CERTAIN GEOGRAPHICAL AREAS AND 307 00:16:13,160 --> 00:16:15,200 COMMUNITIES AS YOU LIST VARIOUS 308 00:16:15,200 --> 00:16:16,480 CONDITIONS IN WHICH THERE'S 309 00:16:16,480 --> 00:16:20,000 HEALTH DISPARITIES THOSE 310 00:16:20,000 --> 00:16:21,120 COMMUNITIES SEEM TO BE 311 00:16:21,120 --> 00:16:21,680 DISPROPORTIONATELY OVER 312 00:16:21,680 --> 00:16:23,200 REPRESENTED AND OVER BURDENED. 313 00:16:23,200 --> 00:16:25,880 AND YET AS I THINK ALL OF YOU 314 00:16:25,880 --> 00:16:30,440 KNOW IN COUNCIL, MANY OF THE -- 315 00:16:30,440 --> 00:16:35,800 MANY OF THE NIH INVESTMENTS GOES 316 00:16:35,800 --> 00:16:36,760 TO THE COASTS AND NOT 317 00:16:36,760 --> 00:16:38,560 PARTICULARLY OFTEN TO THE SAME 318 00:16:38,560 --> 00:16:43,600 AREAS THAT HAD THE GREATEST 319 00:16:43,600 --> 00:16:45,000 DISPARITIES AND MOST VULNERABLE 320 00:16:45,000 --> 00:16:46,640 WITH THE MOST CHALLENGING HEALTH 321 00:16:46,640 --> 00:16:46,880 STATUS. 322 00:16:46,880 --> 00:16:48,640 I THINK THAT'S SOMETHING AS WE 323 00:16:48,640 --> 00:16:51,600 DO A STRATEGIC REFRESH AND WE 324 00:16:51,600 --> 00:16:52,800 THINK ABOUT OUR INVESTMENT 325 00:16:52,800 --> 00:16:56,560 PORTFOLIO THAT WE THINK ABOUT 326 00:16:56,560 --> 00:16:57,640 ADDRESSING SINCE THAT'S WHERE 327 00:16:57,640 --> 00:17:07,440 OUR MISSION CHALLENGES ARE. 328 00:17:07,440 --> 00:17:09,320 TOWARD THAT END THE STRATEGIC 329 00:17:09,320 --> 00:17:10,560 REFRESH GIVES US AN OPPORTUNITY 330 00:17:10,560 --> 00:17:12,760 TO REFLECT ON SOME OF THE 331 00:17:12,760 --> 00:17:15,920 INVESTMENTS AND HOW WE CAN 332 00:17:15,920 --> 00:17:19,680 INCORPORATE DIFFERENTRP MODELS D 333 00:17:19,680 --> 00:17:19,960 PARADIGMS. 334 00:17:19,960 --> 00:17:24,680 THIS ONE INDICATING THE SOCIAL 335 00:17:24,680 --> 00:17:27,200 ECOLOGICAL FRAME OF PERSPECTIVE 336 00:17:27,200 --> 00:17:32,320 ON THIS ANDG IN A I-DIMENSIONAL 337 00:17:32,320 --> 00:17:33,400 MULTI-LEVEL WAY RECOGNIZING 338 00:17:33,400 --> 00:17:34,520 GENETICS AND BEHTIF THE 339 00:17:34,520 --> 00:17:40,120 INDIVIDUAL AND THE FAMILY AND 340 00:17:40,120 --> 00:17:43,000 COMMUNITY ENVIRONMENT. 341 00:17:43,000 --> 00:17:45,680 WE NOW HAVE THE TOOLS AND 342 00:17:45,680 --> 00:17:47,440 CAPABILITIES TO DO THESE AT 343 00:17:47,440 --> 00:17:48,320 DEPTH AS WELL AS SCALE. 344 00:17:48,320 --> 00:17:50,240 THE PROGRA HELP US BRAIN 345 00:17:50,240 --> 00:17:52,480 STORM WILL ENABLE TO DO THAT 346 00:17:52,480 --> 00:17:53,040 MORE EFFECTIVELY. 347 00:17:53,040 --> 00:17:57,200 AND PARTICULARLY RELATED TO THE 348 00:17:57,200 --> 00:17:58,240 GEOGRAPHIC DISTRIBUTION OF SOME 349 00:17:58,240 --> 00:18:00,240 OF THOSE HIGH-RISK COMMUNITIES, 350 00:18:00,240 --> 00:18:02,840 WE THINK IT'S IMPORTANT TO 351 00:18:02,840 --> 00:18:04,480 DEVELOP PROGRAMS THAT REFLECT 352 00:18:04,480 --> 00:18:09,360 AND TARGET THOSE MOST AT-RISK 353 00:18:09,360 --> 00:18:10,320 COMMUNITIES BECAUSE IF WE'RE 354 00:18:10,320 --> 00:18:11,280 GOING TO UNDERSTAND THE DRIVERS 355 00:18:11,280 --> 00:18:13,520 AND GOING TO INTERVENE TO MAKE A 356 00:18:13,520 --> 00:18:16,480 DIFFERENCE, THIS IS WHERE I 357 00:18:16,480 --> 00:18:19,520 BELIEVE WE DO NDO EMPHASIZE. 358 00:18:19,520 --> 00:18:22,480 SO, WE'RE EXCITED THE EFFORT OF 359 00:18:22,480 --> 00:18:24,400 THE SEAL PROGRAM THOSE DESIGN TO 360 00:18:24,400 --> 00:18:27,000 ADDRESS COVID-19 DISPARITIES IS 361 00:18:27,000 --> 00:18:30,040 MAKING A STRATEGIC PIVOT AS A 362 00:18:30,040 --> 00:18:32,200 PLATFORM TO ENHANCE 363 00:18:32,200 --> 00:18:34,840 COMMUNITY-ENGAGED RESEARCH 364 00:18:34,840 --> 00:18:36,400 RELEVANT TO HEALTH EQUITY AND G 365 00:18:36,400 --> 00:18:40,560 ACROSS MULTIPLE DISORDERS ANDDE 366 00:18:40,560 --> 00:18:43,720 DISEASES AND BECOMING A 367 00:18:43,720 --> 00:18:45,320 TRANS-NIH PLATFORM TO ADDRESS 368 00:18:45,320 --> 00:18:47,920 HEALTH EQUITY FROM A 369 00:18:47,920 --> 00:18:52,280 COMMUNITY-ENGAGED RESEARCH 370 00:18:52,280 --> 00:18:52,640 PARADIGM. 371 00:18:52,640 --> 00:18:54,880 SIMILARLY, THE SAME 372 00:18:54,880 --> 00:18:55,480 COMMUNITY-ENGAGED RESEARCH 373 00:18:55,480 --> 00:19:00,280 PLATFORM IS AMENABLE TO 374 00:19:00,280 --> 00:19:02,680 TARGETING AND PARTNERING WITH 375 00:19:02,680 --> 00:19:06,640 SPECIFIC POPULATIONS AND 376 00:19:06,640 --> 00:19:07,920 CERTAINLY THOSE POPULATIONS 377 00:19:07,920 --> 00:19:10,200 AFFECTED BY RACE, ETHNIC 378 00:19:10,200 --> 00:19:12,680 DISPARITIES HAVE BEEN A KEY 379 00:19:12,680 --> 00:19:12,920 TARGET. 380 00:19:12,920 --> 00:19:14,080 IN PARTICULAR SEALS HAD A 381 00:19:14,080 --> 00:19:17,040 SPECIFIC OUTREACH ARE RELATED TO 382 00:19:17,040 --> 00:19:20,280 INDIGENOUS POPULATION, NATIVE 383 00:19:20,280 --> 00:19:22,440 AMERICANS BOTH IN ALASKA, 384 00:19:22,440 --> 00:19:24,200 HAWAI'I, PACIFIC ISLANDERS AS 385 00:19:24,200 --> 00:19:27,280 S OTHER TRIBAL NATIONS. 386 00:19:27,280 --> 00:19:29,880 SO, THE INSTITUTE'S BEING VERY 387 00:19:29,880 --> 00:19:33,400 INTENTIONAL ABOUT THOSE 388 00:19:33,400 --> 00:19:35,360 COLLABORATIVE PARTNERSHIPS WHERE 389 00:19:35,360 --> 00:19:40,120 WE KNOW THAT IT'S CRITICAL TO 390 00:19:40,120 --> 00:19:43,040 HAVE TRUSTWORTHY RELATIONSHIPS 391 00:19:43,040 --> 00:19:46,960 THAT ARE SUSTAINABLE AND AGAIN 392 00:19:46,960 --> 00:19:47,560 COLLABORATION WITH COMMUNITY. 393 00:19:47,560 --> 00:19:53,040 HAVING PLATFORMS THAT HAVE THAT 394 00:19:53,040 --> 00:19:53,920 SENSIBILITY AND PERSPECTIVE IS 395 00:19:53,920 --> 00:19:54,080 KEY. 396 00:19:54,080 --> 00:19:56,000 SO WE LOOK FORWARD TO CONTINUE 397 00:19:56,000 --> 00:19:59,000 TO BUILD OUT THE SEAL PLATFORM. 398 00:19:59,000 --> 00:20:00,960 SIMILARLY RELATED TO THOSE 399 00:20:00,960 --> 00:20:02,600 GEOGRAPHIC DISPARITIES WE'RE 400 00:20:02,600 --> 00:20:05,600 EXCITED ABOUT THE ONGOING ROLL 401 00:20:05,600 --> 00:20:07,280 OUT OF RURAL AND LOOKING AT SOME 402 00:20:07,280 --> 00:20:13,720 OF THE KEY REGIONS THAT ARE 403 00:20:13,720 --> 00:20:17,080 EXPERIENCINGY DECLINES 404 00:20:17,080 --> 00:20:18,960 IN CARDIOVASCULAR HEALTH 405 00:20:18,960 --> 00:20:19,920 RELATIVELY SPEAKING. 406 00:20:19,920 --> 00:20:21,080 CERTAINLY NOT THE EVER FALLING 407 00:20:21,080 --> 00:20:22,320 RATES WE'RE SEEING IN OTHER 408 00:20:22,320 --> 00:20:24,040 PARTS OF THE COUNTRY. 409 00:20:24,040 --> 00:20:25,560 SO HERE'S A GREAT OPPORTUNITY 410 00:20:25,560 --> 00:20:28,160 AGAIN TO DRILL DOWN AND MAKE A 411 00:20:28,160 --> 00:20:30,600 DIFFERENCE IN RURAL AMERICA. 412 00:20:30,600 --> 00:20:33,520 AND THEN FINALLY RELATED TO THE 413 00:20:33,520 --> 00:20:35,280 COHORT STUDIES SOMETHING I 414 00:20:35,280 --> 00:20:37,320 BELIEVE THAT'S ACTUALLY ON THE 415 00:20:37,320 --> 00:20:43,640 TABLE FOR COUNCIL C THIS CYCLE 416 00:20:43,640 --> 00:20:48,640 RELATE TO ENSURING OUR 417 00:20:48,640 --> 00:20:50,600 COMMUNITY-BASED COHORTS ARE 418 00:20:50,600 --> 00:20:54,800 REFLECTIVE AND BUILDING OUT OUR 419 00:20:54,800 --> 00:20:59,160 CAPABILITY RELATED TO 420 00:20:59,160 --> 00:21:01,520 ASIAN-AMERICAN POPULATIONS 421 00:21:01,520 --> 00:21:10,400 INCLUDING NATIVE HAWAIIANS ANDI 422 00:21:10,400 --> 00:21:12,600 PACIFIC ISLANDERS. 423 00:21:12,600 --> 00:21:16,040 THIS IS IS A COMPLEMENTARY 424 00:21:16,040 --> 00:21:17,120 COMPONENT THAT BRINGS IN THE 425 00:21:17,120 --> 00:21:17,640 DIVERSITY OF THE ASIAN 426 00:21:17,640 --> 00:21:24,280 POPULATION. 427 00:21:24,280 --> 00:21:27,720 THESE ARE AIC A APPROACHES 428 00:21:27,720 --> 00:21:29,000 WE'RE TAKING TO ADDRESS WHAT'S 429 00:21:29,000 --> 00:21:30,280 BEEN A CHALLENGE IN CL AND 430 00:21:30,280 --> 00:21:31,680 ETHNIC DISPARITIES AND DOING 431 00:21:31,680 --> 00:21:37,640 THAT IN A VERY STRATEGIC WAY. 432 00:21:37,640 --> 00:21:43,600 TOWARD THAT END ONE EXAMPLE THAT 433 00:21:43,600 --> 00:21:47,640 RELATED TO INEQUITIES IN 434 00:21:47,640 --> 00:21:49,640 MATERNAL HEALTH IN PARTICULAR 435 00:21:49,640 --> 00:21:54,720 THE CHALLENGES OF MATERNAL CARE 436 00:21:54,720 --> 00:21:56,560 DESERTS IN THE SAME HIGH-RISK 437 00:21:56,560 --> 00:21:59,480 COMMUNITIES WE'RE ENCOURAGED BY 438 00:21:59,480 --> 00:22:00,080 PROGRESS PROGRAMMATICALLY IN 439 00:22:00,080 --> 00:22:02,120 PURSUIT OF THE VISION IN THIS 440 00:22:02,120 --> 00:22:02,320 SPACE. 441 00:22:02,320 --> 00:22:03,840 IT'S AN AREA THAT CLEARLY IS 442 00:22:03,840 --> 00:22:08,760 RELEVANT TO OUR PORTFOLIO GIVEN 443 00:22:08,760 --> 00:22:11,520 THE COMPLICATIONS OF HEART, LUNG 444 00:22:11,520 --> 00:22:14,800 AND BLOOD DISORDERS THAT ARE 445 00:22:14,800 --> 00:22:16,440 PART OF MATERNAL MORBIDITY AND 446 00:22:16,440 --> 00:22:19,720 MORTALITY AND DEVELOPING THOSE 447 00:22:19,720 --> 00:22:23,280 PROGRAMMATIC ATCAPA. 448 00:22:23,280 --> 00:22:23,760 INCLUSIVE THE 449 00:22:23,760 --> 00:22:27,480 E DCS EFFORT WITH 450 00:22:27,480 --> 00:22:31,280 THE ENRICH PROGRAM OF EARLY RVE 451 00:22:31,280 --> 00:22:33,200 CARDIOVASCULAR HEALTH INHERS 452 00:22:33,200 --> 00:22:34,080 AND CHILDREN. 453 00:22:34,080 --> 00:22:38,000 TREATING THAT AS A DIAD WITH 454 00:22:38,000 --> 00:22:38,320 INTERVENTIONS. 455 00:22:38,320 --> 00:22:40,920 YOU CAN SEE WHERE THE ENTITIES 456 00:22:40,920 --> 00:22:43,240 ARE LOCATED AGAIN STRIVING TO GO 457 00:22:43,240 --> 00:22:46,760 TO WHERE THE VEXING CHALLENGES 458 00:22:46,760 --> 00:22:48,520 ARE AND THAT'S ALSO COMPLEMENTED 459 00:22:48,520 --> 00:22:50,280 BY ANOTHER PD THAT TAKES 460 00:22:50,280 --> 00:22:54,920 MORE OF A COMMUNITY-ENGAGED 461 00:22:54,920 --> 00:22:56,560 IMPLEMENTATION SCIENCE LENS AND 462 00:22:56,560 --> 00:22:59,440 THAT'S THE MATERNAL HEALTH 463 00:22:59,440 --> 00:23:00,720 COMMUNITY IMPLEMENTATION PROGRAM 464 00:23:00,720 --> 00:23:03,640 AND MOST RECENTLY NOT SHOWN HERE 465 00:23:03,640 --> 00:23:07,200 BUT THAT'S BEEN EXTENDED TO BE 466 00:23:07,200 --> 00:23:11,440 PART OF A TRANS-NIH PROGRAM IN 467 00:23:11,440 --> 00:23:15,440 MATERNAL HEALTH CALLED IMPROVE 468 00:23:15,440 --> 00:23:18,200 IN WHICH THE SAME PROGRAMMATIC 469 00:23:18,200 --> 00:23:21,600 TEAMS ARE LEANING IN TO ADVANCE 470 00:23:21,600 --> 00:23:23,720 THE NHLBI PERSPECTIVE BUT IN A 471 00:23:23,720 --> 00:23:26,640 TRANS-NIH WAY IN THE IMPROVE 472 00:23:26,640 --> 00:23:28,400 PROGRAM AND WE'RE DELIGHTED 473 00:23:28,400 --> 00:23:30,080 AGAIN IT'S AITOMPLEMENTARY PIECE 474 00:23:30,080 --> 00:23:31,360 HELPING TO DRIVE 475 00:23:31,360 --> 00:23:33,240 COMMUNITY-ENGAGED RESEARCH AND 476 00:23:33,240 --> 00:23:35,360 IMPLEMENTATION SCIENCE IN THIS 477 00:23:35,360 --> 00:23:40,000 SPACE RELATIVE TO HEART, LUNG, 478 00:23:40,000 --> 00:23:41,480 BLOOD AND SLEEP RESEARCH. 479 00:23:41,480 --> 00:23:44,360 THESE ARE THE PLATFORMS WITH 480 00:23:44,360 --> 00:23:46,120 MATERNAL HEALTH AS THE EXEMPLAR 481 00:23:46,120 --> 00:23:46,360 CASES. 482 00:23:46,360 --> 00:23:50,960 THIS GIVES AN OPPORTUNITY REALLY 483 00:23:50,960 --> 00:23:54,160 TO ADDRESS THE SOCIAL 484 00:23:54,160 --> 00:23:56,200 DETERMINATES THE MULTI-LEVEL 485 00:23:56,200 --> 00:23:57,520 CHALLENGES IN WAYS WE HOPE WILL 486 00:23:57,520 --> 00:23:59,400 MOVE THE NEEDLE AND MAKE A 487 00:23:59,400 --> 00:24:02,960 DIFFERENCE. 488 00:24:02,960 --> 00:24:06,640 CLEARLY, YOU ALL ARE WELL AWARE 489 00:24:06,640 --> 00:24:09,040 OF THOSE DISPARITIES AS I 490 00:24:09,040 --> 00:24:12,280 MENTIONED BEFORE IN MATERNAL 491 00:24:12,280 --> 00:24:18,120 HEALTH AND IN MANY WAYS WE'VE 492 00:24:18,120 --> 00:24:19,320 OFTEN TALKED ABOUTN PREGNANCY 493 00:24:19,320 --> 00:24:22,640 BEING A STRESS TEST IN WHICH THE 494 00:24:22,640 --> 00:24:24,920 MORBIDITIES OF GESTATIONAL 495 00:24:24,920 --> 00:24:28,600 DIABETES, PREECLAMPSIA AND 496 00:24:28,600 --> 00:24:33,200 CARDIO MYOPATHY MAY BECOME 497 00:24:33,200 --> 00:24:36,840 MANIFEST TO THE DEGREE D WHICH 498 00:24:36,840 --> 00:24:40,080 A BIRTH HAVING 499 00:24:40,080 --> 00:24:41,680 LATER IN LIFE AND HAVE 500 00:24:41,680 --> 00:24:44,000 COMORBIDITIES SUCH AS DIABETES 501 00:24:44,000 --> 00:24:46,080 AND HYPERTENSION AND I THINK 502 00:24:46,080 --> 00:24:47,040 THIS REFLECTS BOTH A CHALLENGE 503 00:24:47,040 --> 00:24:50,160 IN HEALTH DISPARITIES AND ALSO 504 00:24:50,160 --> 00:24:52,320 AN OPPORTUNITY BECAUSE IT REALLY 505 00:24:52,320 --> 00:24:54,720 HAS THE MULTI-DIMENSIONAL 506 00:24:54,720 --> 00:24:58,960 COMPONENTS TO IT WE CAN ADDRESS. 507 00:24:58,960 --> 00:25:01,360 SO ONE OF THE QUESTIONS BECOMES 508 00:25:01,360 --> 00:25:04,320 HOW ARE WE GOING TO BECOME MORE 509 00:25:04,320 --> 00:25:06,520 EFFECTIVE AT PREDICTING, 510 00:25:06,520 --> 00:25:11,240 PREEMPTING AND PREVENTING HEART, 511 00:25:11,240 --> 00:25:12,680 LUNG, BLOOD AND SLEEP DISORDERS 512 00:25:12,680 --> 00:25:13,640 AND ONE OF THOSE OPPORTUNITIES 513 00:25:13,640 --> 00:25:16,560 THAT SHOULD BE PART OF THE 514 00:25:16,560 --> 00:25:17,800 STRATEGIC VISION REFRESH OVER 515 00:25:17,800 --> 00:25:20,960 THE NEXT FIVE TO 10 YEARS IS TO 516 00:25:20,960 --> 00:25:24,720 LEVERAGE THE TOOLS AND ANALYTICS 517 00:25:24,720 --> 00:25:26,720 AND CAPACITY TO UNDERSTAND 518 00:25:26,720 --> 00:25:29,640 THINGS BOTH AT A BASIC LEVEL, 519 00:25:29,640 --> 00:25:32,320 FUNDAMENTAL LEVEL AND 520 00:25:32,320 --> 00:25:33,360 SINGLE-CELL RESOLUTION OF ALMOST 521 00:25:33,360 --> 00:25:36,200 EVERY MOLECULE AND CELL AND 522 00:25:36,200 --> 00:25:39,440 ORGAN WITH TIME IN AN 523 00:25:39,440 --> 00:25:42,600 INTEGRATIVE WAY THAT I THINK 524 00:25:42,600 --> 00:25:43,960 WE'LL BE ABLE TO BE MORE 525 00:25:43,960 --> 00:25:47,040 MANIFEST IN THE NEXT FIVE YEARS 526 00:25:47,040 --> 00:25:49,800 AND HAVE THAT BASIC 527 00:25:49,800 --> 00:25:50,960 UNDERSTANDING ALSO TRANSLATE 528 00:25:50,960 --> 00:25:55,200 INTO OUR BETTER UNDERSTANDING OF 529 00:25:55,200 --> 00:25:57,240 PERTURBATIONS THAT OCCUR IN 530 00:25:57,240 --> 00:25:59,600 DISEASE AND THEN ADD THESE OTHER 531 00:25:59,600 --> 00:26:02,000 LAYERS OF THE ENVIRONMENTAL 532 00:26:02,000 --> 00:26:02,680 EXPOSURES MO THAT AS 533 00:26:02,680 --> 00:26:05,880 NGTHE GENETIC BACKGROUND. 534 00:26:05,880 --> 00:26:10,880 ALL THOSE TOOLS INCREASINGLY IN 535 00:26:10,880 --> 00:26:14,000 OUR GRASP AND CREATING THE 536 00:26:14,000 --> 00:26:16,920 RESOURCES SUCH THAT HLBS 537 00:26:16,920 --> 00:26:18,640 SCIENTISTS CAN LEVERAGE ALL THE 538 00:26:18,640 --> 00:26:20,520 DIFFERENT TOOLS, TECHNOLOGIES 539 00:26:20,520 --> 00:26:24,680 AND DATA SOURCES IN A ROBUST, 540 00:26:24,680 --> 00:26:25,960 INTEGRATIVE WAY. 541 00:26:25,960 --> 00:26:30,680 HOPEFULLY LEVERAGING THE TOOLS 542 00:26:30,680 --> 00:26:35,160 IN SCIENCE, MACHINE LEARNING AND 543 00:26:35,160 --> 00:26:36,640 ARTIFICIAL INTELLIGENCE TAKING 544 00:26:36,640 --> 00:26:39,960 AND HOPE THE CATALYST WILL 545 00:26:39,960 --> 00:26:43,880 HELP LEVERAGE ALL THE 546 00:26:43,880 --> 00:26:44,840 TIES ACROSS THE 547 00:26:44,840 --> 00:26:48,880 PORTFOLIO, MATERNAL HEALTH ONLY 548 00:26:48,880 --> 00:26:49,400 BEING ONE EXAMPLE. 549 00:26:49,400 --> 00:26:52,040 WHERE PERHAPS THIS IS BE AN 550 00:26:52,040 --> 00:26:55,160 OPPORTUNITYRT US DO GREATER 551 00:26:55,160 --> 00:26:56,120 TECHNO DEVELOPMENT 552 00:26:56,120 --> 00:26:58,280 PARTICULARLY IN THINKING ABOUT 553 00:26:58,280 --> 00:27:00,920 THE AREAS MOST AT RISK, THOSE 554 00:27:00,920 --> 00:27:02,600 COMMUNITIES WHERE IN ESSENCE 555 00:27:02,600 --> 00:27:04,960 THEY'RE IN MATERNAL CARE 556 00:27:04,960 --> 00:27:05,200 DESERTS. 557 00:27:05,200 --> 00:27:08,360 IS THERE AN OPPORTUNITY TO 558 00:27:08,360 --> 00:27:10,080 LEVERAGE TECHNOLOGY IN THE 559 00:27:10,080 --> 00:27:12,360 ANALYTIC TOOLS IN WAYS WE START 560 00:27:12,360 --> 00:27:16,000 TO ERODE THE BARRIERS OF ACCESS 561 00:27:16,000 --> 00:27:18,400 TO HIGH-QUALITY MATERNAL HEALTH 562 00:27:18,400 --> 00:27:21,960 TO ALL COMMUNITIES AND SO THIS 563 00:27:21,960 --> 00:27:25,120 BLEND OF HIGH-TECH AS WELL AS 564 00:27:25,120 --> 00:27:27,640 HIGH-TOUCH THAT MAYT WITH 565 00:27:27,640 --> 00:27:31,760 COMMUNITY HEALTH WORKERS A 566 00:27:31,760 --> 00:27:33,480 DOULAS MAY BE A CONVERGENT 567 00:27:33,480 --> 00:27:34,720 OPPORTUNITY OUR 568 00:27:34,720 --> 00:27:36,240 COMMUNITY-ENGAGED RESEARCH AND 569 00:27:36,240 --> 00:27:37,040 IMPLEMENTATION SCIENCE CAN MAKE 570 00:27:37,040 --> 00:27:40,200 POSSIBLE FOR THE HIGH-RISK 571 00:27:40,200 --> 00:27:42,440 COMMUNITIES AND WOMEN AT RISK. 572 00:27:42,440 --> 00:27:47,440 INDEED WE'RE LEVERAGING IN THE 573 00:27:47,440 --> 00:27:49,880 IMPROVE PROGRAM ONE OF THE 574 00:27:49,880 --> 00:27:51,360 FAVORABLE OUTCOMES OF THE 575 00:27:51,360 --> 00:27:53,400 PANDEMIC TO PLUG INTO THE 576 00:27:53,400 --> 00:27:57,480 ENGINEERING COMMUNITY OF NIBIB 577 00:27:57,480 --> 00:28:01,040 AND THE RAD X THAT LED TO RAPID 578 00:28:01,040 --> 00:28:02,240 DIAGNOSTICS AND TESTING IN THE 579 00:28:02,240 --> 00:28:03,400 PANDEMIC. 580 00:28:03,400 --> 00:28:05,840 TO USE SOME OF THE SAME 581 00:28:05,840 --> 00:28:07,680 INNOVATION FUNNELS AND PLATFORMS 582 00:28:07,680 --> 00:28:10,120 TO TARGET NOW TO LUNG, 583 00:28:10,120 --> 00:28:11,840 BLOOD, SLEEP SCIENCE AS WELL. 584 00:28:11,840 --> 00:28:14,920 WE'RE LOOKINGE FORWARD TO LOOKG 585 00:28:14,920 --> 00:28:17,760 TO GETTING OUTSIDE THE BOX A 586 00:28:17,760 --> 00:28:18,040 BIT. 587 00:28:18,040 --> 00:28:19,960 PERHAPS EVEN LEVERAGING WHAT YOU 588 00:28:19,960 --> 00:28:22,280 HEARD -- WHAT YOU'LLOU HEAR ABO 589 00:28:22,280 --> 00:28:25,520 IN TERMS OF THE CATALYZE PROGRAM 590 00:28:25,520 --> 00:28:27,120 IN DEVELOPING INNOVATIVE 591 00:28:27,120 --> 00:28:30,120 TECHNOLOGY TO ADDRESS SOME OF 592 00:28:30,120 --> 00:28:37,880 THESE CHALLENGES. 593 00:28:37,880 --> 00:28:41,360 I GUESS I HAVE A WHAT-IF IN 594 00:28:41,360 --> 00:28:42,320 APPLYING THE TECHNOLOGIES. 595 00:28:42,320 --> 00:28:45,600 THINKING ABOUT POSTPARTUM 596 00:28:45,600 --> 00:28:48,440 DEPRESSION OR PREECLAMPSIA THAT 597 00:28:48,440 --> 00:28:54,040 OCCURS AFTER DISCHARGE OR CARDIO 598 00:28:54,040 --> 00:28:58,280 MYOPATHY THAT BECOMES MANIFEST 599 00:28:58,280 --> 00:29:00,600 POST CHARGE IN THE MATERNAL CARE 600 00:29:00,600 --> 00:29:01,000 DESERTS. 601 00:29:01,000 --> 00:29:03,920 WHAT IF WE STARTED TO LEVERAGE 602 00:29:03,920 --> 00:29:05,720 THE CAPABILITIES OF TECHNOLOGIES 603 00:29:05,720 --> 00:29:12,080 AND MONITORING THE 24/7/365 604 00:29:12,080 --> 00:29:14,280 COUPLES TO MACHINE LEARNING, 605 00:29:14,280 --> 00:29:20,360 A.I. ALGORITHM CAN DO ALERTS AND 606 00:29:20,360 --> 00:29:27,960 MAYBE DO DIAGNOSTIC ASSESSMENT 607 00:29:27,960 --> 00:29:32,800 THIS IS THIS BE PART OF 608 00:29:32,800 --> 00:29:34,160 STRATEGIC VISION REFRESH. 609 00:29:34,160 --> 00:29:38,640 THIS IS FROM A PAPER FROM THE 610 00:29:38,640 --> 00:29:40,240 V.A. IN WHICH IT WASN'TAS TO 611 00:29:40,240 --> 00:29:42,040 SCALE BUT WAS INTERESTING IN 612 00:29:42,040 --> 00:29:45,000 REGARD TO ENGAGING WITH A COHORT 613 00:29:45,000 --> 00:29:53,600 OF V.A. PATIENTS THAT HAVE BEEND 614 00:29:53,600 --> 00:30:03,360 WITH CERTAIN SENSOR CAPABILITIES 615 00:30:03,360 --> 00:30:06,040 TO TEST WHAT THE DISCHARGE 616 00:30:06,040 --> 00:30:07,520 BASELINE WAS IN HOPES OF 617 00:30:07,520 --> 00:30:08,760 FIGURING OUT WHETHER THEY CAN 618 00:30:08,760 --> 00:30:11,680 PREDICT WHO WOULD BE 619 00:30:11,680 --> 00:30:13,160 RE-HOSPITALIZED BASED ON THE O 620 00:30:13,160 --> 00:30:14,840 CONTINUOUS MONITORING OF HEARTO 621 00:30:14,840 --> 00:30:16,760 RATE AND OTHER BLOOD SAMPLING 622 00:30:16,760 --> 00:30:19,080 CAPABILITIES OF THE 623 00:30:19,080 --> 00:30:20,520 WEARABLE SENSORS. 624 00:30:20,520 --> 00:30:22,520 INDEED THERE WAS EVIDENCE 625 00:30:22,520 --> 00:30:24,920 LOOKING AT THAT SOME OF THE DATA 626 00:30:24,920 --> 00:30:27,880 IN WHICH THEY COULD TRAIN THEM 627 00:30:27,880 --> 00:30:30,160 ON BASELINE AND FOLLOW THAT 628 00:30:30,160 --> 00:30:32,480 PREDICTIVE MODEL TO SEE IF 629 00:30:32,480 --> 00:30:36,720 THERE'S DEVIATIONS FROM THAT 630 00:30:36,720 --> 00:30:38,200 OPTIMIZED POST-HOSPITAL BASELINE 631 00:30:38,200 --> 00:30:40,400 AND WHETHER THEY WERE SLIPPING 632 00:30:40,400 --> 00:30:43,600 INTO HEART FAILURE AGAIN AND THE 633 00:30:43,600 --> 00:30:45,680 ALGORITHM IN THIS PARTICULAR 634 00:30:45,680 --> 00:30:48,400 CASE BUT REALLY PROBABLY 635 00:30:48,400 --> 00:30:49,600 INDICATIVE OF THE FORMATIVE 636 00:30:49,600 --> 00:30:53,000 NATURE OF THE FIELD AND ONE WITH 637 00:30:53,000 --> 00:30:54,960 A LOT OF PROMISE IN WHICH WE ARE 638 00:30:54,960 --> 00:30:58,240 STARTING TO SEE THE CONVERGENCE 639 00:30:58,240 --> 00:30:59,800 OF THE TECHNOLOGIES IN 640 00:30:59,800 --> 00:31:01,960 COMPUTATIONAL MEDICINE IF YOU 641 00:31:01,960 --> 00:31:04,040 WILL. 642 00:31:04,040 --> 00:31:05,760 AND TOWARD THAT END TO GET WHAT 643 00:31:05,760 --> 00:31:09,240 IF AND THIS I STARTING TO 644 00:31:09,240 --> 00:31:10,000 FORESHADOW A LITTLE BIT OF HOW 645 00:31:10,000 --> 00:31:11,720 WE MAY CHALLENGE YOU ALL WHEN 646 00:31:11,720 --> 00:31:13,560 YOU COME IN THE FALL AND HELP US 647 00:31:13,560 --> 00:31:17,720 BRING STORM THE OPPORTUNITIES 648 00:31:17,720 --> 00:31:23,400 LOOKING AHEAD OF THE NOTION OF A 649 00:31:23,400 --> 00:31:25,880 DIGITAL TRIN AND HANGING OUT 650 00:31:25,880 --> 00:31:27,320 WITH OTHER DISCIPLINES AND THE 651 00:31:27,320 --> 00:31:28,040 ENGINEERING. 652 00:31:28,040 --> 00:31:29,680 THEY LOOK AT US DOCTORS AND SAY, 653 00:31:29,680 --> 00:31:33,800 YOU KNOW,E WE ARE DE 654 00:31:33,800 --> 00:31:39,680 BASICALLYSI EMPIRICAL MEDICINE D 655 00:31:39,680 --> 00:31:41,600 MORE UNTIL THEY BECOMEY 656 00:31:41,600 --> 00:31:43,440 PRE-RENAL AND STOP PEEING AND 657 00:31:43,440 --> 00:31:45,000 THEN DRY AND THEN SENDING THEM 658 00:31:45,000 --> 00:31:48,200 OUT AND MAKING THESE EMPIRICAL 659 00:31:48,200 --> 00:31:50,680 KINDS OF GUESSES AND 660 00:31:50,680 --> 00:31:53,600 UNFORTUNATELYING HALF OF 661 00:31:53,600 --> 00:31:58,200 THEM DIE WITH HEART FAILURE AND 662 00:31:58,200 --> 00:31:59,080 OVER FIVE YEARS. 663 00:31:59,080 --> 00:32:00,920 WE SHOULD START TO GET BETTER AT 664 00:32:00,920 --> 00:32:02,560 BEING ABLE TO PREDICT SOME OF 665 00:32:02,560 --> 00:32:09,600 THOSE OUTCOMES AND HOPEFULLY 666 00:32:09,600 --> 00:32:11,560 PREEMPT THEM AND PREVENT THEM. 667 00:32:11,560 --> 00:32:13,360 THAT'S WHAT ENGINEERS DO THEY 668 00:32:13,360 --> 00:32:14,600 DON'T SEND UP AIRPLANES AND SEE 669 00:32:14,600 --> 00:32:17,600 IF THAT WORKS AND WAIT TO SEE 670 00:32:17,600 --> 00:32:18,400 HOW MANY CRASH. 671 00:32:18,400 --> 00:32:20,440 THEY'VE ALREADY SIMULATED WHAT'S 672 00:32:20,440 --> 00:32:22,600 NECESSARY TO GET THE RIGHT 673 00:32:22,600 --> 00:32:24,880 FLIGHT AND CAPABILITIES. 674 00:32:24,880 --> 00:32:27,400 MOREOVER, TO THEN HAVE A SENSE 675 00:32:27,400 --> 00:32:29,120 OF HOW IT'S FUNCTIONING, FLIGHT 676 00:32:29,120 --> 00:32:31,280 AFTER FLIGHT AFTER FLIGHT AS TO 677 00:32:31,280 --> 00:32:33,280 WHETHER THAT PANEL NEEDS TO BE 678 00:32:33,280 --> 00:32:34,960 CHANGED OR THAT ENGINE NEEDS TO 679 00:32:34,960 --> 00:32:38,640 BE ADJUSTED BY ALWAYS LOOKING 680 00:32:38,640 --> 00:32:40,360 BACK AT THAT SIMULATED MODEL AND 681 00:32:40,360 --> 00:32:43,320 SEEING DEVIATIONS AND MAKING THE 682 00:32:43,320 --> 00:32:48,760 RIGHT ADJUSTMENTS IN THE ACTUAL 683 00:32:48,760 --> 00:32:49,920 PHYSICAL WITH THE ENVIRONMENT. 684 00:32:49,920 --> 00:32:53,000 AS YOU PLAY THAT OUT IN YOUR 685 00:32:53,000 --> 00:32:57,600 AHEAD AS A THOUGHT EXPERIMENT, 686 00:32:57,600 --> 00:33:02,200 AS WE GET BETTER AND BETTER WITH 687 00:33:02,200 --> 00:33:05,280 EVERY O MOLECULE IN IT 688 00:33:05,280 --> 00:33:09,040 UNDER NORMAL PHYSIOLOGY AND 689 00:33:09,040 --> 00:33:10,640 PERTURBATION AND WHAT'S TO STOP 690 00:33:10,640 --> 00:33:13,320 US FROM HAVING DIGITAL TWINS FOR 691 00:33:13,320 --> 00:33:14,720 PREGNANCY? 692 00:33:14,720 --> 00:33:17,280 WHAT'S TO STOP US FROM HAVING 693 00:33:17,280 --> 00:33:22,600 DIGITAL TWINS FOR ASTHMA OR COPD 694 00:33:22,600 --> 00:33:25,920 OR HEART FAILURE? 695 00:33:25,920 --> 00:33:27,880 I WOULD HOPE THAT'S AVERAGING 696 00:33:27,880 --> 00:33:30,200 THE DATA SCIENCE AND ANALYTICS 697 00:33:30,200 --> 00:33:32,800 AT HAND NOW AS WE TALK LARGE 698 00:33:32,800 --> 00:33:34,160 LANGUAGE MODELS AND ALL SORTS OF 699 00:33:34,160 --> 00:33:45,120 THINGS WE SHOULD BE ABLE TO BE 700 00:33:45,480 --> 00:33:49,280 TERMS OF OUR AGENDA. 701 00:33:49,280 --> 00:33:50,840 TO CONCLUDE, ONE OF THE KEY 702 00:33:50,840 --> 00:33:53,280 THINGS WE BELIEVE WOULD BE PART 703 00:33:53,280 --> 00:33:54,720 OF THE STRATEGIC VISION REFRESH 704 00:33:54,720 --> 00:33:58,080 AND VISIONSI FOR THE NEXT 5 TO 705 00:33:58,080 --> 00:34:00,880 YEARS IS TO START TO LEVERAGE 706 00:34:00,880 --> 00:34:02,520 THE TECHNOLOGIES AND CAPABLES 707 00:34:02,520 --> 00:34:04,960 WITH THE TOP MED AND OTHER 708 00:34:04,960 --> 00:34:07,680 REGISTRIES OR COMMUNITY-BASED 709 00:34:07,680 --> 00:34:09,280 COHORTS OR COMMUNITY-ENGAGED 710 00:34:09,280 --> 00:34:12,880 RESEARCH PLATFORMS IN 711 00:34:12,880 --> 00:34:14,520 IMPLEMENTATION SCIENCE INTA 712 00:34:14,520 --> 00:34:16,880 THAT APPRECIATES THE 713 00:34:16,880 --> 00:34:17,800 MULTI-DIMENSIONAL NATURE OF 714 00:34:17,800 --> 00:34:19,920 HEALTH AND DISEASE AND ALSO HOW 715 00:34:19,920 --> 00:34:23,120 OUR RESEARCH AGENDA CAN BE 716 00:34:23,120 --> 00:34:27,120 ADVANCED BY INTEGRATING THESE 717 00:34:27,120 --> 00:34:29,920 VARIOUS INPUTS IN WAYS THAT 718 00:34:29,920 --> 00:34:32,120 LEVERAGES THE COMPUTATIONAL 719 00:34:32,120 --> 00:34:34,200 POWER AND ANALYTICAL TOOLS OF 720 00:34:34,200 --> 00:34:35,960 MACHINE LEARNING AND A.I. IN 721 00:34:35,960 --> 00:34:37,320 WAYS THAT WE PROBABLY COULDN'T 722 00:34:37,320 --> 00:34:42,680 HAVE PREDICTED 5 TO 10 YEARS AGO 723 00:34:42,680 --> 00:34:45,160 AND EXCITED WHAT WE HOPE YOU'LL 724 00:34:45,160 --> 00:34:46,840 COME UP WITH THIS FALL AND WE'LL 725 00:34:46,840 --> 00:34:48,760 START BRAIN STORMING HOW DO WE 726 00:34:48,760 --> 00:34:52,320 LEVERAGE THESE CAPABILITIES TO 727 00:34:52,320 --> 00:34:56,200 FULFILL OUR MISSION MORE 728 00:34:56,200 --> 00:34:59,040 EFFECTIVELY PREEMPT HEART, LUNG 729 00:34:59,040 --> 00:35:08,080 AND BLOOD SLEEP DISORDERS. 730 00:35:08,080 --> 00:35:09,640 AND THAT'S WHAT WE'LL PUT BEFORE 731 00:35:09,640 --> 00:35:12,920 YOU AND GET YOUR CREATIVE ENERGY 732 00:35:12,920 --> 00:35:15,800 AND BRAIN POWER HELPING US THINK 733 00:35:15,800 --> 00:35:18,600 ABOUT THE NEXT FIVE YEARS AND 734 00:35:18,600 --> 00:35:21,160 HOW WE CANSH THE STRATEGIC 735 00:35:21,160 --> 00:35:23,640 VISION IN A WAY THAT WILL BE 736 00:35:23,640 --> 00:35:25,160 TRANSFORMATIVE TO OUR SCIENTIFIC 737 00:35:25,160 --> 00:35:28,960 COMMUNITY AND OUR PATIENTS. 738 00:35:28,960 --> 00:35:32,080 WE LOOK FORWARD TO THE FALL AND 739 00:35:32,080 --> 00:35:33,160 THAT BRAIN STORMING SESSION AND 740 00:35:33,160 --> 00:35:36,080 I'LL STOP THERE. 741 00:35:36,080 --> 00:35:37,880 >>THANK YOU, DR. GIBBONS. 742 00:35:37,880 --> 00:35:39,120 DOES ANYONE HAVE COMMENTS OR 743 00:35:39,120 --> 00:35:49,560 QUESTIONS FOR DR. GIBBONS? 744 00:36:02,960 --> 00:36:08,720 I GUESS NO ONE HAS QUESTIONS BE 745 00:36:08,720 --> 00:36:09,120 ENLIGHTENING. 746 00:36:09,120 --> 00:36:10,080 >>OR ASLEEP. 747 00:36:10,080 --> 00:36:13,000 >>NEP ONE WOULD BE ASLEEP. 748 00:36:13,000 --> 00:36:14,400 WE'LL TAKE ANOTHER QUICK BREAK 749 00:36:14,400 --> 00:36:15,040 TO GET LUNCH. 750 00:36:15,040 --> 00:36:16,800 IF YOU ORDERED LUNCH, IT'S JUST 751 00:36:16,800 --> 00:36:19,040 AROUND THE CORNER. 752 00:36:19,040 --> 00:36:20,720 IF YOU DIDN'T ORDER LUNCH THEN I 753 00:36:20,720 --> 00:36:22,720 GUESS YOU'RE WAITING BECAUSE 754 00:36:22,720 --> 00:36:24,000 THERE ISN'T ANY PLACE FOR YOU TO 755 00:36:24,000 --> 00:36:27,680 GO AND GET IT IN THIS BUILDING 756 00:36:27,680 --> 00:36:30,720 SO, UM, WE'LL BE BACK IN FIVE 757 00:36:30,720 --> 00:36:32,360 MINUTES. 758 00:36:32,360 --> 00:36:34,040 SO THE NEXT THING ON OUR AGENDA 759 00:36:34,040 --> 00:36:37,000 THIS MORNING OR AFTERNOON NOW IS 760 00:36:37,000 --> 00:36:38,480 WE'RE GOING TO BE HEARING FROM 761 00:36:38,480 --> 00:36:40,880 THE NHLBI DIVISION OF LUNG 762 00:36:40,880 --> 00:36:42,800 DISEASES ABOUT A PROPOSED 763 00:36:42,800 --> 00:36:44,320 REORGANIZATION AND THAT WILL BE 764 00:36:44,320 --> 00:36:47,560 PRESENTED BY THE DIVISION 765 00:36:47,560 --> 00:36:48,480 DIRECTOR, DR. JIM KILEY. 766 00:36:48,480 --> 00:36:52,480 >>THANK YOU, GOOD AFTERNOON 767 00:36:52,480 --> 00:36:54,040 ALL. 768 00:36:54,040 --> 00:36:56,240 GARY SET THIS UP A BIT AND I'LL 769 00:36:56,240 --> 00:36:57,600 TRY TO BE BRIEF AND COVER THE 770 00:36:57,600 --> 00:36:59,440 KEY POINTS OF WHAT I THINK ARE 771 00:36:59,440 --> 00:37:00,440 IMPORTANT FOR US TO UNDERSTAND 772 00:37:00,440 --> 00:37:02,360 AND SERVES AS THE FIRST OF A 773 00:37:02,360 --> 00:37:03,600 COUPLE PUBLIC HEARINGS WE'RE 774 00:37:03,600 --> 00:37:04,600 HAVING RELATED TO THIS 775 00:37:04,600 --> 00:37:06,800 REORGANIZATION BECAUSE IT'S PART 776 00:37:06,800 --> 00:37:08,600 OF THE WHOLE PROCESS WITHIN THE 777 00:37:08,600 --> 00:37:11,840 GOVERNMENT TO DO CHANGES IN THE 778 00:37:11,840 --> 00:37:12,440 STRUCTURE THERE'S A LOT OF 779 00:37:12,440 --> 00:37:12,640 STEPS. 780 00:37:12,640 --> 00:37:15,640 I'LL SPARE YOU ALL THE STEPS AND 781 00:37:15,640 --> 00:37:17,160 TRY TO CUT TO THE CHASE OF WHAT 782 00:37:17,160 --> 00:37:18,480 WE'RE TRYING TO DO HERE. 783 00:37:18,480 --> 00:37:21,720 IT'S REALLY BUILT OFF TWO 784 00:37:21,720 --> 00:37:26,320 THINGS, ENVISIONING THE FUTURE 785 00:37:26,320 --> 00:37:27,680 INSTRUCTION FOR THE FUTURE OF 786 00:37:27,680 --> 00:37:29,960 LUNG DISEASES AND CAPTURE 787 00:37:29,960 --> 00:37:30,840 GROWTH. 788 00:37:30,840 --> 00:37:34,040 IT'S AN AREA THAT'S SEEN 789 00:37:34,040 --> 00:37:35,760 SUBSTANTIAL GROWTH AND WANT TO 790 00:37:35,760 --> 00:37:38,400 ALIGN OURSELVES INTERNALLY WITH 791 00:37:38,400 --> 00:37:40,080 THE EXTERNAL GROWTH THAT'S 792 00:37:40,080 --> 00:37:40,640 OCCURRING IN THE COMMUNITY. 793 00:37:40,640 --> 00:37:44,760 SO I'M GOING TO TELL YOU A BIT 794 00:37:44,760 --> 00:37:45,880 ABOUT WHERE WE'VE BEEN, WHERE WE 795 00:37:45,880 --> 00:37:47,440 ARE AND HOW TO GO FORWARD FROM 796 00:37:47,440 --> 00:37:49,200 HERE AND HOPEFULLY WE'LL GET A 797 00:37:49,200 --> 00:37:52,840 SENSE AND GET FEEDBACK FROM YOU. 798 00:37:52,840 --> 00:37:54,200 SO THIS IS THE CURRENT STRUCTURE 799 00:37:54,200 --> 00:37:56,800 THAT YOU SEE ON THE LEFT-HAND 800 00:37:56,800 --> 00:38:02,360 SIDE OF THE SLIDE WHICH IS 801 00:38:02,360 --> 00:38:04,080 REALLY THE WAY IN WHICH THE 802 00:38:04,080 --> 00:38:05,760 DIVISION HAS BEEN STRUCTURED 803 00:38:05,760 --> 00:38:07,560 OVER ABOUT THE PAST 20 YEARS. 804 00:38:07,560 --> 00:38:11,280 IT'S REALLY QUITE SIMPLE WITH 805 00:38:11,280 --> 00:38:13,200 THE OFFICE OF THE DIRECTOR PRO 806 00:38:13,200 --> 00:38:14,520 BRANCHES A LUNG BRANCH AND 807 00:38:14,520 --> 00:38:16,200 AIRWAY BRANCH THAT'S CAPTURED 808 00:38:16,200 --> 00:38:18,440 THE TOTAL OF SLEEP, PULMONARY 809 00:38:18,440 --> 00:38:20,560 AND CRITICAL CARE MEDICINE. 810 00:38:20,560 --> 00:38:23,160 THAT REALLY COVERS THE ENTIRETY 811 00:38:23,160 --> 00:38:26,200 OF THE FIELD FROM DNA MOLECULES 812 00:38:26,200 --> 00:38:27,480 UP THROUGH IMPLEMENTATION. 813 00:38:27,480 --> 00:38:29,560 NOW, ONE OF THE THINGS I PUT OUT 814 00:38:29,560 --> 00:38:32,880 THE SIDE HERE RIGHT AWAY IS THAT 815 00:38:32,880 --> 00:38:34,440 WE ARE NOT REALLY DOING ANYTHING 816 00:38:34,440 --> 00:38:37,560 AT THE PRESENT TIME TO MAKE ANY 817 00:38:37,560 --> 00:38:38,520 CHANGES TO THE NATIONAL CENTER 818 00:38:38,520 --> 00:38:40,320 ON SLEEP DISORDERS RESEARCH. 819 00:38:40,320 --> 00:38:41,960 YOU SEE THAT IN THE CURRENT 820 00:38:41,960 --> 00:38:43,040 ORGANIZATIONAL STRUCTURE BECAUSE 821 00:38:43,040 --> 00:38:45,920 AT THE PRESENT TIME IS WHERE THE 822 00:38:45,920 --> 00:38:46,400 NCSDR LANDS. 823 00:38:46,400 --> 00:38:49,760 WHY IS THAT THE CASE? 824 00:38:49,760 --> 00:38:51,400 FIRST, WE DID RESTRUCTURING OVER 825 00:38:51,400 --> 00:38:55,360 THE PAST TWO OR THREE YEARS. 826 00:38:55,360 --> 00:38:58,240 WE HAVE POINTED A NEW DIRECTOR, 827 00:38:58,240 --> 00:38:59,480 DR. BROWN HAS BEEN IN THE 828 00:38:59,480 --> 00:39:01,640 POSITION A COME YEARS NOW. 829 00:39:01,640 --> 00:39:04,720 WE ALSO DOUBLED THE SIZE OF THE 830 00:39:04,720 --> 00:39:05,720 SUPPORT STAFF AND PROGRAM HAS 831 00:39:05,720 --> 00:39:08,320 GROWN IN A WAY THAT HAS ALLOWED 832 00:39:08,320 --> 00:39:11,080 IT TO EXPAND INTO THE AREAS THAT 833 00:39:11,080 --> 00:39:12,640 ARE REQUIRED THROUGH ITS 834 00:39:12,640 --> 00:39:13,840 LEGISLATIVE MANDATE. 835 00:39:13,840 --> 00:39:15,160 SO WE DON'T BELIEVE AT THE 836 00:39:15,160 --> 00:39:17,160 PRESENT TIME WE NEED TO MAKE 837 00:39:17,160 --> 00:39:22,480 MUCH IN TERMS OF CHANGES TO THE 838 00:39:22,480 --> 00:39:23,360 OVER ALL CENTER. 839 00:39:23,360 --> 00:39:27,280 WE THINK IT IS OPTIMALLY 840 00:39:27,280 --> 00:39:29,520 FULFILLING THE CONGRESSIONAL 841 00:39:29,520 --> 00:39:31,280 MANDATE AND AS THE FULL SUPPORT 842 00:39:31,280 --> 00:39:34,920 OF NHLBI LEADERSHIP TO DO SO AND 843 00:39:34,920 --> 00:39:35,880 IS IN GOOD SHAPE. 844 00:39:35,880 --> 00:39:38,360 YOU CAN SEE WHERE THE FOCUS 845 00:39:38,360 --> 00:39:40,440 NEEDS TO BE NOW IS ON PULMONARY 846 00:39:40,440 --> 00:39:41,560 AND CRITICAL CARE RESEARCH. 847 00:39:41,560 --> 00:39:43,440 WE NEED TO MAKE THESE A LITTLE 848 00:39:43,440 --> 00:39:48,280 BIT MORE GRANULAR IN TERMS OF 849 00:39:48,280 --> 00:39:51,760 WHERE THESE AREAS ARE -- WHAT IS 850 00:39:51,760 --> 00:39:53,280 ENCOMPASSED WITHIN THE AREAS. 851 00:39:53,280 --> 00:39:54,480 AND THERE'S SIGNIFICANT GROWTH 852 00:39:54,480 --> 00:39:57,560 IN THESE TWO BRANCHES AND THE 853 00:39:57,560 --> 00:39:59,720 GROWTH HAS BEEN IN TERMS OF THE 854 00:39:59,720 --> 00:40:01,560 NUMBER AND THE VALUE OF GRANT 855 00:40:01,560 --> 00:40:03,480 AWARDS AND CONTRACTS AS WELL AS 856 00:40:03,480 --> 00:40:04,520 THE SIZE OF THE DIVISION. 857 00:40:04,520 --> 00:40:06,360 THE INSTITUTE'S BEEN VERY 858 00:40:06,360 --> 00:40:07,680 GENEROUS IN TERMS OF STAFFING 859 00:40:07,680 --> 00:40:09,440 THE DIVISION. 860 00:40:09,440 --> 00:40:11,960 WE'VE HAD ALMOST A 50% BROTHER 861 00:40:11,960 --> 00:40:18,560 OVER THE PAST FOUR OR FIVE YEARS 862 00:40:18,560 --> 00:40:21,160 PARALLEL A SUBSTANTIAL INCREASE 863 00:40:21,160 --> 00:40:23,400 AND THESE ARE AREAS WITHIN LUNG, 864 00:40:23,400 --> 00:40:26,360 PULMONARY AND CRITICAL CARE 865 00:40:26,360 --> 00:40:27,720 MEDICINE EMERGING AND THERE ARE 866 00:40:27,720 --> 00:40:30,560 SOME CHALLENGES IN TERMS OF 867 00:40:30,560 --> 00:40:32,760 BEING ABLE TO COVER THE BREADTH 868 00:40:32,760 --> 00:40:34,320 OF THE FIELD RIGHT NOW. 869 00:40:34,320 --> 00:40:35,840 SO THERE'S A LOT OF -- I SAID 870 00:40:35,840 --> 00:40:38,360 THIS ALREADY INCREASING VOLUME 871 00:40:38,360 --> 00:40:41,880 OF RESEARCH. 872 00:40:41,880 --> 00:40:44,640 THERE'S LIMITED REPRESENTATION 873 00:40:44,640 --> 00:40:49,760 IT FALLS INTO A BIG BUCKET. 874 00:40:49,760 --> 00:40:50,880 AND FINALLY THERE'S LIMITED 875 00:40:50,880 --> 00:40:53,160 POTENTIAL FOR PROMOTION, 876 00:40:53,160 --> 00:40:54,320 RETENTION AND OPPORTUNITIES THAT 877 00:40:54,320 --> 00:40:57,080 REALLY ALLOW STAFF TO GROW AND 878 00:40:57,080 --> 00:40:59,800 DEVELOP WITHIN THE BRANCH AND 879 00:40:59,800 --> 00:41:00,480 THE INSTITUTE. 880 00:41:00,480 --> 00:41:02,240 AS YOU'VE SEEN WE'VE BEGIN IN 881 00:41:02,240 --> 00:41:03,400 THE PAST YEAR BUILDING OUT THE 882 00:41:03,400 --> 00:41:05,280 WHOLE NEW STRUCTURE. 883 00:41:05,280 --> 00:41:07,080 WE HAVE A WHOLE NEW LEADERSHIP 884 00:41:07,080 --> 00:41:12,600 TEAM AND EXCITED TO HAVE GUS AND 885 00:41:12,600 --> 00:41:14,360 SAMIDA JOIN US AS PART OF THE 886 00:41:14,360 --> 00:41:17,080 LEADERSHIP TEAM AND APPOINTED A 887 00:41:17,080 --> 00:41:18,520 BRANCH CHIEF AND DR. CRAIG IN 888 00:41:18,520 --> 00:41:20,320 THE LUNG BRANCH AND A MENTIONED 889 00:41:20,320 --> 00:41:21,720 DR. BROWN RECENTLY APPOINTED 890 00:41:21,720 --> 00:41:23,560 ADDS THE HEAD OF THE DIRECTOR OF 891 00:41:23,560 --> 00:41:24,400 THE SLEEP CENTER. 892 00:41:24,400 --> 00:41:26,000 YOU CAN SEE THE OVER ALL 893 00:41:26,000 --> 00:41:26,680 LEADERSHIP OF THE DIVISION IS 894 00:41:26,680 --> 00:41:29,680 ALSO CHANGING. 895 00:41:29,680 --> 00:41:32,840 SO LET ME JUST SHOW YOU WHAT THE 896 00:41:32,840 --> 00:41:35,640 PROPOSED DLD BRANCH EXPANSION 897 00:41:35,640 --> 00:41:37,120 LOOKS LIKE AND MAYBE TO QUELL 898 00:41:37,120 --> 00:41:38,560 ANYBODY'S FEARS WE'RE NOT TAKING 899 00:41:38,560 --> 00:41:40,440 OVER THE INSTITUTE. 900 00:41:40,440 --> 00:41:46,400 THIS IS A MODEST, I THINK, 901 00:41:46,400 --> 00:41:48,280 EXPANSION BUT IT IS AN EXPANSION 902 00:41:48,280 --> 00:41:52,160 AND WE'RE GOING FROM TWO 903 00:41:52,160 --> 00:41:53,920 BRANCHES TO FOUR BRANCHES AND WE 904 00:41:53,920 --> 00:41:55,960 BELIEVE THIS ALIGNMENT IS REALLY 905 00:41:55,960 --> 00:41:56,840 DRIVEN BY THE SCIENCE. 906 00:41:56,840 --> 00:42:00,560 IT'S REALLY DESIGN TO HAVE THE 907 00:42:00,560 --> 00:42:01,960 MOST COHESIVE SCIENTIFIC 908 00:42:01,960 --> 00:42:02,200 ALIGNMENT. 909 00:42:02,200 --> 00:42:03,640 THE NEW STRUCTURE, AS YOU CAN 910 00:42:03,640 --> 00:42:08,000 SEE HERE, WILL ALIGN WITH THESE 911 00:42:08,000 --> 00:42:09,040 FIVE UNITS WITHIN THE DIVISION 912 00:42:09,040 --> 00:42:11,640 AND THE BENEFITS OF THIS IT WILL 913 00:42:11,640 --> 00:42:13,560 INCREASE SCIENTIFIC FOCUS ON THE 914 00:42:13,560 --> 00:42:15,520 PROGRAM AREAS WITHIN THE BRANCH. 915 00:42:15,520 --> 00:42:17,560 IT GIVES MORE REPRESENTATION OF 916 00:42:17,560 --> 00:42:19,320 THE RESEARCH PROGRAMS INCLUDING 917 00:42:19,320 --> 00:42:22,360 AT THE LEADERSHIP LEVEL. 918 00:42:22,360 --> 00:42:24,400 IT INCREASES THE ADMINISTRATIVE 919 00:42:24,400 --> 00:42:25,880 FOCUS SO THE BRANCH CHIEFS DO 920 00:42:25,880 --> 00:42:27,320 NOT HAVE QUITE AS MANY DIRECT 921 00:42:27,320 --> 00:42:30,560 REPORTS THEY HAVE TO 922 00:42:30,560 --> 00:42:34,280 CONTINUOUSLY USE THEIR TIME TO 923 00:42:34,280 --> 00:42:36,680 DEVELOP, PROMOTE PROFESSIONAL 924 00:42:36,680 --> 00:42:38,360 DEVELOPMENT AND PROMOTION 925 00:42:38,360 --> 00:42:39,000 OPPORTUNITIES FOR BOTH WITHIN 926 00:42:39,000 --> 00:42:40,720 AND OUTSIDE THE DIVISION AND 927 00:42:40,720 --> 00:42:41,200 INSTITUTE. 928 00:42:41,200 --> 00:42:43,480 SO THE STRUCTURE IS REALLY BUILT 929 00:42:43,480 --> 00:42:45,840 TO GROW TO GO WHERE THE SCIENCE 930 00:42:45,840 --> 00:42:50,360 IS GOING AND TO RETAIN DIVISION 931 00:42:50,360 --> 00:42:51,280 IDENTITY. 932 00:42:51,280 --> 00:42:55,960 WHY THE FOUR BRANCHES IN THE 933 00:42:55,960 --> 00:42:56,160 NCSDR? 934 00:42:56,160 --> 00:42:57,960 I THOUGHT THIS WOULD BE A QUICK 935 00:42:57,960 --> 00:42:59,600 WAY TO GIVE YOU A SENSE OF WHAT 936 00:42:59,600 --> 00:43:01,040 WE ENVISION FALLING WITHIN THE 937 00:43:01,040 --> 00:43:03,560 FIVE BRANCHES IN TERMS OF THE 938 00:43:03,560 --> 00:43:03,960 OVER ALL SCIENCE. 939 00:43:03,960 --> 00:43:07,080 THIS IS A HIGH-LEVEL BREAKDOWN 940 00:43:07,080 --> 00:43:08,360 OF THE PROGRAMS THAT FALL UNDER 941 00:43:08,360 --> 00:43:09,800 EACH BRANCH. 942 00:43:09,800 --> 00:43:12,240 THEY'RE RELATED RESEARCH IS 943 00:43:12,240 --> 00:43:12,480 PAIRED. 944 00:43:12,480 --> 00:43:16,480 IT'S NOT PERFECT BUT IT ALLOWS 945 00:43:16,480 --> 00:43:19,720 US TO ALIGN DISEASED AREAS WITH 946 00:43:19,720 --> 00:43:20,640 DISEASE AGNOSTIC AREAS AS WELL 947 00:43:20,640 --> 00:43:22,040 AS BEING ABLE TO MEET SOME OF 948 00:43:22,040 --> 00:43:23,800 THE ADMINISTRATIVE REQUIREMENTS 949 00:43:23,800 --> 00:43:25,960 THAT WE NEED TO ALSO ADHERE TO 950 00:43:25,960 --> 00:43:27,880 IN ANY KIND OF RESTRUCTURING. 951 00:43:27,880 --> 00:43:29,960 I WON'T GO THROUGH ALL THIS BUT 952 00:43:29,960 --> 00:43:33,160 FOR MOST OF YOU CAN SEE IT HAS A 953 00:43:33,160 --> 00:43:34,800 RELATIVELY LOGICAL FLOW TO IT. 954 00:43:34,800 --> 00:43:36,960 THE TWO NEW THINGS YOU'LL SEE AS 955 00:43:36,960 --> 00:43:41,360 A BRANCH THAT REVEALS RESTR 956 00:43:41,360 --> 00:43:46,480 RESTRICTIVE AND VASCULAR LUNG 957 00:43:46,480 --> 00:43:53,040 DISEASES GROWINGLY AND -- 958 00:43:53,040 --> 00:43:56,360 GROWING RAPIDLY AND LUNG 959 00:43:56,360 --> 00:43:58,400 DISEASES AND RESTRICTIVE AND 960 00:43:58,400 --> 00:44:00,920 VASCULAR LUNG DISEASES AND WE 961 00:44:00,920 --> 00:44:03,200 THINK THEY'RE A NICE WAY TO MAKE 962 00:44:03,200 --> 00:44:05,200 SENSE STRATEGICALLY AND 963 00:44:05,200 --> 00:44:08,360 IMPLEMENTABLE TO MAKE THIS REAL 964 00:44:08,360 --> 00:44:10,280 ALL SUBMITTING GRANT 965 00:44:10,280 --> 00:44:11,560 APPLICATIONS AND WANTED TO KNOW 966 00:44:11,560 --> 00:44:14,160 WHO TO TALK TO ABOUT YOUR 967 00:44:14,160 --> 00:44:15,320 PARTICULAR AREA OF RESEARCH. 968 00:44:15,320 --> 00:44:18,880 ALSO IMPORTANT IN ALL THIS IS 969 00:44:18,880 --> 00:44:20,760 THE DIVISION MAINTAINS SOME 970 00:44:20,760 --> 00:44:22,480 DIVISION-WIDE IDENTITY BUT 971 00:44:22,480 --> 00:44:24,520 THERE'S A LOT OF CROSS-TALK THAT 972 00:44:24,520 --> 00:44:27,440 WILL OCCUR WITHIN THE BRANCHES 973 00:44:27,440 --> 00:44:29,720 AND WITHIN THE DIVISION AND A 974 00:44:29,720 --> 00:44:33,440 LOT OF RELATIONSHIPS CAN BE 975 00:44:33,440 --> 00:44:36,760 BUILT OF THE INTERACTIONS ACROSS 976 00:44:36,760 --> 00:44:40,040 DLD AND ACROSS THE INSTITUTE. 977 00:44:40,040 --> 00:44:40,800 WHERE ARE WE NOW? 978 00:44:40,800 --> 00:44:42,680 WE WANT TO USE THE MEETING TODAY 979 00:44:42,680 --> 00:44:45,480 AS A WAY TO INFORM THE COMMUNITY 980 00:44:45,480 --> 00:44:47,440 ABOUT THE RESTRUCTURING OF THE 981 00:44:47,440 --> 00:44:47,720 DIVISION. 982 00:44:47,720 --> 00:44:49,680 WE WANT TO HEAR BACK FROM YOU AS 983 00:44:49,680 --> 00:44:51,240 COUNCIL MEMBERS AND THE PUBLIC 984 00:44:51,240 --> 00:44:53,120 ON WHAT YOU THINK ABOUT THIS. 985 00:44:53,120 --> 00:44:55,720 WE'LL ALSO, TOMORROW, HAVE A 986 00:44:55,720 --> 00:44:58,480 TWITTER ENGAGEMENT THAT WILL 987 00:44:58,480 --> 00:45:02,480 WORK WITH OUR COLLEAGUES IN 988 00:45:02,480 --> 00:45:04,520 OSPEEC TO HELP BROADCAST THIS 989 00:45:04,520 --> 00:45:08,120 MORE BROADLY AND THE SECOND OVER 990 00:45:08,120 --> 00:45:09,920 ALL HEARING AS OUR REQUIRED 991 00:45:09,920 --> 00:45:15,360 STEPS IN THE PROCESS AND HAVE A 992 00:45:15,360 --> 00:45:19,360 DLD REORG REEVENTS PAGE AND 993 00:45:19,360 --> 00:45:22,120 WE'LL PUT THESE IN A FINAL 994 00:45:22,120 --> 00:45:24,920 PACKAGE TO NIH FOR APPROVAL. 995 00:45:24,920 --> 00:45:27,040 WE HOPE IT WILL MOF ALONG 996 00:45:27,040 --> 00:45:29,080 RELATIVELY QUICKLY BUT MAY TAKE 997 00:45:29,080 --> 00:45:34,280 UP TO 12 MORE MONTHS TO 998 00:45:34,280 --> 00:45:44,480 COMPLETE. 999 00:45:56,480 --> 00:46:01,480 I'LL BE HAPPY TO TAKE QUESTIONS 1000 00:46:01,480 --> 00:46:02,840 AND THANK YOU FOR YOUR ATTENTION 1001 00:46:02,840 --> 00:46:03,640 AND CONSIDERATION OF THE 1002 00:46:03,640 --> 00:46:14,080 REORGANIZATION PROPOSAL. 1003 00:46:16,080 --> 00:46:18,480 >>THIS IS THE RIGHT THING TO DO 1004 00:46:18,480 --> 00:46:19,280 AND FORWARD LEANING. 1005 00:46:19,280 --> 00:46:21,360 YOU COMMENTED HOW THE BUCKETS OF 1006 00:46:21,360 --> 00:46:23,560 DIFFERENT TOPICS WILL GO IN AND 1007 00:46:23,560 --> 00:46:28,440 FOUR DIFFERENT BRANCHES. 1008 00:46:28,440 --> 00:46:30,440 COULD YOU MAYBE EXPAND HOW A 1009 00:46:30,440 --> 00:46:34,240 CROSS-FUNCTIONAL HYPOTHESIS FOR 1010 00:46:34,240 --> 00:46:37,240 A GRANT SAY STEM CELLS AND COPD 1011 00:46:37,240 --> 00:46:39,560 TWO DIFFERENT SUBSECTIONS 1012 00:46:39,560 --> 00:46:40,720 BECAUSE IT'S SOMETHING IN MY OWN 1013 00:46:40,720 --> 00:46:42,160 PERSONAL EXPERIENCE AND OTHER 1014 00:46:42,160 --> 00:46:43,240 PEOPLE I KNOW HAD ISSUES WITH 1015 00:46:43,240 --> 00:46:43,480 THAT. 1016 00:46:43,480 --> 00:46:50,840 HOW DO YOU GET THE RIGHT PEOPLE 1017 00:46:50,840 --> 00:46:54,360 THAT WILL FOCUS ON THE TOPIC AND 1018 00:46:54,360 --> 00:46:57,200 HOW THAT WILL CROSS SECTION WILL 1019 00:46:57,200 --> 00:46:57,480 HAPPEN. 1020 00:46:57,480 --> 00:47:05,640 >>YOU SAW THE VERTICAL VIEW OF 1021 00:47:05,640 --> 00:47:06,200 THE DIVISION. 1022 00:47:06,200 --> 00:47:09,360 THERE'S ALSO A HORIZONTAL 1023 00:47:09,360 --> 00:47:13,680 COMPONENT AND IN TRANSLATIONAL, 1024 00:47:13,680 --> 00:47:15,240 FUNCTIONAL GENOMICS AND THREE OR 1025 00:47:15,240 --> 00:47:18,480 FOUR WE'VE IDENTIFIED WE THINK 1026 00:47:18,480 --> 00:47:20,360 WILL CUT -- THEY DON'T FIT 1027 00:47:20,360 --> 00:47:25,920 NICELY INTO ONE OF THE VERTICAL. 1028 00:47:25,920 --> 00:47:27,560 WE HOPE THE STAFF WILL PROMOTE 1029 00:47:27,560 --> 00:47:30,640 AND MAKE SURE THE SCIENCE YOU'RE 1030 00:47:30,640 --> 00:47:32,000 TALKING ABOUT RELATED TO STEM 1031 00:47:32,000 --> 00:47:33,760 CELLS, LUNG DEVELOPMENT AND 1032 00:47:33,760 --> 00:47:37,400 MAYBE PROGRESSION TO DISEASE 1033 00:47:37,400 --> 00:47:39,200 WILL ALL MAKE SURE THAT HAS A 1034 00:47:39,200 --> 00:47:40,680 NATURAL HOME AND GIVEN THE 1035 00:47:40,680 --> 00:47:42,080 ATTENTION WE THINK IT DESERVES. 1036 00:47:42,080 --> 00:47:44,800 THAT'S THE KEY PIECE I THINK YOU 1037 00:47:44,800 --> 00:47:47,200 RAISED IS MAKING SURE THAT THOSE 1038 00:47:47,200 --> 00:47:49,280 AREAS DON'T GET LOST OR ORPHANED 1039 00:47:49,280 --> 00:47:50,440 IN THE WHOLE PROCESS. 1040 00:47:50,440 --> 00:47:51,880 RIGHT NOW SOMEBODY WILL CALL UP 1041 00:47:51,880 --> 00:47:54,040 AND SAY I WANT TO DO THAT KIND 1042 00:47:54,040 --> 00:47:56,920 OF RESEARCH, WELL, WHERE DOES IT 1043 00:47:56,920 --> 00:47:57,920 FALL? 1044 00:47:57,920 --> 00:47:59,720 WHERE DOES IT FALL WITHIN THE 1045 00:47:59,720 --> 00:48:00,000 INSTITUTE. 1046 00:48:00,000 --> 00:48:01,520 WE WANT TO GIVE IT MORE CLARITY. 1047 00:48:01,520 --> 00:48:06,680 THANK YOU, GOOD QUESTION. 1048 00:48:06,680 --> 00:48:09,440 >>DR. SOL FIRST AND THEN 1049 00:48:09,440 --> 00:48:09,720 DR. ENBAR. 1050 00:48:09,720 --> 00:48:10,440 >>THANK YOU. 1051 00:48:10,440 --> 00:48:18,720 I JUST WANTED TO CONGRATULATE 1052 00:48:18,720 --> 00:48:20,280 YOU AND THE AREA IS WONDERFUL 1053 00:48:20,280 --> 00:48:23,280 AND IMPORTANT IN RESEARCH AND 1054 00:48:23,280 --> 00:48:30,120 WILL OFFER OPPORTUNITIES TO ALSO 1055 00:48:30,120 --> 00:48:31,680 PROGRAMMATICALLY WORK ACROSS 1056 00:48:31,680 --> 00:48:36,840 INSTITUTES WITH PEDIATRIC LUNG 1057 00:48:36,840 --> 00:48:38,400 DISEASE AND I DON'T KNOW IF 1058 00:48:38,400 --> 00:48:40,760 THERE'S PRELIMINARY THOUGHTS 1059 00:48:40,760 --> 00:48:42,400 ABOUT THAT BUT WOULD CERTAINLY 1060 00:48:42,400 --> 00:48:45,080 OPEN THE DOOR TO 1061 00:48:45,080 --> 00:48:47,200 ACROSS-INSTITUTE INITIATIVES 1062 00:48:47,200 --> 00:48:49,840 LIKE SOME IN THE BLOOD DISEASES 1063 00:48:49,840 --> 00:48:50,120 DIVISION. 1064 00:48:50,120 --> 00:48:51,280 >>GREAT, THANK YOU. 1065 00:48:51,280 --> 00:48:52,720 ANOTHER GREAT COMMENT. 1066 00:48:52,720 --> 00:48:56,120 WE ALREADY HAVE QUITE A FEW 1067 00:48:56,120 --> 00:48:58,280 INTERACTIONS WITH NICHD, FOR 1068 00:48:58,280 --> 00:49:00,680 INSTANCE, IN TERMS OF MATERNAL 1069 00:49:00,680 --> 00:49:03,920 HEALTH AND PREMATURITY AND HAVE 1070 00:49:03,920 --> 00:49:07,640 NETWORKS THEY INTERACTED WITH IN 1071 00:49:07,640 --> 00:49:11,040 TERMS OF PEDIATRIC LUNG DISEASES 1072 00:49:11,040 --> 00:49:12,400 AS WELL AS SLEEP. 1073 00:49:12,400 --> 00:49:15,760 THE NEW MOMS-TO-BE STUDY HAS A 1074 00:49:15,760 --> 00:49:17,000 BIG SLEEP COMPONENT IN IT AND 1075 00:49:17,000 --> 00:49:19,200 COMPLETED THE PREGNANCY PART OF 1076 00:49:19,200 --> 00:49:19,440 THIS. 1077 00:49:19,440 --> 00:49:21,000 SPOT ON. 1078 00:49:21,000 --> 00:49:22,760 THESE ARE AREAS WE CAN CONTINUE 1079 00:49:22,760 --> 00:49:24,680 TO BUILD OFF OF AND PUTTING THE 1080 00:49:24,680 --> 00:49:25,920 IDENTITY ON PEDIATRICS WILL 1081 00:49:25,920 --> 00:49:28,200 ALLOW US TO DO THAT IN A MORE 1082 00:49:28,200 --> 00:49:28,920 FORMAL WAY. 1083 00:49:28,920 --> 00:49:30,720 WE HAVE ABSOLUTELY FABULOUS 1084 00:49:30,720 --> 00:49:33,720 STAFF WE RECRUITED OVER THE PAST 1085 00:49:33,720 --> 00:49:36,520 FEW YEARS WHO HAVE EXPERTISE IN 1086 00:49:36,520 --> 00:49:37,680 PEDIATRICS AND LUNG DEVELOPMENT 1087 00:49:37,680 --> 00:49:39,440 AND PEDIATRIC CRITICAL CARE. 1088 00:49:39,440 --> 00:49:40,880 AND THESE ARE ALL GROWTH AREAS 1089 00:49:40,880 --> 00:49:42,320 AS WE SEE FOR THE FUTURE. 1090 00:49:42,320 --> 00:49:44,160 WE'RE EXCITED THIS. 1091 00:49:44,160 --> 00:49:50,760 THANK YOU FOR YOUR COMMENT. 1092 00:49:50,760 --> 00:49:52,560 >>I LIKE THE STRUCTURE. 1093 00:49:52,560 --> 00:49:55,880 I THINK IT'S GREAT FOR THE 1094 00:49:55,880 --> 00:49:56,640 REASONS YOU CITE. 1095 00:49:56,640 --> 00:49:59,360 I'M GOING TO ECHO BOTH THE LAST 1096 00:49:59,360 --> 00:50:00,400 TWO COMMENTS. 1097 00:50:00,400 --> 00:50:02,040 ONE QUESTION I HAVE AS YOU 1098 00:50:02,040 --> 00:50:04,480 REPRESENTED THIS, HOW DO YOU 1099 00:50:04,480 --> 00:50:08,080 BRING TOGETHER THE PREVENTION 1100 00:50:08,080 --> 00:50:09,880 POPULATION ISSUES IN 1101 00:50:09,880 --> 00:50:10,560 CAULAR ROUTE BUT IT 1102 00:50:10,560 --> 00:50:12,200 SOUNDS LIKE ACROSS CUT ON THAT 1103 00:50:12,200 --> 00:50:12,440 ONE. 1104 00:50:12,440 --> 00:50:15,280 >>THAT'S ANOTHER ONE THAT IS 1105 00:50:15,280 --> 00:50:15,600 CROSS-CUTTING. 1106 00:50:15,600 --> 00:50:18,160 >>THAT INTERFACES WITH THE 1107 00:50:18,160 --> 00:50:18,920 HEART PROGRAM. 1108 00:50:18,920 --> 00:50:20,840 WE'VE DONE QUITE A BIT IN THE 1109 00:50:20,840 --> 00:50:22,160 LAST FEW YEARS. 1110 00:50:22,160 --> 00:50:25,200 YOU HEARD ABOUT LUNG HEALTH AND 1111 00:50:25,200 --> 00:50:25,800 HAD INITIATIVES TOGETHER. 1112 00:50:25,800 --> 00:50:28,680 YOU POINTED OUT THE ASIAN 1113 00:50:28,680 --> 00:50:30,440 INITIATIVE THAT WILL LAUNCH, 1114 00:50:30,440 --> 00:50:32,240 HEART, LUNG, BLOOD, SLEEP. 1115 00:50:32,240 --> 00:50:34,080 I THINK WE DON'T WANT TO JUST 1116 00:50:34,080 --> 00:50:36,440 PUT A DIVISION IN PLACE THAT ARE 1117 00:50:36,440 --> 00:50:38,480 PART OF THEE D THAT IS A 1118 00:50:38,480 --> 00:50:41,880 SHARED KIND OF AREA AND THE 1119 00:50:41,880 --> 00:50:43,520 EXPERTISE REALLY THE STRONG 1120 00:50:43,520 --> 00:50:44,760 EXPERTISE IS IN THE HEART 1121 00:50:44,760 --> 00:50:45,000 PROGRAM. 1122 00:50:45,000 --> 00:50:47,720 TO LEVERAGE THAT 1123 00:50:47,720 --> 00:50:47,960 EXPERTISE. 1124 00:50:47,960 --> 00:50:49,600 >>THE OTHER GENERAL COMMENT IN 1125 00:50:49,600 --> 00:50:51,800 TERMS OF LINKAGES TO OTHER 1126 00:50:51,800 --> 00:50:53,920 INSTITUTES AND CENTERS IS I 1127 00:50:53,920 --> 00:50:55,800 THINK FROM A COMMUNITY 1128 00:50:55,800 --> 00:51:00,280 PERSPECTIVE, CRITICAL CARE A 1129 00:51:00,280 --> 00:51:04,120 WHERE DO CERTAIN ASPECTS COME 1130 00:51:04,120 --> 00:51:06,400 ALONG AND SOME OTHER PIECES 1131 00:51:06,400 --> 00:51:09,360 OVERLAP SEPSIS AND IS THE 1132 00:51:09,360 --> 00:51:10,880 CRITICAL CARE ISSUES WITH 1133 00:51:10,880 --> 00:51:11,720 LONG-TERM OUTCOMES HASN'T REALLY 1134 00:51:11,720 --> 00:51:14,440 HAD A DEFINED HOME WITHIN NIH. 1135 00:51:14,440 --> 00:51:17,320 SO I THINK THERE'S A LOT OF 1136 00:51:17,320 --> 00:51:19,720 POTENTIAL HERE FOR GROWING THAT 1137 00:51:19,720 --> 00:51:22,800 AND I THINK THOSE ISSUES ARE 1138 00:51:22,800 --> 00:51:23,080 IMPORTANT. 1139 00:51:23,080 --> 00:51:25,600 I THINK THIS IS A MAJOR STEP 1140 00:51:25,600 --> 00:51:25,880 FORWARD. 1141 00:51:25,880 --> 00:51:26,920 >>THANKS, DAVID. 1142 00:51:26,920 --> 00:51:29,880 I THINK THE ONE BRANCH, THE 1143 00:51:29,880 --> 00:51:33,960 ACUTE AND INFECTIOUS LUNG 1144 00:51:33,960 --> 00:51:36,160 DISEASE BRANCH WE HAVE DONE A 1145 00:51:36,160 --> 00:51:37,760 LOT TO GET THAT WORKED OUT IN 1146 00:51:37,760 --> 00:51:40,840 TERMS OF ASSIGNMENTS. 1147 00:51:40,840 --> 00:51:43,080 WE HAVE PROGRAMS IN TERMS OF 1148 00:51:43,080 --> 00:51:43,480 BASIC CLINICAL. 1149 00:51:43,480 --> 00:51:44,680 WE'RE MAKING PROGRESS. 1150 00:51:44,680 --> 00:51:46,480 IN TERMS OF THE SEPSIS COMMUNITY 1151 00:51:46,480 --> 00:51:48,080 THEY KNOW WHERE TO GO. 1152 00:51:48,080 --> 00:51:49,680 I THINK THEY KNOW NOW WHERE TO 1153 00:51:49,680 --> 00:51:49,840 GO. 1154 00:51:49,840 --> 00:51:51,760 IT'S TAKEN A WHILE TO GET THERE 1155 00:51:51,760 --> 00:51:53,320 BUT THEY KNOW WHERE TO MAKE THE 1156 00:51:53,320 --> 00:51:53,600 CALL. 1157 00:51:53,600 --> 00:51:56,120 I THINK WE CAN FIND THE RIGHT 1158 00:51:56,120 --> 00:51:58,760 HOME FOR THEM FAIRLY QUICKLY AND 1159 00:51:58,760 --> 00:51:59,280 LOGICALLY. 1160 00:51:59,280 --> 00:52:00,880 WE'RE EXCITE ABOUT THAT AS WELL. 1161 00:52:00,880 --> 00:52:03,480 I THINK WE CAN GET THIS TO PLAY 1162 00:52:03,480 --> 00:52:05,840 OUT IN A WAY THAT WORKS FOR ALL. 1163 00:52:05,840 --> 00:52:08,200 >>THANK YOU AND 1164 00:52:08,200 --> 00:52:08,600 CONGRATULATIONS. 1165 00:52:08,600 --> 00:52:09,400 >>THANKS. 1166 00:52:09,400 --> 00:52:11,000 >>THANK YOU, DR. KILEY. 1167 00:52:11,000 --> 00:52:13,840 I'M NOT SEEING ANY OTHER RAISED 1168 00:52:13,840 --> 00:52:15,360 BUT SURE YOU'LL GET COMMENTS 1169 00:52:15,360 --> 00:52:16,680 TOMORROW MAYBE AT YOUR TWITTER 1170 00:52:16,680 --> 00:52:19,720 SESSION AND OTHER ASPECTS OF 1171 00:52:19,720 --> 00:52:22,800 THIS YOU PLANNED. 1172 00:52:22,800 --> 00:52:24,120 NEXT, WHAT WE'VE GOT ON THE 1173 00:52:24,120 --> 00:52:26,520 AGENDA IS OUR SPEAKER FOR THE 1174 00:52:26,520 --> 00:52:29,960 DIVISION OF INTRAMURAL RESEARCH, 1175 00:52:29,960 --> 00:52:32,520 DR. SEAN AGBOR-ENOH. 1176 00:52:32,520 --> 00:52:35,240 HE RECEIVED HIS DEGREE FROM 1177 00:52:35,240 --> 00:52:37,040 UNIVERSITY OF CAMEROON AND 1178 00:52:37,040 --> 00:52:39,640 GEORGETOWN AND WAS A CHIEF 1179 00:52:39,640 --> 00:52:41,200 RESIDENT AT JOHNS HOPKINS AND 1180 00:52:41,200 --> 00:52:43,720 HAD A JOINT FELLOWSHIP IN 1181 00:52:43,720 --> 00:52:45,840 PULMONARY AND CRITICAL AREA 1182 00:52:45,840 --> 00:52:49,320 ATTAT 1183 00:52:49,320 --> 00:52:53,840 JOHNS HOPKINS AND IS A TENURE 1184 00:52:53,840 --> 00:52:55,720 TRACK INVESTIGATOR AT NHLBI AND 1185 00:52:55,720 --> 00:52:57,120 HIS RESEARCH AIMS TO IDENTIFY 1186 00:52:57,120 --> 00:52:59,520 NOVEL APPROACHES TO DETECT AND 1187 00:52:59,520 --> 00:53:00,920 TREAT TRANSPLANT REJECTION. 1188 00:53:00,920 --> 00:53:04,120 A MAJOR COMPLICATION THAT 1189 00:53:04,120 --> 00:53:06,160 CONTRIBUTES TO THE UNUSUALLY 1190 00:53:06,160 --> 00:53:07,800 HIGH MORTALITY IN LUNG 1191 00:53:07,800 --> 00:53:09,280 TRANSPLANT PATIENTS. 1192 00:53:09,280 --> 00:53:11,800 A VERY SAD THING INDEED. 1193 00:53:11,800 --> 00:53:13,320 HE LEADS A MULTI-CENTER 1194 00:53:13,320 --> 00:53:15,560 CONSORTIUM AND ALLIANCE FOR 1195 00:53:15,560 --> 00:53:17,880 TRANSPLANTATION, GRAFT, TO 1196 00:53:17,880 --> 00:53:22,400 PROVIDE A PATIENT COHORT AND 1197 00:53:22,400 --> 00:53:23,480 RESEARCH INFRASTRUCTURE FOR HIS 1198 00:53:23,480 --> 00:53:24,320 RESEARCH. 1199 00:53:24,320 --> 00:53:26,840 HIS WORK DEMONSTRATES THE NOVEL 1200 00:53:26,840 --> 00:53:29,560 BLOOD TESTS, CELL-FREE DNA 1201 00:53:29,560 --> 00:53:31,480 REJECTION EARLIER THAN THE 1202 00:53:31,480 --> 00:53:33,840 INVASIVE GOLD STANDARD THE 1203 00:53:33,840 --> 00:53:40,000 BIOPSY AND THE CELL TEST HAS 1204 00:53:40,000 --> 00:53:43,040 BEEN ADOPTED INTO ROUTINE 1205 00:53:43,040 --> 00:53:44,880 CENTERS TO PREDICT REJECTION AND 1206 00:53:44,880 --> 00:53:47,680 SHIFTS TO REDEFINE ACUTE 1207 00:53:47,680 --> 00:53:48,760 REJECTION TO IDENTIFY BETTER 1208 00:53:48,760 --> 00:53:49,320 TREATMENT OPPORTUNITIES. 1209 00:53:49,320 --> 00:53:51,800 HIS MECHANISTIC STUDIES IDENTIFY 1210 00:53:51,800 --> 00:53:57,520 BETTER DRUG TARGETS FOR ACUTE 1211 00:53:57,520 --> 00:53:57,800 REJECTION. 1212 00:53:57,800 --> 00:53:59,120 HE'S PLANNING CLINICAL TRIALS TO 1213 00:53:59,120 --> 00:54:03,040 TEST THE BENEFIT. 1214 00:54:03,040 --> 00:54:05,800 IT'S WORTH NOTING HE'S RECEIVED 1215 00:54:05,800 --> 00:54:06,480 RECOGNITION NATIONALLY AND 1216 00:54:06,480 --> 00:54:07,720 INTERNATIONALLY AND NAMED ONE OF 1217 00:54:07,720 --> 00:54:09,440 THE 1,000 INSPIRING BLACK 1218 00:54:09,440 --> 00:54:11,760 SCIENTISTS IN AMERICA IN 2020. 1219 00:54:11,760 --> 00:54:13,960 HE'S ALSO BEEN INDUCTED INTO THE 1220 00:54:13,960 --> 00:54:16,400 AMERICAN SOCIETY OF CLINICAL 1221 00:54:16,400 --> 00:54:18,640 INVESTIGATOR IN 2023 AND RECEIVE 1222 00:54:18,640 --> 00:54:22,360 THE 2021 JAMES T WILL ARSON 1223 00:54:22,360 --> 00:54:25,080 AWARD FOR THE BEST MANUSCRIPT 1224 00:54:25,080 --> 00:54:26,800 PUBLISHED IN CIRCULATION IN THE 1225 00:54:26,800 --> 00:54:27,720 PRECEDING 12 MONTHS. 1226 00:54:27,720 --> 00:54:29,040 THANK YOU FOR COMING. 1227 00:54:29,040 --> 00:54:30,160 WE LOOK FORWARD TO HEARING YOUR 1228 00:54:30,160 --> 00:54:31,720 TALK. 1229 00:54:31,720 --> 00:54:41,960 >>THANK YOU. 1230 00:54:53,160 --> 00:54:55,760 THANK YOU FOR THE KIND 1231 00:54:55,760 --> 00:54:56,080 INTRODUCTION. 1232 00:54:56,080 --> 00:54:57,840 I'VE SEEN LUNG TRANSPLANT 1233 00:54:57,840 --> 00:55:05,440 STATIS -- TRANSPLANTATION 1234 00:55:05,440 --> 00:55:05,680 PATIENTS. 1235 00:55:05,680 --> 00:55:07,200 PATIENTS WITH ADVANCED LUNG 1236 00:55:07,200 --> 00:55:08,960 DISEASE, DR. KILEY JUST TALKED 1237 00:55:08,960 --> 00:55:13,280 ABOUT PATIENTS WITH DIFFERENT 1238 00:55:13,280 --> 00:55:14,720 LUNG DISEASES AT VERY ADVANCED 1239 00:55:14,720 --> 00:55:17,800 STAGES OF THE LUNG DISEASES THE 1240 00:55:17,800 --> 00:55:21,680 PATIENTS HAVE NO ADDITIONAL 1241 00:55:21,680 --> 00:55:27,000 TREATMENT. 1242 00:55:27,000 --> 00:55:28,600 WE GIVE THEM A CHANCE AT A 1243 00:55:28,600 --> 00:55:29,240 SECOND LIFE. 1244 00:55:29,240 --> 00:55:39,680 JUST LISTEN TO THIS STORY. 1245 00:56:02,160 --> 00:56:03,640 >>IT'S SUCH A GOOD VIDEO JUST 1246 00:56:03,640 --> 00:56:05,280 THE IMAGES WILL TELL THE STORY. 1247 00:56:05,280 --> 00:56:07,720 THEN I CAN PLUG IN SOME WORDS AS 1248 00:56:07,720 --> 00:56:14,080 WELL. 1249 00:56:14,080 --> 00:56:24,440 HELP IS ON THE WAY. 1250 00:56:39,520 --> 00:56:42,600 >>HE WAS JUST 8 YEARS OLD IN A 1251 00:56:42,600 --> 00:56:44,880 CROSSWALK WHEN STRUCK BY A CAR. 1252 00:56:44,880 --> 00:56:45,960 HIS PARENTS HAD A TERRIBLE 1253 00:56:45,960 --> 00:56:47,280 DECISION TO MAKE. 1254 00:56:47,280 --> 00:56:51,320 JUST A FEW DOORS DOWN, 1255 00:56:51,320 --> 00:56:53,040 HOKESTEIN LAY 1256 00:56:53,040 --> 00:56:53,240 DYING. 1257 00:56:53,240 --> 00:56:58,880 >>I GOT TO THINKING THAT IF MY 1258 00:56:58,880 --> 00:57:00,360 SON DIDN'T MAKE IT MAYBE THAT 1259 00:57:00,360 --> 00:57:00,960 LITTLE BOY WOULD. 1260 00:57:00,960 --> 00:57:11,440 >>FOR THEM TO SAY YES HOW DO 1261 00:57:12,760 --> 00:57:13,640 YOU PUT THAT INTO WORDS. 1262 00:57:13,640 --> 00:57:15,560 >>FOR MORE THAN 20 YEARS THE 1263 00:57:15,560 --> 00:57:16,880 FAMILIES SEARCHED FOR EACH 1264 00:57:16,880 --> 00:57:17,360 EITHER. 1265 00:57:17,360 --> 00:57:19,840 >>IT'S SURREAL AND EXCITING HIS 1266 00:57:19,840 --> 00:57:21,600 S STILL BEATING INSIDE MY 1267 00:57:21,600 --> 00:57:31,720 CHEST. 1268 00:57:33,800 --> 00:57:35,440 >>ALWAYS APPRECIATING THE GIFT 1269 00:57:35,440 --> 00:57:36,320 THEY GAVE US. 1270 00:57:36,320 --> 00:57:44,360 >>GIVING A GIFT OF LIFE IS THE 1271 00:57:44,360 --> 00:57:45,160 GREATEST THING ANYONE CAN DO FOR 1272 00:57:45,160 --> 00:57:52,600 SOMEONE ELSE. 1273 00:57:52,600 --> 00:57:54,680 >>JOHN HOKESTEIN 20 YEARS AFTER 1274 00:57:54,680 --> 00:57:56,720 RECEIVING THE HEART THE MOTHER 1275 00:57:56,720 --> 00:58:00,880 CAN LISTEN TO HER SON'S 1276 00:58:00,880 --> 00:58:02,720 HEARTBEATING IN JOHN HOKESTEIN. 1277 00:58:02,720 --> 00:58:04,560 HE'SKE CURRENTLY ANT MEDICAL STT 1278 00:58:04,560 --> 00:58:05,920 IN HARVARD GRADUATING THIS YEAR 1279 00:58:05,920 --> 00:58:09,320 WITH THE AIM OF GOING INTO 1280 00:58:09,320 --> 00:58:19,760 THORACIC TRANSPLANTATION. 1281 00:58:20,320 --> 00:58:26,680 THIS THE STORIES ARE NOT ALWAYS 1282 00:58:26,680 --> 00:58:27,960 GLORIOUS AND THE IMMUNE SYSTEM 1283 00:58:27,960 --> 00:58:31,160 CAN THEN LEADTH DIFFERENT FORMS 1284 00:58:31,160 --> 00:58:33,760 OF REJECTION IT COULD BE ACUTE 1285 00:58:33,760 --> 00:58:37,320 CELLULAR REJECTION OR AN 1286 00:58:37,320 --> 00:58:39,760 ANTIBODY REJECTION, AMR. 1287 00:58:39,760 --> 00:58:41,320 IN ADDITION, THE LUNGS ARE 1288 00:58:41,320 --> 00:58:45,280 EXPOSED TO MULTIPLE, MULTIPLE 1289 00:58:45,280 --> 00:58:47,320 INFECTIONS AND THE ENVIRONMENT 1290 00:58:47,320 --> 00:58:48,000 AS WELL. 1291 00:58:48,000 --> 00:58:55,240 SO MULTIPLE INSULTS THAT WITHIN 1292 00:58:55,240 --> 00:58:57,720 FIVE TO SEVEN YEARS OF 1293 00:58:57,720 --> 00:58:59,720 TRANSPLANTATION, 50%, HALF OF 1294 00:58:59,720 --> 00:59:02,360 LUNG TRANSPLANT PATIENTS 1295 00:59:02,360 --> 00:59:06,000 OTHERWISE WILL NOT SURVIVE 1296 00:59:06,000 --> 00:59:06,720 BECAUSE THEY'LL LOSE. 1297 00:59:06,720 --> 00:59:09,320 THIS GRAPH WHILE I WAS IN 1298 00:59:09,320 --> 00:59:14,920 RESIDENCY AT JOHNS HOPKINS MADE 1299 00:59:14,920 --> 00:59:19,240 ME SWITCH MY SPECIALTY, 1300 00:59:19,240 --> 00:59:24,160 DR. GIBBONS, NO OFFENSE TO 1301 00:59:24,160 --> 00:59:24,760 PULMONARY MEDICINE. 1302 00:59:24,760 --> 00:59:27,200 JUST LOOK AT THIS. 1303 00:59:27,200 --> 00:59:30,960 HOW CAN THIS BE ACCEPTABLE? 1304 00:59:30,960 --> 00:59:33,160 RE LIED RESEARCH SSION. 1305 00:59:33,160 --> 00:59:43,080 THE REST IS REALLY JUST ONGOING. 1306 00:59:43,080 --> 00:59:44,760 AND THIS RESULTS FROM 1307 00:59:44,760 --> 00:59:46,560 COMPLICATIONS OF REJECTION AND 1308 00:59:46,560 --> 00:59:46,800 INFECTION. 1309 00:59:46,800 --> 00:59:50,280 AND IN THE LUNG DUE TO THE VERY 1310 00:59:50,280 --> 00:59:52,840 LARGE PULMONARY RESERVE, THESE 1311 00:59:52,840 --> 00:59:57,440 ARE OFTEN INITIALLY CLINICALLY 1312 00:59:57,440 --> 00:59:57,640 CITED. 1313 00:59:57,640 --> 01:00:00,200 THIS IS A LUNG TRANSPLANT 1314 01:00:00,200 --> 01:00:00,800 PROVIDER HERE. 1315 01:00:00,800 --> 01:00:05,160 SOMEONE LIKE ME, INSERTS A 1316 01:00:05,160 --> 01:00:07,080 BRONCHIAL SCOPE THROUGH THE NOSE 1317 01:00:07,080 --> 01:00:08,440 AND MOUTH INTO THEIR LUNGS TO 1318 01:00:08,440 --> 01:00:10,000 TAKE BITS AND PIECES OF THE LUNG 1319 01:00:10,000 --> 01:00:13,520 TO LOOK FOR REJECTION. 1320 01:00:13,520 --> 01:00:16,840 ON TOP IS A TIME LINE FROM 1321 01:00:16,840 --> 01:00:19,000 TRANSPLANTATION TO TWO YEARS 1322 01:00:19,000 --> 01:00:21,160 INDICATING WHEN THESE PATIENTS 1323 01:00:21,160 --> 01:00:27,920 GET BRONC JOE SHIAL SCOPY. 1324 01:00:27,920 --> 01:00:32,840 YOU CAN SEE WHETHER THE PATIENT 1325 01:00:32,840 --> 01:00:34,200 HAS SYMPTOMS WILL GET 1326 01:00:34,200 --> 01:00:34,520 SURVEILLANCE. 1327 01:00:34,520 --> 01:00:39,880 IF THEY DO HAVE SYMPTOMS THEY'LL 1328 01:00:39,880 --> 01:00:42,000 GET ADDITIONAL BRONCHOSCOPY. 1329 01:00:42,000 --> 01:00:45,600 AND THE PATIENTS GET UP TO 20, 1330 01:00:45,600 --> 01:00:47,280 25 HEART BIOPSIES IN THE FIRST 1331 01:00:47,280 --> 01:00:49,120 YEAR OF TRANSPLANTATION ALONE. 1332 01:00:49,120 --> 01:00:52,080 YOU CAN IMAGINE, GOING INTO 1333 01:00:52,080 --> 01:00:54,240 SOMEBODY'S LUNG OR HEART TO GET 1334 01:00:54,240 --> 01:00:59,680 PIECES IS CLEARLY AN INVASIVE 1335 01:00:59,680 --> 01:01:03,800 PROCESS AND ASSOCIATED WITH 1336 01:01:03,800 --> 01:01:06,560 MULTIPLE COMPLICATIONS AND THE 1337 01:01:06,560 --> 01:01:08,040 HISTOPATHOLOGY HAS ITS OWN 1338 01:01:08,040 --> 01:01:09,160 PROBLEMS. 1339 01:01:09,160 --> 01:01:15,800 THIS APPROACH OVER ALL CAN OFTEN 1340 01:01:15,800 --> 01:01:20,440 MISS REJECTION OR DIAGNOSIS AT 1341 01:01:20,440 --> 01:01:22,520 LATE STAGES AT WHICH POINT 1342 01:01:22,520 --> 01:01:24,080 TREATMENT IS INEFFECTIVE LEADING 1343 01:01:24,080 --> 01:01:24,440 TO FAILURE. 1344 01:01:24,440 --> 01:01:29,160 CLEARLY WE NEED AN ALTERNATIVE 1345 01:01:29,160 --> 01:01:32,200 APPROACH. 1346 01:01:32,200 --> 01:01:34,200 TRANSPLANTATION MAY OFFER THE 1347 01:01:34,200 --> 01:01:34,440 SOLUTION. 1348 01:01:34,440 --> 01:01:36,200 THE FACT THAT TRANSPLANTATION 1349 01:01:36,200 --> 01:01:40,040 OFFERS THE MIXING OF GENOMES, I 1350 01:01:40,040 --> 01:01:41,720 KEEP TELLING COLLEAGUES AT OTHER 1351 01:01:41,720 --> 01:01:43,680 PLACES, IF YOU TRULY WANT TO 1352 01:01:43,680 --> 01:01:47,080 STUDY HOW THE GENOME ADAPTS IN A 1353 01:01:47,080 --> 01:01:49,040 NEW ENVIRONMENT STUDY 1354 01:01:49,040 --> 01:01:49,400 TRANSPLANTATION. 1355 01:01:49,400 --> 01:01:54,720 YOU TAKE A LIVING GENOME FROM 1356 01:01:54,720 --> 01:01:57,160 ONE PERSON AND PLACE IT IN A 1357 01:01:57,160 --> 01:01:58,200 DIFFERENT ENVIRONMENT CREATES 1358 01:01:58,200 --> 01:01:59,160 TOO MANY OPPORTUNITIES OF 1359 01:01:59,160 --> 01:02:01,120 LOOKING AT HOW THE GENOME CAN 1360 01:02:01,120 --> 01:02:02,440 ADAPT TO DIFFERENT ENVIRONMENT. 1361 01:02:02,440 --> 01:02:04,520 COMING BACK TO US FOR REJECTION 1362 01:02:04,520 --> 01:02:06,480 THOUGH THIS MIXTURE OF TWO 1363 01:02:06,480 --> 01:02:09,520 GENOMES CREATES AN OPPORTUNITY 1364 01:02:09,520 --> 01:02:16,080 TO MONITOR FOR REJECTION BY 1365 01:02:16,080 --> 01:02:26,640 LOOKING AT BLOOD MOLECULES AND 1366 01:02:28,280 --> 01:02:32,760 HERE WE'RE TRYING TO FIND BETTER 1367 01:02:32,760 --> 01:02:34,160 WAYS OF DIAGNOSING REJECTION. 1368 01:02:34,160 --> 01:02:38,560 WE'RE READY TO MOVE OUR RESEARCH 1369 01:02:38,560 --> 01:02:40,360 INTO PHASE 2 WHICH IS 1370 01:02:40,360 --> 01:02:42,400 INTERVENTIONS. 1371 01:02:42,400 --> 01:02:46,840 NOW THAT WE KNOW, CAN WE DO 1372 01:02:46,840 --> 01:02:49,120 SOMETHING TO IMPROVE THAT 1373 01:02:49,120 --> 01:02:51,600 PATIENT'S OUTCOME? 1374 01:02:51,600 --> 01:02:52,880 THAT'S WHERE I'M HOPING TO GO 1375 01:02:52,880 --> 01:02:54,320 BUT WE'VE DONE PHASE 1 AND READY 1376 01:02:54,320 --> 01:02:56,280 TO GO INTO PHASE 2. 1377 01:02:56,280 --> 01:03:01,720 PHASE 1, WE STARTED WITH THREE 1378 01:03:01,720 --> 01:03:03,440 AIMS TO DEVELOP TOOLS AND 1379 01:03:03,440 --> 01:03:06,760 REDEFINE ACUTE REJECTION AND 1380 01:03:06,760 --> 01:03:09,360 IDENTIFY WHO AND WHEN TO TREAT 1381 01:03:09,360 --> 01:03:13,000 AND BUILD A CONSORTIUM OR 1382 01:03:13,000 --> 01:03:15,880 INFRASTRUCTURE TO DEVELOP THE 1383 01:03:15,880 --> 01:03:19,360 TESTS AND DO STUDIES TO TEST FOR 1384 01:03:19,360 --> 01:03:27,520 THE HIGH UTILITY. 1385 01:03:27,520 --> 01:03:30,880 WHAT IS THE CELL-FREE SOME 1386 01:03:30,880 --> 01:03:32,800 CONTENTS REMAINS IN THE BLOOD 1387 01:03:32,800 --> 01:03:33,960 AND BECAUSE IT'S OUT OF THE CELL 1388 01:03:33,960 --> 01:03:37,960 IT'S FREE FROM CELLS WE CALL IT 1389 01:03:37,960 --> 01:03:40,120 CELL-FREE DNA. 1390 01:03:40,120 --> 01:03:43,120 THEY'RE FRAGMENTS OF NUCLEIC 1391 01:03:43,120 --> 01:03:45,200 ACID CIRCULATING IN BLOOD. 1392 01:03:45,200 --> 01:03:48,520 THEY'RE QUITE ABUNDANT. 1393 01:03:48,520 --> 01:03:53,160 IF YOU CAN IMAGINE CELLS ALL 1394 01:03:53,160 --> 01:04:01,040 OVER RELIEVING -- RELEASING 1395 01:04:01,040 --> 01:04:03,920 BLOOD AND THIS IS BILLION WITH A 1396 01:04:03,920 --> 01:04:07,120 "B", FRAGMENTS OF SO QUITE 1397 01:04:07,120 --> 01:04:10,480 ABUNDANT AND DNA SO IT'S 1398 01:04:10,480 --> 01:04:11,840 PACKAGED WITH VERY RICH BIOLOGY 1399 01:04:11,840 --> 01:04:14,240 INFORMATION WHICH YOU CAN 1400 01:04:14,240 --> 01:04:19,600 HARVEST BY JUST STUDYING PLASMA 1401 01:04:19,600 --> 01:04:22,640 IN BLOOD. 1402 01:04:22,640 --> 01:04:24,320 LET'S COME TO TRANSPLANTATION 1403 01:04:24,320 --> 01:04:25,920 THE MIXTURE AND IT COMES FROM A 1404 01:04:25,920 --> 01:04:27,680 DIFFERENT PERSON THAT BE THE 1405 01:04:27,680 --> 01:04:28,040 RECIPIENT. 1406 01:04:28,040 --> 01:04:30,360 THEREFORE THE DNA IN THE LUNG IS 1407 01:04:30,360 --> 01:04:33,000 DIFFERENT FROM THE DNA IN THE 1408 01:04:33,000 --> 01:04:33,680 RECIPIENT. 1409 01:04:33,680 --> 01:04:36,720 IF YOU COLLECT BLOOD AND ISOLATE 1410 01:04:36,720 --> 01:04:38,960 PLASMA FROM THAT TRANSPLANT 1411 01:04:38,960 --> 01:04:41,160 PATIENT YOU'LL GET CELL-FREE DNA 1412 01:04:41,160 --> 01:04:45,000 FROM THE RECIPIENT OR IN GREEN, 1413 01:04:45,000 --> 01:04:48,160 CELL-FREE DNA FROM THAT AND USE 1414 01:04:48,160 --> 01:04:49,880 ANY METHOD OF INTEREST DIGITAL 1415 01:04:49,880 --> 01:04:54,240 DROP LET CPR, SEQUENCING, ANY 1416 01:04:54,240 --> 01:04:56,240 METHOD TO LOOK AT THE MATERIAL 1417 01:04:56,240 --> 01:05:00,080 AND ONE CAN LOOK AT THE FRACTION 1418 01:05:00,080 --> 01:05:04,680 OF DERMAL-DERIVED CELL-FREE DNA 1419 01:05:04,680 --> 01:05:06,440 AS A MARKER OF REJECTION. 1420 01:05:06,440 --> 01:05:07,320 DOES IT WORK? 1421 01:05:07,320 --> 01:05:08,680 LET ME START WITH THIS SLIDE. 1422 01:05:08,680 --> 01:05:12,960 THIS IS A STUDY WE INITIALLY DID 1423 01:05:12,960 --> 01:05:15,760 WITH INVESTIGATORS FROM STANFORD 1424 01:05:15,760 --> 01:05:17,960 WHEN HANNAH VALENTINE WAS HERE 1425 01:05:17,960 --> 01:05:22,720 BEFORE SHE MOVED TO STANFORD. 1426 01:05:22,720 --> 01:05:25,120 THEY DID REPLICATE ANALYSIS OF 1427 01:05:25,120 --> 01:05:30,680 THE SAMPLES IB OUR LAB AND AT 1428 01:05:30,680 --> 01:05:32,040 STANFORD. 1429 01:05:32,040 --> 01:05:34,560 YOU CAN SEE AND IN BLUE IS 1430 01:05:34,560 --> 01:05:36,200 ANALYSIS AT STANFORD. 1431 01:05:36,200 --> 01:05:38,240 AND THE GENOME IS PRETTY BIG. 1432 01:05:38,240 --> 01:05:41,360 THERE'S MANY REASONS WHY THIS IS 1433 01:05:41,360 --> 01:05:45,120 CORRECT. 1434 01:05:45,120 --> 01:05:48,920 HERE IS A PATIENT THIS IS A 1435 01:05:48,920 --> 01:05:51,000 HEART TRANSPLANT PATIENT WITH 1436 01:05:51,000 --> 01:05:55,160 REJECTION AND THE PATIENT 1437 01:05:55,160 --> 01:05:57,160 DEVELOPS REJECTION AND THE 1438 01:05:57,160 --> 01:06:00,800 LEVELS COME BACK DOWN. 1439 01:06:00,800 --> 01:06:04,960 AT THE NIH WE DO NOT HAVE A 1440 01:06:04,960 --> 01:06:06,360 LUNG, HEART, TRANSPLANT PROGRAM 1441 01:06:06,360 --> 01:06:12,520 AND WE GUIDE IT TOWARDS CREATING 1442 01:06:12,520 --> 01:06:14,440 AN INFRASTRUCTURE OR 1443 01:06:14,440 --> 01:06:18,320 INTERRUPTION A CONSORTIUM AND 1444 01:06:18,320 --> 01:06:19,920 CALL IT GENOMIC RESEARCH 1445 01:06:19,920 --> 01:06:27,040 ALLIANCE FOR TRANSPLANTATION OR 1446 01:06:27,040 --> 01:06:28,200 GRAFT. 1447 01:06:28,200 --> 01:06:33,200 IT'S A COMBINATION OF NHLBI 1448 01:06:33,200 --> 01:06:33,680 PROGRAMS. 1449 01:06:33,680 --> 01:06:37,120 IT'S EASY TO DRIVE UP, MEET UP 1450 01:06:37,120 --> 01:06:40,600 WITH CO-INVESTIGATORS AND THEY 1451 01:06:40,600 --> 01:06:42,120 HAVE BEEN THE INFRASTRUCTURE IN 1452 01:06:42,120 --> 01:06:44,680 MY MIND AND THE FOUNDATION FOR 1453 01:06:44,680 --> 01:06:46,560 THE FINDINGS I'LL SHOW YOU GOING 1454 01:06:46,560 --> 01:06:46,920 FORWARD. 1455 01:06:46,920 --> 01:06:49,120 IN THIS CONSORTIUM WE 1456 01:06:49,120 --> 01:06:50,120 STANDARDIZED SAMPLE COLLECTION 1457 01:06:50,120 --> 01:06:53,480 ACROSS ALL THE DIFFERENT CENTERS 1458 01:06:53,480 --> 01:06:57,160 AND BUILD COMMITTEES WHICH ARE 1459 01:06:57,160 --> 01:06:58,400 EXPERT PHYSICIANS FROM ACROSS 1460 01:06:58,400 --> 01:07:00,160 THE COUNTRY TO ADJUDICATE ALL 1461 01:07:00,160 --> 01:07:01,960 STUDY END POINTS. 1462 01:07:01,960 --> 01:07:04,920 IT'S BEEN HIGH FUNCTIONING. 1463 01:07:04,920 --> 01:07:10,360 WE HAVE ABOUT 690 SUBJECTS AND 1464 01:07:10,360 --> 01:07:11,960 MANY BIO SPECIMENS FOR RESEARCH. 1465 01:07:11,960 --> 01:07:15,080 COMING BACK TO THE ADJUDICATION 1466 01:07:15,080 --> 01:07:18,480 COMMITTEES IN TRANSPLANTATION, 1467 01:07:18,480 --> 01:07:21,160 THIS IS THE FIELD THINKS IT'S AN 1468 01:07:21,160 --> 01:07:24,040 IMPORTANT ASPECT BECAUSE IF YOU 1469 01:07:24,040 --> 01:07:26,520 TAKE A HUNDRED TRANSPLANT 1470 01:07:26,520 --> 01:07:29,120 DOCTORS IN THE SAME ROOM AND ASK 1471 01:07:29,120 --> 01:07:31,000 WHAT DIAGNOSIS THE PATIENT HAS 1472 01:07:31,000 --> 01:07:32,080 YOU MAY HAVE DIFFERENT ANSWERS. 1473 01:07:32,080 --> 01:07:34,000 NOT MAY, BUT YOU WILL HAVE 1474 01:07:34,000 --> 01:07:36,560 DIFFERENCE ANSWERS. 1475 01:07:36,560 --> 01:07:37,120 ACU 1476 01:07:37,120 --> 01:07:39,400 ADJUDICATED FOR THE STUDY END 1477 01:07:39,400 --> 01:07:42,600 POINTS IS RELEVANT TO BETTER 1478 01:07:42,600 --> 01:07:45,000 CHARACTERIZE TRANSPLANT 1479 01:07:45,000 --> 01:07:45,400 POSITIONS. 1480 01:07:45,400 --> 01:07:52,720 THIS IS THE CONSENSUS 1481 01:07:52,720 --> 01:07:53,960 HISTOPATHOLOGY TEAM AND ONE 1482 01:07:53,960 --> 01:07:56,480 EVERY SIX MONTHS THEY'LL FLY TO 1483 01:07:56,480 --> 01:07:58,320 THE NIH AND LOOK AT EVERY SLIDE 1484 01:07:58,320 --> 01:08:02,760 THAT IS COLLECTED AT THE CENTERS 1485 01:08:02,760 --> 01:08:04,320 OF EVERY PATIENT AND BETTER 1486 01:08:04,320 --> 01:08:07,640 CHARACTERIZE THEM FOR REJECTION. 1487 01:08:07,640 --> 01:08:09,360 WITH THIS INFRASTRUCTURE WE THEN 1488 01:08:09,360 --> 01:08:10,520 EMBARK ON TWO STUDIES. 1489 01:08:10,520 --> 01:08:15,400 ONE IN LUNG AND ONE IN HEART. 1490 01:08:15,400 --> 01:08:20,400 THE 169 PATIENTS IN LUNG AND WE 1491 01:08:20,400 --> 01:08:22,560 COLLECT SAMPLES AND MEASURE 1492 01:08:22,560 --> 01:08:26,360 CELL-FREE DNA ASKING HOW GOOD IS 1493 01:08:26,360 --> 01:08:28,520 CELL-FREE DNA IN DIAGNOSING 1494 01:08:28,520 --> 01:08:29,120 REJECTION? 1495 01:08:29,120 --> 01:08:34,680 THE FIRST THING WE REPORTED IS 1496 01:08:34,680 --> 01:08:38,760 THE LEVEL OF DDC DNA IN PLASMA 1497 01:08:38,760 --> 01:08:41,640 CORRELATES WITH THE SEVERITY OF 1498 01:08:41,640 --> 01:08:43,000 REJECTION IN BIOPSY. 1499 01:08:43,000 --> 01:08:45,160 IF YOU TAKE THE GRAPH HERE 1500 01:08:45,160 --> 01:08:52,840 GERMAL DERIVED CELL ON THE Y 1501 01:08:52,840 --> 01:08:54,800 AXIS AND GOING FROM ZERO TO 1 TO 1502 01:08:54,800 --> 01:08:57,280 2 YOU SEE INCREASES LEVELS OF 1503 01:08:57,280 --> 01:08:59,320 CELL-FREE DNA. 1504 01:08:59,320 --> 01:09:01,360 THIS IS IN MY MIND WHERE THE 1505 01:09:01,360 --> 01:09:04,720 POWER OF THE TECHNOLOGY IS. 1506 01:09:04,720 --> 01:09:07,120 IMAGINE THIS SLIDE HERE, TIMES 1507 01:09:07,120 --> 01:09:13,160 ZERO IS THE TIME THE BIOPSY 1508 01:09:13,160 --> 01:09:16,680 WHERE THE PATIENT SHOWS SYMPTOMS 1509 01:09:16,680 --> 01:09:20,000 AND IF YOU LOOK AT THE LEVELS AT 1510 01:09:20,000 --> 01:09:20,600 THAT TIME IT'S HIGH. 1511 01:09:20,600 --> 01:09:23,840 MORE IMPORTANTLY, TWO TO FOUR 1512 01:09:23,840 --> 01:09:24,760 MONTHS BEFORE THE BIOPSY SHOWS 1513 01:09:24,760 --> 01:09:28,960 SIGNS OF REJECTION OR BEFORE THE 1514 01:09:28,960 --> 01:09:31,080 PATIENT SHOWS ANY SIGNS OFFALO 1515 01:09:31,080 --> 01:09:33,160 GRAPH DISCUSSION YOU HAVE 1516 01:09:33,160 --> 01:09:35,920 ELEVATIONS OF CELL-FREE DNA IN 1517 01:09:35,920 --> 01:09:39,880 THE CASE OF ANTIBODY REJECTION 1518 01:09:39,880 --> 01:09:43,920 AND SHOW THE SAME IN HEART 1519 01:09:43,920 --> 01:09:47,160 TRANSPLANT AS WELL AND 1520 01:09:47,160 --> 01:09:48,080 IDENTIFIES AN EARLY TIME POINT 1521 01:09:48,080 --> 01:09:50,040 FOR WHICH WE CAN INTERVENE. 1522 01:09:50,040 --> 01:10:00,600 THE WORK HERE ALLOW ME TO THEN 1523 01:10:04,840 --> 01:10:06,680 ALLOW ME TO LOOK AT THE 1524 01:10:06,680 --> 01:10:09,080 LEADERSHIP AND I MET WITH OUR 1525 01:10:09,080 --> 01:10:10,240 LEADERSHIP TEAM AND THEY SAID IF 1526 01:10:10,240 --> 01:10:11,720 YOU WANT TO DO THE SCIENCE, YOU 1527 01:10:11,720 --> 01:10:15,960 WANT TO DO IT AND DO IT WELL. 1528 01:10:15,960 --> 01:10:21,640 SO WE SET UP THE GRAPH IN THAT 1529 01:10:21,640 --> 01:10:21,880 MANNER. 1530 01:10:21,880 --> 01:10:26,720 THE SAMPLE COLLECTION HAS TO BE 1531 01:10:26,720 --> 01:10:28,040 RIGOROUS AND THE END POINTS HAVE 1532 01:10:28,040 --> 01:10:30,640 TO BE RIGOROUS AND DOING IT THAT 1533 01:10:30,640 --> 01:10:33,080 WAY THE WORK BECAME MORE 1534 01:10:33,080 --> 01:10:34,240 ACCEPTED WITHIN THE TRANSPLANT 1535 01:10:34,240 --> 01:10:34,720 COMMUNITY. 1536 01:10:34,720 --> 01:10:38,280 TAKE THE NEXT SLIDE, FOR 1537 01:10:38,280 --> 01:10:38,520 EXAMPLE. 1538 01:10:38,520 --> 01:10:40,600 THIS IS ON HEART TRANSPLANTATION 1539 01:10:40,600 --> 01:10:43,280 ON JULY 1 WHEN I WAS ASKED TO 1540 01:10:43,280 --> 01:10:48,440 SEND THE SLIDES IT'S BEEN 1541 01:10:48,440 --> 01:10:49,920 DOWNLOADED 11,540 TIMES ACROSS 1542 01:10:49,920 --> 01:10:50,640 THE WORLD. 1543 01:10:50,640 --> 01:10:53,080 I WAS TRYING TO FIND COUNTRIES 1544 01:10:53,080 --> 01:10:56,000 FOR WHICH IT HAS NOT BEEN 1545 01:10:56,000 --> 01:10:57,040 DOWNLOADED I COULDN'T FIND THAT 1546 01:10:57,040 --> 01:10:59,640 AND THOUGH IT WAS PUBLISHED IN 1547 01:10:59,640 --> 01:11:04,280 2001 OR SO, IT'S STILL BEING 1548 01:11:04,280 --> 01:11:06,640 DOWNLOADED 250 TO 400 TIMES 1549 01:11:06,640 --> 01:11:07,040 EVERY MONTH. 1550 01:11:07,040 --> 01:11:09,000 THAT'S ONE THING. 1551 01:11:09,000 --> 01:11:15,880 SECONDLY, THIS IS WHERE I THINK 1552 01:11:15,880 --> 01:11:20,600 THIS DEEP DRIVER IN THE FIELD OF 1553 01:11:20,600 --> 01:11:22,280 TRANSPLANTATION AND THEN IF YOU 1554 01:11:22,280 --> 01:11:24,920 CONSIDER CELL-FREE DNA AS THE 1555 01:11:24,920 --> 01:11:25,960 GOLD STANDARD AND LEVELS GREATER 1556 01:11:25,960 --> 01:11:28,360 THAN 0 TO 2.5 SUGGEST SOMETHING 1557 01:11:28,360 --> 01:11:29,360 IS BAD OR LESS THAN THAT. 1558 01:11:29,360 --> 01:11:32,840 IF YOU DO THAT, YOU DO THAT AND 1559 01:11:32,840 --> 01:11:39,560 THIS IS WHAT WE SEE. 1560 01:11:39,560 --> 01:11:42,440 ONLY 20% OF THEM WHERE THE 1561 01:11:42,440 --> 01:11:44,800 BYPASS SHOWS SIGNS OF POSITIVE, 1562 01:11:44,800 --> 01:11:49,240 80% OF THE CELL-FREE DNA LEVELS 1563 01:11:49,240 --> 01:11:51,400 THAT ARE HIGH THE BIOPSY SHOWS 1564 01:11:51,400 --> 01:11:52,120 THEY'RE NEGATIVE. 1565 01:11:52,120 --> 01:11:54,160 IF YOU LOOK AT WHETHER IT'S 1566 01:11:54,160 --> 01:11:57,840 POSITIVE, NO, IF YOU LOOK AT 1567 01:11:57,840 --> 01:12:00,360 THAT 80%, 76% THE PATIENT WILL 1568 01:12:00,360 --> 01:12:03,560 GET A REJECTION IN THE FUTURE OR 1569 01:12:03,560 --> 01:12:14,080 THEY HAVE AN ALO GRAPH AND SEEMS 1570 01:12:20,080 --> 01:12:22,280 LIKE AN EARLY INDICATION OF 1571 01:12:22,280 --> 01:12:23,160 SOMETHING NOT RIGHT. 1572 01:12:23,160 --> 01:12:29,120 IT PICK UP BUT ONLY 1 IN 4 1573 01:12:29,120 --> 01:12:29,680 CLINICALLY ELEVATIONS OF 1574 01:12:29,680 --> 01:12:39,920 CELL-FREE DNA. 1575 01:12:48,600 --> 01:12:55,160 AND THIS WORK RECEIVE THE JAMES 1576 01:12:55,160 --> 01:12:58,720 T. WILLARSON AWARD. 1577 01:12:58,720 --> 01:13:03,960 AND WHAT HAS CELL-FREE DNA 1578 01:13:03,960 --> 01:13:08,360 ENABLED US TO DO? 1579 01:13:08,360 --> 01:13:10,360 WHO AND WHEN TO TREAT. 1580 01:13:10,360 --> 01:13:13,440 EARLY DETECTION AND LEVELS OF 1581 01:13:13,440 --> 01:13:16,800 CELL-FREE DNA IN THE EARLY 1582 01:13:16,800 --> 01:13:18,240 POST-TRANSPLANT PERIOD PREDICT 1583 01:13:18,240 --> 01:13:19,920 FAILURE AND PREDICT TIME FROM 1584 01:13:19,920 --> 01:13:24,880 TRANSPLANT PATIENT TO WHEN THE 1585 01:13:24,880 --> 01:13:28,800 PATIENT WILL AND BLO PATIENTS 1586 01:13:28,800 --> 01:13:30,000 AT TRANSPLANTATION DEVELOP HIGH 1587 01:13:30,000 --> 01:13:31,360 LEVELS OF CELL-FREE DNA. 1588 01:13:31,360 --> 01:13:34,640 THEY THEN GO ON TO SHOW 1589 01:13:34,640 --> 01:13:37,040 INCREASING LEVELS OF CELL-FREE 1590 01:13:37,040 --> 01:13:43,120 DNA AND SHOW POORER OUTCOMES 1591 01:13:43,120 --> 01:13:45,160 COMPARED TO PATIENTS WITH 1592 01:13:45,160 --> 01:13:51,000 EUROPEAN ASSENCESTRY PROVIDING 1593 01:13:51,000 --> 01:13:54,240 BIOLOGICAL DIFFERENCE IN WHY 1594 01:13:54,240 --> 01:13:57,400 THEY MAY HAVE POORER OUTCOMES. 1595 01:13:57,400 --> 01:14:00,800 CELL-FREE DNA HAS ALLOWED US TO 1596 01:14:00,800 --> 01:14:03,240 SEE WHO SHOULD BE TREATED AND 1597 01:14:03,240 --> 01:14:06,680 WHEN. 1598 01:14:06,680 --> 01:14:17,080 I'LL SKIP THIS SLIDE. 1599 01:14:17,080 --> 01:14:20,480 AND YOU CAN SET UP YOUR RESEARCH 1600 01:14:20,480 --> 01:14:22,680 INFRASTRUCTURE AND PUBLISHING 1601 01:14:22,680 --> 01:14:25,600 WORK IT BECOMES MORE EASILY 1602 01:14:25,600 --> 01:14:25,840 ACCEPTED. 1603 01:14:25,840 --> 01:14:28,240 AND IT'S GONE TO RECEIVE AWARDS 1604 01:14:28,240 --> 01:14:30,320 NATIONALLY AND INVITED 1605 01:14:30,320 --> 01:14:30,920 COLLABORATORS FROM DIFFERENT 1606 01:14:30,920 --> 01:14:35,680 PARTS OF THE WORLD AS WELL. 1607 01:14:35,680 --> 01:14:38,520 AND BEFORE I GO ON, THEN COVID 1608 01:14:38,520 --> 01:14:39,120 CAME. 1609 01:14:39,120 --> 01:14:44,360 WHEN COVID CAME, EVERYTHING WENT 1610 01:14:44,360 --> 01:14:47,680 ON THE PAUSE FOR A LITTLE BIT 1611 01:14:47,680 --> 01:14:50,200 AND THEN AN IDEA CAME UP. 1612 01:14:50,200 --> 01:14:53,520 WHEN COVID CAME UP TRANSPLANT 1613 01:14:53,520 --> 01:14:54,960 PATIENTS ARE IMMUNOCOMPROMISED. 1614 01:14:54,960 --> 01:14:56,600 YOU DON'T WANT THEM OUTSIDE. 1615 01:14:56,600 --> 01:14:58,240 YOU WANT THEM IN THEIR HOUSE. 1616 01:14:58,240 --> 01:15:01,200 HOW WILL THEY COME TO CLINIC TO 1617 01:15:01,200 --> 01:15:04,280 GET BIOPSIES? 1618 01:15:04,280 --> 01:15:08,320 HOSPITALS WERE STRUCK AND 1619 01:15:08,320 --> 01:15:09,080 TRANSPLANT CENTERS WERE STRUCK 1620 01:15:09,080 --> 01:15:10,960 AND NOBODY ENVISIONED COVID AND 1621 01:15:10,960 --> 01:15:14,240 WHO WILL YOU POINT THE FINGER 1622 01:15:14,240 --> 01:15:14,520 TO? 1623 01:15:14,520 --> 01:15:17,360 BOTH PHYSICIANS AND DOCTORS WERE 1624 01:15:17,360 --> 01:15:17,560 STUCK. 1625 01:15:17,560 --> 01:15:20,080 THEN WE FOUND A PARTNERSHIP WITH 1626 01:15:20,080 --> 01:15:23,960 AN INDUSTRY PARTNER WHICH I 1627 01:15:23,960 --> 01:15:28,000 THOUGHT GREAT BECAUSE THEY HAVE 1628 01:15:28,000 --> 01:15:29,160 THE INFRASTRUCTURE AND WE 1629 01:15:29,160 --> 01:15:34,160 LAUNCHED A STUDY THE ANALYSIS 1630 01:15:34,160 --> 01:15:36,960 FOR LONG MONITORING. 1631 01:15:36,960 --> 01:15:39,680 THE COMPANY OBTAINED FDA 1632 01:15:39,680 --> 01:15:42,160 COMPASSIONATE USE APPROVAL OF 1633 01:15:42,160 --> 01:15:42,880 CELL-FREE DAP. 1634 01:15:42,880 --> 01:15:49,120 WE ARRANGE D FOR PEOPLE TO GO T 1635 01:15:49,120 --> 01:15:51,160 THE PATIENT'S HOMES AND YOU CAN 1636 01:15:51,160 --> 01:15:52,520 MONITOR THEM MOSTLY FROM THEIR 1637 01:15:52,520 --> 01:15:57,400 HOMES AND THE DOCTORS AND WE 1638 01:15:57,400 --> 01:16:01,640 COULD THEN GUIDE PHYSICIANS TO 1639 01:16:01,640 --> 01:16:02,360 USE THAT TO MONITOR FOR 1640 01:16:02,360 --> 01:16:12,760 INFECTION AND REJECTION. 1641 01:16:16,240 --> 01:16:18,320 IF THESE LEVELS ARE LESS IT'S AN 1642 01:16:18,320 --> 01:16:19,120 ALL CLEAR. 1643 01:16:19,120 --> 01:16:23,240 A 99% PREDICTIVE VALUE. 1644 01:16:23,240 --> 01:16:26,400 IF THE LEVELS ARE BETWEEN 0.5 1645 01:16:26,400 --> 01:16:28,280 AND 1, WAIT, BE MORE CAREFUL. 1646 01:16:28,280 --> 01:16:32,200 CHECK THE PATIENT MORE OFTEN. 1647 01:16:32,200 --> 01:16:33,680 THEY'LL GO TO TWO-WEEK 1648 01:16:33,680 --> 01:16:34,000 MONITORING. 1649 01:16:34,000 --> 01:16:35,800 IF THE LEVELS ARE 1% OR HIGHER, 1650 01:16:35,800 --> 01:16:43,440 THAT'S A RED LIGHT. 1651 01:16:43,440 --> 01:16:46,040 BRING THE PATIENT IN AND FIGURE 1652 01:16:46,040 --> 01:16:48,200 OUT WHAT'S WRONG AND IF YOU 1653 01:16:48,200 --> 01:16:50,880 DON'T FIND ANYTHING, GO BACK TO 1654 01:16:50,880 --> 01:16:52,200 MONTHLY MONITORING BUT BE MORE 1655 01:16:52,200 --> 01:16:53,840 CAREFUL BECAUSE IT'S USUALLY AN 1656 01:16:53,840 --> 01:16:54,840 EARLY SIGN SOMETHING BAD IS 1657 01:16:54,840 --> 01:16:56,440 GOING TO HAPPEN. 1658 01:16:56,440 --> 01:16:59,080 IF YOU FIND SOME INFECTION OR 1659 01:16:59,080 --> 01:17:00,680 REJECTION YOU TREAT IT. 1660 01:17:00,680 --> 01:17:03,480 WE USE CELL-FREE DNA AS 1661 01:17:03,480 --> 01:17:05,120 SURVEILLANCE MONITORING INSTEAD 1662 01:17:05,120 --> 01:17:15,760 OF BRONCHO SCOPEE AND WE'RE ABE 1663 01:17:25,720 --> 01:17:36,440 IT AVOID 82% OF INVASIE IIVE 1664 01:17:45,160 --> 01:17:46,840 BRONCHOSCOPY AND NOW IN PLACE IN 1665 01:17:46,840 --> 01:17:49,080 U.S. AND CANADA. 1666 01:17:49,080 --> 01:17:51,480 THE CELL-FREE TEST IS BEING USED 1667 01:17:51,480 --> 01:17:53,640 AT JOHNS HOPKINS BASED ON THE 1668 01:17:53,640 --> 01:17:55,640 PROTOCOL PROPOSED IN THE STUDY 1669 01:17:55,640 --> 01:17:56,640 HERE. 1670 01:17:56,640 --> 01:18:01,920 HOWEVER, THE TEST HAS ONE FLAW 1671 01:18:01,920 --> 01:18:04,280 STILL. 1672 01:18:04,280 --> 01:18:08,160 ACUTE REJECTION AND INFECTION 1673 01:18:08,160 --> 01:18:09,560 ARE COMMON IN LUNG TRANSPLANT 1674 01:18:09,560 --> 01:18:10,400 PATIENT. 1675 01:18:10,400 --> 01:18:13,960 BOTH LEAD TO AN ELEVATION IN 1676 01:18:13,960 --> 01:18:14,600 CELL-FREE DAP AND IF PATIENT 1677 01:18:14,600 --> 01:18:17,480 HAVE A CELL-FREE DNA YOU DON'T 1678 01:18:17,480 --> 01:18:21,440 FLOW IF IT'S FROM INFECTION OR 1679 01:18:21,440 --> 01:18:21,720 REJECTION? 1680 01:18:21,720 --> 01:18:30,680 IT CAN TELL YOU SOMETHING IS 1681 01:18:30,680 --> 01:18:33,120 WRONG AND IT'S A RULE-OUT TEST. 1682 01:18:33,120 --> 01:18:35,560 IT'S NOT A SPECIFIC TEST. 1683 01:18:35,560 --> 01:18:37,120 CAN WE IDENTIFY A SPECIFIC TEST. 1684 01:18:37,120 --> 01:18:46,640 IF YOU THINK ABOUT IT, AND YOU 1685 01:18:46,640 --> 01:18:51,240 AND THERE'S NEUTROPHILS AROUND 1686 01:18:51,240 --> 01:18:53,120 THE CAPILLARIES OF ORGANS AND 1687 01:18:53,120 --> 01:18:55,440 TISSUES OPPOSED TO ACUTE 1688 01:18:55,440 --> 01:19:03,280 CELLULAR REJECTION WHICH THE 1689 01:19:03,280 --> 01:19:04,600 LYMPHOCYTIC PROCESS AND THE 1690 01:19:04,600 --> 01:19:06,520 REJECTION OR INFECTION FOR THAT 1691 01:19:06,520 --> 01:19:08,960 MATTER THAT INVOLVE DIFFERENT 1692 01:19:08,960 --> 01:19:10,600 CELLS AND DIFFERENT TISSUE 1693 01:19:10,600 --> 01:19:11,760 TYPES. 1694 01:19:11,760 --> 01:19:13,320 THESE ARE THE TISSUE TYPES THAT 1695 01:19:13,320 --> 01:19:15,200 WOULD BE PRODUCING CELL-FREE 1696 01:19:15,200 --> 01:19:15,440 DNA. 1697 01:19:15,440 --> 01:19:22,760 SO IF YOU THINK ABOUT IT, ONE IS 1698 01:19:22,760 --> 01:19:25,120 LOOKING AT EPIGENETIC 1699 01:19:25,120 --> 01:19:26,800 FINGERPRINTS ON CELL-FREE DNA. 1700 01:19:26,800 --> 01:19:29,680 WHILE THE DNA SEQUENCE IN YOUR 1701 01:19:29,680 --> 01:19:33,320 ENTIRE BODY IS IDENTICAL, THE 1702 01:19:33,320 --> 01:19:35,360 EPIGENETIC FINGERPRINTS ARE 1703 01:19:35,360 --> 01:19:37,960 DISTINCT. 1704 01:19:37,960 --> 01:19:40,760 INDEED THEY CONFER THE HEART TO 1705 01:19:40,760 --> 01:19:47,600 BE ABLE TO BEAT, THE LUNG TO DO 1706 01:19:47,600 --> 01:19:50,480 RESPIRATION AND BLOOD TO DO WHAT 1707 01:19:50,480 --> 01:19:53,160 IT DOES BEST AND IT'S THE 1708 01:19:53,160 --> 01:19:55,760 EPIGENETIC FINGERPRINT THAT 1709 01:19:55,760 --> 01:19:58,360 CONFER FUNCTION AND TISSUE 1710 01:19:58,360 --> 01:19:59,240 SPECIFICITY. 1711 01:19:59,240 --> 01:20:03,760 THESE ARE PRESERVED ON CELL-FREE 1712 01:20:03,760 --> 01:20:04,000 DNA. 1713 01:20:04,000 --> 01:20:07,160 IF I CAN SEQUENCE CELL-FREE DNA 1714 01:20:07,160 --> 01:20:11,720 I SCAN THE SIGNATURES ON THE 1715 01:20:11,720 --> 01:20:13,120 CELL-FREE DNA AND COULD THEN 1716 01:20:13,120 --> 01:20:15,640 PROVIDE A WHOLE BODY MOLECULAR 1717 01:20:15,640 --> 01:20:16,640 INJURY SCAN. 1718 01:20:16,640 --> 01:20:21,560 THE ANSWER IS YES BUT ALLOW ME 1719 01:20:21,560 --> 01:20:25,440 TO SHOW YOU A FEW SLIDES TO SHOW 1720 01:20:25,440 --> 01:20:26,960 THAT'S THE CASE. 1721 01:20:26,960 --> 01:20:31,160 WE HAVE CELL-FREE DNA AND WE 1722 01:20:31,160 --> 01:20:35,400 QUANTITATE THAT BY DIGITAL 1723 01:20:35,400 --> 01:20:42,320 DROPLETS AND LOOK AT DNA 1724 01:20:42,320 --> 01:20:42,640 METHYLATION. 1725 01:20:42,640 --> 01:20:46,480 AND THEN WE ALL KNOW THERE ARE 1726 01:20:46,480 --> 01:20:50,800 WELL-KNOWN SIGNATURES OF 1727 01:20:50,800 --> 01:20:52,800 TISSUE-SPECIFIC DNA METHYLATION 1728 01:20:52,800 --> 01:20:55,160 SIGNATURES AND THEY'RE WELL 1729 01:20:55,160 --> 01:20:56,880 KNOWN OF THE LUNGS. 1730 01:20:56,880 --> 01:21:00,000 EVERY TISSUE TYPE HAS DNA 1731 01:21:00,000 --> 01:21:01,040 METHYLATION SIGNATURES THAT ARE 1732 01:21:01,040 --> 01:21:01,440 TISSUE SPECIFIC. 1733 01:21:01,440 --> 01:21:05,240 THIS IS WELL KNOWN AND WELL 1734 01:21:05,240 --> 01:21:06,240 PUBLISHED. 1735 01:21:06,240 --> 01:21:10,240 IF WE KNOW THAT, WE SCAN THE 1736 01:21:10,240 --> 01:21:12,760 CELL-FREE DNA TO IDENTIFY THE 1737 01:21:12,760 --> 01:21:16,080 TISSUES WHICH IT'S COMING FROM. 1738 01:21:16,080 --> 01:21:20,240 AND I'LL SKIP THE SLIDE. 1739 01:21:20,240 --> 01:21:23,560 YOU CAN DO THIS LOOKING AT GENE 1740 01:21:23,560 --> 01:21:26,680 EXPRESSION THE MODIFICATION OF 1741 01:21:26,680 --> 01:21:28,200 CHROMATIN ALSO IS ALSO TISSUE 1742 01:21:28,200 --> 01:21:28,680 SPECIFIC. 1743 01:21:28,680 --> 01:21:31,160 YOU CAN GRAT THE MODIFICATION, 1744 01:21:31,160 --> 01:21:33,640 LOOK AT THE TISSUE-SPECIFIC MARK 1745 01:21:33,640 --> 01:21:37,000 TORE IDENTIFY WHERE THE 1746 01:21:37,000 --> 01:21:38,920 CELL-FREE -- MARKER TO IDENTIFY 1747 01:21:38,920 --> 01:21:40,600 WHERE THE CELL-FREE DNA IS 1748 01:21:40,600 --> 01:21:41,080 COMING FROM. 1749 01:21:41,080 --> 01:21:44,080 THESE ARE PATIENTS WITH 1750 01:21:44,080 --> 01:21:44,360 COVID-19. 1751 01:21:44,360 --> 01:21:48,160 ON THE Y AXIS IS THE AMOUNT AND 1752 01:21:48,160 --> 01:21:49,120 X AXIS IS DAYS FROM 1753 01:21:49,120 --> 01:21:50,400 HOSPITALIZATION OF THE PATIENTS. 1754 01:21:50,400 --> 01:21:53,120 THE KEY TO YOUR RIGHT ARE THE 1755 01:21:53,120 --> 01:21:54,600 DIFFERENT TISSUE TYPES PRODUCING 1756 01:21:54,600 --> 01:21:58,160 THE CELL-FREE DNA IN AN INSTANT. 1757 01:21:58,160 --> 01:22:01,120 IF YOU CLICK HERE THESE ARE TWO 1758 01:22:01,120 --> 01:22:04,080 PATIENTS WITH COVID-19 WHO DIED. 1759 01:22:04,080 --> 01:22:07,840 ON ADMISSION YOU CAN SEE 1760 01:22:07,840 --> 01:22:09,800 CELL-FREE DNA LEVELS RANGE FROM 1761 01:22:09,800 --> 01:22:12,320 1,000 TO 1,500. 1762 01:22:12,320 --> 01:22:17,800 BY REFERENCE IN HEALTHY CONTROL 1763 01:22:17,800 --> 01:22:23,760 THE RANGE IS 12% TO 20%. 1764 01:22:23,760 --> 01:22:25,480 THESE ARE HIGH LEVELS OF 1765 01:22:25,480 --> 01:22:26,840 CELL-FREE DNA. 1766 01:22:26,840 --> 01:22:29,080 FROM ADMISSION THE PATIENT GETS 1767 01:22:29,080 --> 01:22:30,960 ALL KIND OF TREATMENT AND 1768 01:22:30,960 --> 01:22:33,840 CELL-FREE DNA LEVELS COME DOWN 1769 01:22:33,840 --> 01:22:37,120 AND THESE PATIENTS GO INTO A 1770 01:22:37,120 --> 01:22:41,440 SECOND INFLAMMATORY PHASE OF 1771 01:22:41,440 --> 01:22:48,040 COVID, EXPONENTIAL RISE OF 1772 01:22:48,040 --> 01:22:50,040 CELL-FREE DNA AND BECAUSE THE 1773 01:22:50,040 --> 01:22:53,080 HALF LIFE IS SO SHORT, YOU CAN 1774 01:22:53,080 --> 01:22:54,600 SAMPLE QUESTIONS FREQUENTLY AND 1775 01:22:54,600 --> 01:22:56,680 ALMOST GIVE YOU A SNAPSHOT OF 1776 01:22:56,680 --> 01:22:58,760 WHAT INJURY PATENTS ARE GOING ON 1777 01:22:58,760 --> 01:23:02,360 IN THE BODY AT THAT INSTANT. 1778 01:23:02,360 --> 01:23:04,760 THE HALF LIFE IS 15 TO 30 1779 01:23:04,760 --> 01:23:06,640 MINUTES OF CELL-FREE DNA. 1780 01:23:06,640 --> 01:23:08,720 IT'S A GOOD SNAPSHOT IN TIME 1781 01:23:08,720 --> 01:23:13,120 COMPARED TO PATIENT WITH 1782 01:23:13,120 --> 01:23:16,600 COVID-19 WHO SURVIVE. 1783 01:23:16,600 --> 01:23:19,240 FIRST PATIENTS 150 TO 600 THEN 1784 01:23:19,240 --> 01:23:22,760 THE TRENDS OF THE CELL-FREE DNA 1785 01:23:22,760 --> 01:23:23,600 DIFFER. 1786 01:23:23,600 --> 01:23:26,280 THE TISSUES PRODUCING THE 1787 01:23:26,280 --> 01:23:27,080 CELL-FREE DNA DIFFER FROM 1788 01:23:27,080 --> 01:23:28,240 PATIENT WHO'S DIE. 1789 01:23:28,240 --> 01:23:29,800 FROM ADMISSION WE CAN ALMOST 1790 01:23:29,800 --> 01:23:35,520 PREDICT PATIENTS WHO NEED ICU 1791 01:23:35,520 --> 01:23:40,200 CARE WITH CARE SUBSEQUENTLY WITH 1792 01:23:40,200 --> 01:23:42,680 GOOD TEST CHARACTERISTIC. 1793 01:23:42,680 --> 01:23:45,080 IS IT ONLY IN COVID? 1794 01:23:45,080 --> 01:23:46,440 NO. 1795 01:23:46,440 --> 01:23:50,920 WE SHOW PATIENTS WITH PULMONARY 1796 01:23:50,920 --> 01:23:51,240 HYPERTENSION. 1797 01:23:51,240 --> 01:23:53,840 THE SECOND-GENERATION CELL-FREE 1798 01:23:53,840 --> 01:23:56,840 DNA APPROACHES ARE BROADLY 1799 01:23:56,840 --> 01:23:58,680 APPLICABLE IN CONDITIONS BEYOND 1800 01:23:58,680 --> 01:23:59,040 TRANSPLANTATION. 1801 01:23:59,040 --> 01:24:02,080 HAVING DEMONSTRATED THE PROOF OF 1802 01:24:02,080 --> 01:24:04,000 CONCEPT WITH TRANSPLANT DOCTORS 1803 01:24:04,000 --> 01:24:09,600 WE TURN OUR ATTENTION BACK TO 1804 01:24:09,600 --> 01:24:13,080 TRANSPLANTATION AND SAID WE 1805 01:24:13,080 --> 01:24:16,960 LOOKED AT CELL-FREE DNA AND CAN 1806 01:24:16,960 --> 01:24:19,240 WE LOOK AT THE TRANSPLANTED 1807 01:24:19,240 --> 01:24:21,080 ORGAN AND WHAT IT'S FACING IN 1808 01:24:21,080 --> 01:24:23,760 THE TRANSPLANT JOURNEY STARTING 1809 01:24:23,760 --> 01:24:28,680 FROM BEFORE TRANSPLANTATION. 1810 01:24:28,680 --> 01:24:30,320 A CREDIT TO GRAFT AND GRAFT 1811 01:24:30,320 --> 01:24:32,400 INVESTIGATORS BECAUSE THEY 1812 01:24:32,400 --> 01:24:33,920 STARTED SAMPLES BEFORE 1813 01:24:33,920 --> 01:24:35,320 TRANSPLANTATION AND COLLECTED 1814 01:24:35,320 --> 01:24:45,840 SERIAL SAMPLES AFTER AS WELL. 1815 01:24:47,280 --> 01:24:49,920 AND THE PATIENTS WILL GO ON TO 1816 01:24:49,920 --> 01:24:51,640 DIE EARLY AND THERE'S INJURY 1817 01:24:51,640 --> 01:24:54,240 FACED WHETHER LUNG, HEARD OR 1818 01:24:54,240 --> 01:24:56,520 KIDNEYS AND THERE'S PROFUSION 1819 01:24:56,520 --> 01:24:57,280 INJURY AND INFECTION OF OTHER 1820 01:24:57,280 --> 01:24:59,840 INJURIES AS WELL. 1821 01:24:59,840 --> 01:25:04,880 SO LET ME ORIENT YOU TO THE 1822 01:25:04,880 --> 01:25:08,040 COPIES OF ML PER CELL-FREE DNA 1823 01:25:08,040 --> 01:25:10,160 UP TO 250,000 AND HEALTHY 1824 01:25:10,160 --> 01:25:12,040 CONTROLS ALL THE WAY DOWN HERE. 1825 01:25:12,040 --> 01:25:14,760 IN TERMS OF COPIES, HEALTHY 1826 01:25:14,760 --> 01:25:17,000 PEOPLE HAVE ABOUT 2,000 COPIES 1827 01:25:17,000 --> 01:25:18,800 OF CELL-FREE DNA PLASMA. 1828 01:25:18,800 --> 01:25:21,040 THAT'S OUR ORIENTATION. 1829 01:25:21,040 --> 01:25:26,200 IF YOU LOOK AT PATIENTS AWAITING 1830 01:25:26,200 --> 01:25:28,800 TRANSPLANTATION YOU HAVE A 1831 01:25:28,800 --> 01:25:30,880 TWOFOLD HIGHER CELL-FREE DNA IN 1832 01:25:30,880 --> 01:25:34,120 THOSE THAN FROM HEALTHY CONTROLS 1833 01:25:34,120 --> 01:25:38,400 AND THE CELL-FREE DNA PREDICT 1834 01:25:38,400 --> 01:25:41,840 TIME TO ALLOGRAFT FAILURE. 1835 01:25:41,840 --> 01:25:49,080 THE INJURY STARTS BEFORE 1836 01:25:49,080 --> 01:25:52,680 TRANSPLANTATION. 1837 01:25:52,680 --> 01:25:54,640 AFTER, ONE TAKE-HOME POINT IS 1838 01:25:54,640 --> 01:25:56,080 THIS SLIDE, THE SECOND SLIDE. 1839 01:25:56,080 --> 01:26:00,440 THIS WAS DONE -- THIS IS SAMPLES 1840 01:26:00,440 --> 01:26:03,160 COLLECTED ON YEAR ONE OF 1841 01:26:03,160 --> 01:26:06,200 TRANSPLANTATION. 1842 01:26:06,200 --> 01:26:10,800 THE PATIENTS HAVE 154 HIGHER 1843 01:26:10,800 --> 01:26:12,400 CELL-FREE DNA THAN HEALTHY 1844 01:26:12,400 --> 01:26:12,680 CONTROLS. 1845 01:26:12,680 --> 01:26:14,200 IT'S A MARKER OF INJURY. 1846 01:26:14,200 --> 01:26:16,880 CAN MEASURE WHAT THE PATIENT IS 1847 01:26:16,880 --> 01:26:18,680 COMING OUT OF THE OPERATING ROOM 1848 01:26:18,680 --> 01:26:19,720 LOOKING AT. 1849 01:26:19,720 --> 01:26:25,640 YOU GO FROM ZERO TO 2.5 FOLD AND 1850 01:26:25,640 --> 01:26:28,200 YES IT COMES DOWN BUT THE LEVELS 1851 01:26:28,200 --> 01:26:31,600 DON'T JUST COME DOWN, IT'S FOUR 1852 01:26:31,600 --> 01:26:33,120 TIMES OF HEALTHY CONTROLS AND 1853 01:26:33,120 --> 01:26:35,760 THE LEVELS REMAIN HIGHER FOR 1854 01:26:35,760 --> 01:26:37,280 LEVELS WHO GO ON TO DEVELOP 1855 01:26:37,280 --> 01:26:38,280 ACUTE REJECTION. 1856 01:26:38,280 --> 01:26:40,800 WITH THESE TECHNOLOGIES AND THE 1857 01:26:40,800 --> 01:26:43,080 INFRASTRUCTURE IN GRAPH WE'RE 1858 01:26:43,080 --> 01:26:44,880 ABLE TO PROFILE INJURY STATES IN 1859 01:26:44,880 --> 01:26:46,320 THE TRANSPLANT PATIENT TO 1860 01:26:46,320 --> 01:26:51,920 IDENTIFY BETTER TIMES IN WHICH 1861 01:26:51,920 --> 01:26:55,200 WE CAN TREAT AND WHEN TO TREAT. 1862 01:26:55,200 --> 01:26:58,480 SO AS I MENTIONED, THESE 1863 01:26:58,480 --> 01:26:59,440 PATIENTS BEFORE TRANSPLANTATION 1864 01:26:59,440 --> 01:27:02,440 ARE ALREADY IN A HEIGHTENED 1865 01:27:02,440 --> 01:27:03,560 INJURY STATE. 1866 01:27:03,560 --> 01:27:06,120 THAT INCREASES AFTER 1867 01:27:06,120 --> 01:27:11,880 TRANSPLANTATION AND PERSISTS 1868 01:27:11,880 --> 01:27:15,480 UNFORTUNATELY, INCREASING THE 1869 01:27:15,480 --> 01:27:17,640 RISK OF ALLOGRAFT FAILURE. 1870 01:27:17,640 --> 01:27:23,080 ALLOW ME TO STOP AND SAY 1871 01:27:23,080 --> 01:27:25,920 CELL-FREE DNA ALLOWED US TO 1872 01:27:25,920 --> 01:27:29,080 DETERMINE EARLIER TIME POINTS TO 1873 01:27:29,080 --> 01:27:37,080 TREAT PATIENTS BEFORE 1874 01:27:37,080 --> 01:27:39,040 IRREVERSIBLE INJURY SETS IN AND 1875 01:27:39,040 --> 01:27:40,880 IDENTIFY RISK PROFILE AND WHO TO 1876 01:27:40,880 --> 01:27:43,000 PAY CLOSER ATTENTION TO AND WHO 1877 01:27:43,000 --> 01:27:43,560 TO TREAT AND WHEN TO TREAT 1878 01:27:43,560 --> 01:27:46,240 EARLY. 1879 01:27:46,240 --> 01:27:48,440 THE DATA I DID NOT SHOW YOU IS 1880 01:27:48,440 --> 01:27:51,200 IF YOU FOLLOW LEVELS OF 1881 01:27:51,200 --> 01:27:53,480 CELL-FREE DNA IT ALSO GIVES AN 1882 01:27:53,480 --> 01:27:55,240 EARLY INDICATION OF WHO IS 1883 01:27:55,240 --> 01:28:00,000 RESPONDING TO TREATMENT. 1884 01:28:00,000 --> 01:28:10,560 SO WE BELIEVE THAT AND THE LAST 1885 01:28:11,320 --> 01:28:16,760 EDITORIAL WE PUBLISHED AND 1886 01:28:16,760 --> 01:28:21,080 FORCED TO RAPIDLY EVOLVE BY THE 1887 01:28:21,080 --> 01:28:22,680 SARS COV2 PANDEMIC THE GROUP LED 1888 01:28:22,680 --> 01:28:26,480 BY SEAN ARBURG USED PRIOR 1889 01:28:26,480 --> 01:28:29,120 KNOWLEDGE WITH CELL-FREE DNA TO 1890 01:28:29,120 --> 01:28:31,280 PROTECT THEIR LONG TRANSPLANT 1891 01:28:31,280 --> 01:28:35,280 RECIPIENTS ON STAFF FROM THE 1892 01:28:35,280 --> 01:28:37,080 RISK OF TRANSMISSION OF SARS 1893 01:28:37,080 --> 01:28:37,680 COV2. 1894 01:28:37,680 --> 01:28:41,200 AS WE MOVE OUT OF THE POINT OF 1895 01:28:41,200 --> 01:28:42,760 CARE THIS REAL-WORLD DATA 1896 01:28:42,760 --> 01:28:45,680 SUGGESTS A NEW ERA OF LUNG 1897 01:28:45,680 --> 01:28:49,080 TRANSPLANT CARE, ONE OF GENOMIC 1898 01:28:49,080 --> 01:28:54,440 EVOLUTION IS DONE. 1899 01:28:54,440 --> 01:28:58,440 THIS IS AN EDITORIAL AND THE 1900 01:28:58,440 --> 01:29:01,040 ACCEPTANCE OF THE WORK, THE 1901 01:29:01,040 --> 01:29:02,680 ADAPTATION OF THE PROTOCOL THAT 1902 01:29:02,680 --> 01:29:03,760 REPROPOSED TO MONITOR PATIENTS 1903 01:29:03,760 --> 01:29:06,320 EVEN WITHOUT A RANDOMIZED 1904 01:29:06,320 --> 01:29:09,520 CONTROL TRIAL, THE CELL-FREE DNA 1905 01:29:09,520 --> 01:29:12,200 IS BEING ADAPTED BY AN 1906 01:29:12,200 --> 01:29:13,760 INCREASING NUMBER OF CENTERS. 1907 01:29:13,760 --> 01:29:16,760 THIS COULD BE POSSIBLE BECAUSE 1908 01:29:16,760 --> 01:29:19,240 OF THE MICROENVIRONMENT WE'VE 1909 01:29:19,240 --> 01:29:21,360 BEEN FORTUNATE TO BE PART OF AND 1910 01:29:21,360 --> 01:29:26,280 THE PROGRAM WHICH HOLDS THE 1911 01:29:26,280 --> 01:29:27,200 COMMUNITY TO IMPLEMENT AS MUCH 1912 01:29:27,200 --> 01:29:29,120 AS RIGOR IN THE WAY WE SET UP 1913 01:29:29,120 --> 01:29:32,560 OUR RESEARCH OBJECTIVES AND 1914 01:29:32,560 --> 01:29:33,080 RESEARCH INFRASTRUCTURE. 1915 01:29:33,080 --> 01:29:35,080 IN MY MIND THIS IS WHAT THE 1916 01:29:35,080 --> 01:29:38,800 EDITORIAL IS HIGHLIGHTING. 1917 01:29:38,800 --> 01:29:41,120 IT'S THAT MICROENVIRONMENT THAT 1918 01:29:41,120 --> 01:29:42,600 I'VE BEEN FOR THE TO BE A PART 1919 01:29:42,600 --> 01:29:42,760 OF. 1920 01:29:42,760 --> 01:29:45,080 WE BELIEVE WE FOUND A TOOL THAT 1921 01:29:45,080 --> 01:29:47,560 WE CAN EFFECTIVELY IDENTIFY 1922 01:29:47,560 --> 01:29:50,720 REJECTION, IDENTIFYING WHO, WHEN 1923 01:29:50,720 --> 01:29:53,800 AND I DIDN'T SHOW YOU SOME DATA 1924 01:29:53,800 --> 01:29:54,640 WITH WHAT. 1925 01:29:54,640 --> 01:29:56,880 WHAT TO USE AND WE'RE READY TO 1926 01:29:56,880 --> 01:29:59,000 MOVE TO THE NEXT PHASE, PHASE 2, 1927 01:29:59,000 --> 01:30:02,560 INTERVENTIONS. 1928 01:30:02,560 --> 01:30:07,240 I'VE BEEN FORTUNATE TO WORK IN 1929 01:30:07,240 --> 01:30:10,080 THE INTRAMURAL PROGRAM BUT TO BE 1930 01:30:10,080 --> 01:30:12,000 HAVE ACCESS OR HAVE FELLOWS THAT 1931 01:30:12,000 --> 01:30:19,040 CAN JOIN THE LAB FROM DIFFERENT 1932 01:30:19,040 --> 01:30:20,000 SPECIALTIES AND ATTRACT 1933 01:30:20,000 --> 01:30:21,080 DIFFERENT SPECIALTIES AND 1934 01:30:21,080 --> 01:30:25,200 THEY'VE COME TO THE LAB IN THE 1935 01:30:25,200 --> 01:30:27,640 LAST TWO YEARS. 1936 01:30:27,640 --> 01:30:33,040 ALLOW ME TO STOP HERE BY GIVING 1937 01:30:33,040 --> 01:30:43,040 A CONGRATULATORY SHOUT OUT AND 1938 01:30:43,040 --> 01:30:47,320 THE WASHINGTON HOSPITAL CENTER 1939 01:30:47,320 --> 01:30:48,240 AND VIRGINIA COMMONWEALTH CENTER 1940 01:30:48,240 --> 01:30:49,480 FORMING THE CONSORTIUM. 1941 01:30:49,480 --> 01:30:55,160 IT'S BEEN A PRIVILEGE WORKING 1942 01:30:55,160 --> 01:31:04,400 HERE AND THERE'S THE OFFICE AND 1943 01:31:04,400 --> 01:31:06,080 I'VE BEEN FORTUNATE TO WORK WITH 1944 01:31:06,080 --> 01:31:06,800 PEOPLEIT DIFFERENT 1945 01:31:06,800 --> 01:31:08,000 BACKGROUNDS AND WAYS OF THINKING 1946 01:31:08,000 --> 01:31:11,920 AND CULTURES AND ALL OF US WITH 1947 01:31:11,920 --> 01:31:12,960 AN EYE TOWARDS THE SAME GOAL. 1948 01:31:12,960 --> 01:31:23,280 THANK YOU SO MUCH. 1949 01:31:27,120 --> 01:31:28,840 ANY QUESTIONS? 1950 01:31:28,840 --> 01:31:31,800 >>THANK YOU FOR SOME FUN WORK 1951 01:31:31,800 --> 01:31:34,960 THOUGH I'M NERVOUS YOU'RE GOING 1952 01:31:34,960 --> 01:31:37,680 TO DRY UP MY SUPPLY OF BIOPSIES 1953 01:31:37,680 --> 01:31:46,600 BY REMOVING THE NEED. 1954 01:31:46,600 --> 01:31:49,080 I CAME FROM THE TRANSPLANT 1955 01:31:49,080 --> 01:31:50,560 MEETING AND A BIG DISCUSSION IN 1956 01:31:50,560 --> 01:31:55,600 THE LUNG TRANSPLANT COMMUNITY IS 1957 01:31:55,600 --> 01:31:59,000 TRYING TO FIGURE OUT WHICH 1958 01:31:59,000 --> 01:32:00,320 PATIENT TO TRANSPLANT FROM THOSE 1959 01:32:00,320 --> 01:32:03,360 WHO RECOVERED FROM COVID AND OUT 1960 01:32:03,360 --> 01:32:05,800 OF THE UNIT BUT STILL HAVE A 1961 01:32:05,800 --> 01:32:06,760 PULMONARY DISABILITY. 1962 01:32:06,760 --> 01:32:07,600 WILL THEY GET BETTER? 1963 01:32:07,600 --> 01:32:10,400 DO I NEED TRANSPLANT? 1964 01:32:10,400 --> 01:32:12,880 HAVE YOU THOUGHT OF LOOKING IN 1965 01:32:12,880 --> 01:32:15,240 THAT POPULATION TO DETERMINE 1966 01:32:15,240 --> 01:32:18,600 WHICH PATIENTS WHICH MAY BE 1967 01:32:18,600 --> 01:32:19,480 PROGRESSING OR THEIR LUNG 1968 01:32:19,480 --> 01:32:21,720 FUNCTION MAY BE IMPROVING INN 1969 01:32:21,720 --> 01:32:24,040 TERMS OF TRACKING YOUR CELL-FREE 1970 01:32:24,040 --> 01:32:24,920 DAP. 1971 01:32:24,920 --> 01:32:32,960 >>THANK YOU VERY MUCH. 1972 01:32:32,960 --> 01:32:34,720 >>YES. 1973 01:32:34,720 --> 01:32:37,480 A TRANSPLANT SURGEON AT U-PENN 1974 01:32:37,480 --> 01:32:40,000 WITH JOSH DIAMOND THE DIRECTOR, 1975 01:32:40,000 --> 01:32:47,240 IS ON THE P MEDICAL SIDETHEY AC 1976 01:32:47,240 --> 01:32:48,240 PATIENTS WHO HAVE TRANSPLANTED 1977 01:32:48,240 --> 01:32:49,760 BECAUSE OF COVID. 1978 01:32:49,760 --> 01:32:51,600 THEY HAVE COLLECTED SERIAL 1979 01:32:51,600 --> 01:32:53,080 SAMPLES ON THE PATIENTS. 1980 01:32:53,080 --> 01:32:57,480 SO WE'VE CREATED A COLLABORATION 1981 01:32:57,480 --> 01:33:04,040 AND WE GOT THE SAMPLES AND WE'RE 1982 01:33:04,040 --> 01:33:04,520 LOOKING INTO THAT. 1983 01:33:04,520 --> 01:33:06,280 I BELIEVE YOUR HYPOTHESIS IS 1984 01:33:06,280 --> 01:33:06,760 CORRECT. 1985 01:33:06,760 --> 01:33:08,320 IN OUR EXPERIENCE WITH OTHER 1986 01:33:08,320 --> 01:33:09,960 DISEASES, TRANSPLANTATION, FOR 1987 01:33:09,960 --> 01:33:12,400 EXAMPLE, WHEN THE PATIENT, 1988 01:33:12,400 --> 01:33:18,280 EVERYBODY'S CELL-FREE DNA IS 1989 01:33:18,280 --> 01:33:23,800 HIGH AND FOR PATIENT WHO'S 1990 01:33:23,800 --> 01:33:25,640 DEVELOP EARLY ALLOGRAFT DEVELOP 1991 01:33:25,640 --> 01:33:28,120 A SECOND RISE IN THE CELL-FREE 1992 01:33:28,120 --> 01:33:30,840 DNA LEVELS BEFORE THEY DEVELOP 1993 01:33:30,840 --> 01:33:32,360 CHRONIC REJECTION. 1994 01:33:32,360 --> 01:33:34,560 WE DON'T HAVE AN ANSWER YET BUT 1995 01:33:34,560 --> 01:33:35,480 HOPEFULLY NEXT YEAR WE WILL. 1996 01:33:35,480 --> 01:33:40,400 >>I WAS ASKING ABOUT THE 1997 01:33:40,400 --> 01:33:46,040 PATIENTS WHO HAVEN'T GOTTEN THE 1998 01:33:46,040 --> 01:33:49,400 TRANSPLANT YET AND DEBATING 1999 01:33:49,400 --> 01:33:59,960 WHETHER THEY NEED A TRANSPLANT. 2000 01:34:02,480 --> 01:34:03,880 THAT WOULD BE INTERESTING. 2001 01:34:03,880 --> 01:34:04,880 >>NICE PRESENTATION. 2002 01:34:04,880 --> 01:34:07,160 IF I'M UNDERSTANDING CORRECTLY, 2003 01:34:07,160 --> 01:34:12,160 THIS MAY BE, DARE I SAY, 2004 01:34:12,160 --> 01:34:13,400 NON-SPECIFIC MARKER OF INJURY 2005 01:34:13,400 --> 01:34:17,160 WITH HEART, LUNG, BLOOD. 2006 01:34:17,160 --> 01:34:18,760 COULD WE USE SOMETHING LIKE THIS 2007 01:34:18,760 --> 01:34:21,400 IN LOOKING IN BIOMARKERS AND 2008 01:34:21,400 --> 01:34:22,960 DISEASE ACTIVITY AND LUNG WERE 2009 01:34:22,960 --> 01:34:25,440 NOT TOO FAR TN T ROAD TO SAY 2010 01:34:25,440 --> 01:34:27,080 BUT T PATEING 2011 01:34:27,080 --> 01:34:30,240 WE THINK MAY 2012 01:34:30,240 --> 01:34:31,680 INTERVENE IN THE DISEASE. 2013 01:34:31,680 --> 01:34:33,400 HAVE YOU LOOKED SERIALLY AT SOME 2014 01:34:33,400 --> 01:34:38,640 OF THOSE PATIENTS, FOR EXAMPLE, 2015 01:34:38,640 --> 01:34:41,040 TO SEE IF OUR CURRENT DRUGS MAY 2016 01:34:41,040 --> 01:34:43,280 REDUCE THE AMOUNT OF CELL-FREE 2017 01:34:43,280 --> 01:34:45,720 DNA OR OTHER DISEASES BECAUSE 2018 01:34:45,720 --> 01:34:48,560 MAYBE IT'S TO SOME EXTENT A 2019 01:34:48,560 --> 01:34:59,080 NON-SPECIFIC DISEASE BIOMARKER. 2020 01:35:02,080 --> 01:35:06,160 >>WITH STEVE NATHAN AND OTHER 2021 01:35:06,160 --> 01:35:08,240 PEOPLE IN THE GRAFT CONSORTIUM 2022 01:35:08,240 --> 01:35:14,080 WE ARE LOOKING AT PATIENTS WITH 2023 01:35:14,080 --> 01:35:14,880 PULMONARY FIBROSIS BEING TREATED 2024 01:35:14,880 --> 01:35:20,760 WITH A NEW DRUG AND WE'RE SAYING 2025 01:35:20,760 --> 01:35:27,920 TO SEE IT SAYS BEFORE TREATMENT 2026 01:35:27,920 --> 01:35:29,800 AND REDUCES TREATMENT? 2027 01:35:29,800 --> 01:35:31,400 IN PLANS TRANSPLANTATION WHEN 2028 01:35:31,400 --> 01:35:34,360 YOU LOOK AT DONOR-DERIVED THE 2029 01:35:34,360 --> 01:35:35,840 CELL-FREE DNA COMING FROM THE 2030 01:35:35,840 --> 01:35:36,200 DONOR LUNG. 2031 01:35:36,200 --> 01:35:38,480 IF YOU LOOK AT THAT IN PATIENTS 2032 01:35:38,480 --> 01:35:40,000 WHO DEVELOP REJECTION, AS I 2033 01:35:40,000 --> 01:35:42,720 SHOWED YOU, THE CELL-FREE DNA 2034 01:35:42,720 --> 01:35:43,480 RISE. 2035 01:35:43,480 --> 01:35:47,120 WHEN YOU TREAT THE PATIENT THE 2036 01:35:47,120 --> 01:35:48,000 CELL-FREE DNA DROPS WITHIN DAYS. 2037 01:35:48,000 --> 01:35:49,800 THE LEVELS ARE DOWN. 2038 01:35:49,800 --> 01:35:52,200 FOR PATIENTS WHO WILL NOT 2039 01:35:52,200 --> 01:35:53,160 RESPOND TO TREATMENT, THE LEVELS 2040 01:35:53,160 --> 01:35:54,480 COME DOWN BUT DON'T GO BACK TO 2041 01:35:54,480 --> 01:35:54,760 BASELINE. 2042 01:35:54,760 --> 01:36:05,040 THEY REMAIN HIGH. 2043 01:36:22,600 --> 01:36:24,240 >>THIS COULD BE DONE IN CUL 2044 01:36:24,240 --> 01:36:29,800 DOOR. 2045 01:36:29,800 --> 01:36:32,240 -- IN CULTURE. 2046 01:36:32,240 --> 01:36:34,200 >>I'M SURE DR. KILEY IS LOOKING 2047 01:36:34,200 --> 01:36:34,760 FORWARD TO IT. 2048 01:36:34,760 --> 01:36:37,120 DOES ANYBODY ELSE HAVE A 2049 01:36:37,120 --> 01:36:37,600 QUESTION? 2050 01:36:37,600 --> 01:36:39,440 I'M NOT SEEING HANDS RAISED. 2051 01:36:39,440 --> 01:36:41,400 DR. GIBBONS -- SORRY, YOU'RE NOT 2052 01:36:41,400 --> 01:36:46,960 ALLOWED TO ASK QUESTIONS. 2053 01:36:46,960 --> 01:36:54,400 >>NICE WORK, SEAN. 2054 01:36:54,400 --> 01:36:57,400 CAN OUT PUT IN CONTEXT WHAT 2055 01:36:57,400 --> 01:36:59,720 YOU'RE DOING WITH THE PROFILES 2056 01:36:59,720 --> 01:37:01,680 ALMOST RELATED TO DAVID'S POINT. 2057 01:37:01,680 --> 01:37:06,360 IF YOU HAVE CELL-FREE DNA I HEAR 2058 01:37:06,360 --> 01:37:14,800 ABOUT PAMPS AND NETS. 2059 01:37:14,800 --> 01:37:19,080 ARE WE GETTING TO A POINT ARE WE 2060 01:37:19,080 --> 01:37:22,320 CAN PROFILE THESE OR WE LOOK AT 2061 01:37:22,320 --> 01:37:24,200 THROUGH A MICROSCOPE TO WHO IS 2062 01:37:24,200 --> 01:37:28,280 DOING WHAT AND WHAT STAGE OF THE 2063 01:37:28,280 --> 01:37:30,520 INJURY IS OVER? 2064 01:37:30,520 --> 01:37:31,720 YOU'RE SPOT ON. 2065 01:37:31,720 --> 01:37:35,680 THE CELL-FREE DNA IS ALSO 2066 01:37:35,680 --> 01:37:36,960 DAMAGE-ASSOCIATED MOLECULAR 2067 01:37:36,960 --> 01:37:37,200 PATHWAY. 2068 01:37:37,200 --> 01:37:41,040 IT'S NOT JUST A BIOMARKER, IT'S 2069 01:37:41,040 --> 01:37:42,520 DIRECTLY INVOLVED IN THE 2070 01:37:42,520 --> 01:37:44,120 PATHOGENESIS OF DISEASE. 2071 01:37:44,120 --> 01:37:45,880 I DID NOT SHOW THAT WORK. 2072 01:37:45,880 --> 01:37:47,360 THAT'S NUMBER ONE. 2073 01:37:47,360 --> 01:37:49,880 NUMBER TWO, THE PROFILE TELLS 2074 01:37:49,880 --> 01:37:54,880 YOU ONCOMING DISEASES. 2075 01:37:54,880 --> 01:37:58,200 IF YOU LOOK AT TRANSPLANTS, TWO 2076 01:37:58,200 --> 01:38:00,240 FOUR MONTHS BEFORE THE BIOPSY 2077 01:38:00,240 --> 01:38:01,480 WHICH SHOWS SIGN OF REJECTION IS 2078 01:38:01,480 --> 01:38:04,760 IT IN TRANSPLANT NOW? 2079 01:38:04,760 --> 01:38:06,880 IF YOU LOOK AT IT WITH PATIENTS 2080 01:38:06,880 --> 01:38:09,000 WITH COVID WE TAKE THE SAMPLES 2081 01:38:09,000 --> 01:38:12,200 AT THE TIME OF ADMISSION ASKING 2082 01:38:12,200 --> 01:38:15,040 THE QUESTION, WHICH PATIENTS 2083 01:38:15,040 --> 01:38:16,920 WILL GET P.E. 2084 01:38:16,920 --> 01:38:20,240 WHICH PATIENTS WILL DEVELOP 2085 01:38:20,240 --> 01:38:23,320 CARDIOVASCULAR MYOPATHY. 2086 01:38:23,320 --> 01:38:24,640 YOU START SEEING EARLY 2087 01:38:24,640 --> 01:38:29,360 INDICATIONS OF THE BIOMARKER 2088 01:38:29,360 --> 01:38:30,480 WHERE THE CHEMICAL MARKERS GO 2089 01:38:30,480 --> 01:38:35,680 OFF. 2090 01:38:35,680 --> 01:38:37,600 WE DON'T HAVE ENOUGH DATA TO 2091 01:38:37,600 --> 01:38:40,160 ANSWER YOUR QUESTION BUT THE 2092 01:38:40,160 --> 01:38:43,680 DATA FROM TRANSPLANT AND THOSE 2093 01:38:43,680 --> 01:38:45,480 FROM COVID AND HYPERTENSION 2094 01:38:45,480 --> 01:38:47,720 INDICATE THE PROFILES ARE 2095 01:38:47,720 --> 01:38:50,000 CLINICALLY RELEVANT AND EARLY 2096 01:38:50,000 --> 01:38:51,000 INDICATORS OF SOMETHING BAD THAT 2097 01:38:51,000 --> 01:38:52,520 IS GOING TO HAPPEN WITH THE 2098 01:38:52,520 --> 01:39:02,680 PATIENTS. 2099 01:39:11,320 --> 01:39:16,960 >>WE LOOKED AT A COHORT OF 2100 01:39:16,960 --> 01:39:19,760 PATIENTS WITH MULTI-SYSTEMIC 2101 01:39:19,760 --> 01:39:22,240 INFLAMMATORY DISEASE IN 2102 01:39:22,240 --> 01:39:22,520 CHILDREN. 2103 01:39:22,520 --> 01:39:31,240 THIS IS A SYNDROME THAT DEVELOPS 2104 01:39:31,240 --> 01:39:33,920 X NUMBER OF WEEKS AFTER COVID. 2105 01:39:33,920 --> 01:39:35,280 A TEAM HAS CHARACTERIZED THE 2106 01:39:35,280 --> 01:39:38,320 PATIENTS IN ADDITION TO CLINICAL 2107 01:39:38,320 --> 01:39:43,440 DATA AND IMMUNOLOGY PHENOTYPE 2108 01:39:43,440 --> 01:39:48,240 THEY COLLECTED PLASMA SAMPLES 2109 01:39:48,240 --> 01:39:51,040 SERIALLY WE MEASURED THE 2110 01:39:51,040 --> 01:39:53,440 CELL-FREE DNA POST MISC. 2111 01:39:53,440 --> 01:39:54,800 IN SOME PATIENT THE LEVEL COMES 2112 01:39:54,800 --> 01:39:55,080 UP. 2113 01:39:55,080 --> 01:39:56,240 NOT FOR ALL. 2114 01:39:56,240 --> 01:40:03,240 WHAT IT MEANS, I DON'T KNOW YET 2115 01:40:03,240 --> 01:40:07,480 BECAUSE WE'RE STILL LOOKING INTO 2116 01:40:07,480 --> 01:40:09,520 THE DATA AND X NUMBER OF MONTHS 2117 01:40:09,520 --> 01:40:14,960 AFTER COVID OR TREATING FOR 2118 01:40:14,960 --> 01:40:15,560 REJECTION OR AFTER PICK YOUR 2119 01:40:15,560 --> 01:40:24,520 DISEASE. 2120 01:40:24,520 --> 01:40:28,760 NOW WE ARE LOOKING TO SEE WHAT 2121 01:40:28,760 --> 01:40:32,840 ARE THE CLINICAL CORRELATES THE 2122 01:40:32,840 --> 01:40:34,160 CELL-FREE DNA IN THESE PATIENTS, 2123 01:40:34,160 --> 01:40:37,040 DO THEY HAVE LONG COVID. 2124 01:40:37,040 --> 01:40:39,760 AND IN THE INTRAMURAL WE HAVE A 2125 01:40:39,760 --> 01:40:42,280 COHORT OF PATIENTS WITH LONG 2126 01:40:42,280 --> 01:40:42,600 COVID. 2127 01:40:42,600 --> 01:40:45,520 WE LOOKED AT THE TOTAL CELL-FREE 2128 01:40:45,520 --> 01:40:47,120 DNA AND IT'S BACK TO BASELINE AS 2129 01:40:47,120 --> 01:40:48,320 HEALTHY CONTROLS. 2130 01:40:48,320 --> 01:40:51,040 WE'RE LOOKING AT THE TISSUE 2131 01:40:51,040 --> 01:40:53,760 TYPES THOUGH THE TOTAL CELL-FREE 2132 01:40:53,760 --> 01:40:56,120 DNA AS AN INDICATION OF GLOBAL 2133 01:40:56,120 --> 01:40:58,160 INJURY IS WITHIN RANGE WHERE THE 2134 01:40:58,160 --> 01:41:01,280 CELL-FREE RANGE FROM THE NEURONS 2135 01:41:01,280 --> 01:41:02,600 AND HEART OR FROM THE DIFFERENT 2136 01:41:02,600 --> 01:41:04,240 TISSUE TYPES ARE BACK TO 2137 01:41:04,240 --> 01:41:07,720 BASELINE. 2138 01:41:07,720 --> 01:41:08,440 WE WOULD BE ABLE TO ANSWER THAT 2139 01:41:08,440 --> 01:41:14,720 QUESTION. 2140 01:41:14,720 --> 01:41:16,000 >>OKAY. 2141 01:41:16,000 --> 01:41:18,280 IT LOOKS LIKE WE COVERED 2142 01:41:18,280 --> 01:41:18,600 EVERYTHING. 2143 01:41:18,600 --> 01:41:20,600 THERE WAS A WONDERFUL COMMENT IN 2144 01:41:20,600 --> 01:41:30,760 THE CHAT. 2145 01:41:31,160 --> 01:41:33,400 WE'RE ALREADY LATE SO GO AHEAD. 2146 01:41:33,400 --> 01:41:35,600 >>THE CELL-FREE DNA GRADUALLY 2147 01:41:35,600 --> 01:41:36,360 GOES UP. 2148 01:41:36,360 --> 01:41:40,840 DO WE KNOW WHEN TO INTERVENE AND 2149 01:41:40,840 --> 01:41:42,440 DOES IT MAKE A DIFFERENCE IN THE 2150 01:41:42,440 --> 01:41:43,240 PROGRESSION OF NATURAL DISEASE? 2151 01:41:43,240 --> 01:41:45,640 >>I DON'T HAVE THE ANSWER YET. 2152 01:41:45,640 --> 01:41:48,000 THAT'S WHERE I'M TRYING TO 2153 01:41:48,000 --> 01:41:50,440 CONVINCE DR. GIBBONS THAT WE'RE 2154 01:41:50,440 --> 01:41:51,680 READY TO GO THERE AND NEED 2155 01:41:51,680 --> 01:41:53,000 INFRASTRUCTURE AND RESOURCES TO 2156 01:41:53,000 --> 01:41:58,120 MOVE THERE. 2157 01:41:58,120 --> 01:42:08,240 THAT'S EXACTLY THE QUESTION AND 2158 01:42:08,240 --> 01:42:09,840 THE CELL-FREE DNA LEVEL IS 2159 01:42:09,840 --> 01:42:10,120 RISING. 2160 01:42:10,120 --> 01:42:11,800 SHOULD WE INTERVENE? 2161 01:42:11,800 --> 01:42:13,440 COULD WE INTERVENE OR WOULD THAT 2162 01:42:13,440 --> 01:42:14,000 MAKE A DIFFERENCE? 2163 01:42:14,000 --> 01:42:18,360 WE WOULD BE ABLE TO ANSWER THAT 2164 01:42:18,360 --> 01:42:18,720 QUESTION. 2165 01:42:18,720 --> 01:42:22,280 YOU TALK TO DR. GIBBONS AND 2166 01:42:22,280 --> 01:42:22,560 DR. CHARLES. 2167 01:42:22,560 --> 01:42:24,800 HE IS NOT HERE. 2168 01:42:24,800 --> 01:42:26,120 HE WAS HERE ALREADY. 2169 01:42:26,120 --> 01:42:28,280 >>SINCE WE'RE ALREADY LATE, IS 2170 01:42:28,280 --> 01:42:34,080 THERE UTILITY OF THE HOST AND 2171 01:42:34,080 --> 01:42:36,520 DONOR TRANSPLANT AND REFLECT THE 2172 01:42:36,520 --> 01:42:41,760 HOST IMMUNE RESPONSE AND THE 2173 01:42:41,760 --> 01:42:49,880 OTHER THE ORGAN. 2174 01:42:49,880 --> 01:42:54,560 AND THE HOST RESPONDS TO THE 2175 01:42:54,560 --> 01:42:57,840 ALLOGRAFT AND THE HOST RESPONDS 2176 01:42:57,840 --> 01:42:59,760 AND THE HOST RESPONSE PREDICTS 2177 01:42:59,760 --> 01:43:04,240 WHAT WILL HAPPEN IN THE 2178 01:43:04,240 --> 01:43:06,280 ALLOGRAFT AND EVEN BEFORE 2179 01:43:06,280 --> 01:43:08,400 TRANSPLANT THE HOST-DERIVED 2180 01:43:08,400 --> 01:43:11,920 CELL-FREE DNA LEVELS GOES UP 2181 01:43:11,920 --> 01:43:15,160 PREDOMINANTLY FROM INNATE IMMUNE 2182 01:43:15,160 --> 01:43:16,240 CELLS. 2183 01:43:16,240 --> 01:43:18,840 THE INNATE IMMUNE CELLS 2184 01:43:18,840 --> 01:43:22,200 CELL-FREE DNA PREDICT SURVIVAL 2185 01:43:22,200 --> 01:43:22,800 OF THE ALLOGRAFT. 2186 01:43:22,800 --> 01:43:24,520 THERE'S SOMETHING ABOUT WHAT THE 2187 01:43:24,520 --> 01:43:26,640 HOST DOES THAT INFLUENCES THE 2188 01:43:26,640 --> 01:43:28,280 LONGEVITY, WHICH WE EXPECT. 2189 01:43:28,280 --> 01:43:30,480 BUT THE COUNTERPART IS IF YOU 2190 01:43:30,480 --> 01:43:33,520 LOOK AT ORGANS WITHIN THE HOST, 2191 01:43:33,520 --> 01:43:36,240 THE KIDNEY, THE LIVER, THESE 2192 01:43:36,240 --> 01:43:38,920 ORGANS ALSO TAKE A HIT IN THE 2193 01:43:38,920 --> 01:43:40,560 LUNG TRANSPLANTATION AND GO TO 2194 01:43:40,560 --> 01:43:40,840 DYSFUNCTION. 2195 01:43:40,840 --> 01:43:47,000 IT COULD BE JUST DUE TO DRUGS. 2196 01:43:47,000 --> 01:43:48,240 THERE'S INHIBITORS THAT CAN DO 2197 01:43:48,240 --> 01:43:51,600 THIS BUT WE HAVE WORK SHOWING 2198 01:43:51,600 --> 01:43:54,080 INCREASING CELL-FREE DNA IN 2199 01:43:54,080 --> 01:43:58,920 BLOOD WILL TRIGGER MITOCHONDRIAL 2200 01:43:58,920 --> 01:44:00,080 PRODUCTION LEADING TO CELL 2201 01:44:00,080 --> 01:44:00,560 DEATH. 2202 01:44:00,560 --> 01:44:03,720 THE CELL-FREE DNA IS NOT JUST 2203 01:44:03,720 --> 01:44:05,040 THERE BUT CAUSING DAMAGE NOT 2204 01:44:05,040 --> 01:44:08,000 ONLY TO THE ALLOGRAFT BUT ALSO 2205 01:44:08,000 --> 01:44:13,520 TO THE RECIPIENT'S ORGAN AS 2206 01:44:13,520 --> 01:44:13,760 WELL. 2207 01:44:13,760 --> 01:44:17,720 THERE'S AN INTERRUPTION AT THE 2208 01:44:17,720 --> 01:44:18,560 MOLECULAR LEVEL BETWEEN THE 2209 01:44:18,560 --> 01:44:19,560 ALLOGRAFT AND HOST. 2210 01:44:19,560 --> 01:44:24,240 WE'RE TRYING TO FIGURE OUT WHAT 2211 01:44:24,240 --> 01:44:27,520 IT MEANS CLINICALLY. 2212 01:44:27,520 --> 01:44:34,640 >>THANK YOU TO TINA AND WE HAVE 2213 01:44:34,640 --> 01:44:35,800 TO MOVE ON. 2214 01:44:35,800 --> 01:44:36,280 THANK YOU FOR YOUR 2215 01:44:36,280 --> 01:44:42,120 THOUGHT-PROVOKING TALK. 2216 01:44:42,120 --> 01:44:43,720 WE FINALLY HAVE GOTTEN TO THE 2217 01:44:43,720 --> 01:44:45,680 POINT IN OUR SYSTEM OUR PLANS 2218 01:44:45,680 --> 01:44:47,840 FOR TODAY WHERE WE'RE GOING TO 2219 01:44:47,840 --> 01:44:49,760 MOVE TO OUR FINAL AGENDA ITEM. 2220 01:44:49,760 --> 01:44:51,320 THAT DOESN'T MEAN IT'S GOING 2221 01:44:51,320 --> 01:44:52,600 TOCK QUICK BUT THAT'S OKAY. 2222 01:44:52,600 --> 01:44:53,200 IT'S IMPORTANT. 2223 01:44:53,200 --> 01:44:55,080 WE'LL VOTE ON THE CONCEPTS. 2224 01:44:55,080 --> 01:44:58,920 SO BEFORE WE PROCEED, WE HAVE A 2225 01:44:58,920 --> 01:44:59,240 FEW REMINDERS. 2226 01:44:59,240 --> 01:45:00,200 IF YOU HAVE COMMENTS RELATED TO 2227 01:45:00,200 --> 01:45:02,240 THE CONCEPTS YOU SHOULD ADDRESS 2228 01:45:02,240 --> 01:45:03,720 ALL THE PANELISTS. 2229 01:45:03,720 --> 01:45:05,800 DON'T ADDRESS THE HOST OF THE 2230 01:45:05,800 --> 01:45:06,040 MEETING. 2231 01:45:06,040 --> 01:45:09,480 IF YOU'RE ENCOUNTERING ZOOM 2232 01:45:09,480 --> 01:45:11,520 TECHNICAL ISSUES CONTACT THE I 2233 01:45:11,520 --> 01:45:12,240 TECH STAFF. 2234 01:45:12,240 --> 01:45:14,880 THEY CAN'T HELP WITH DECISION 2235 01:45:14,880 --> 01:45:16,240 LENS ONLY YOUR LAPTOP AND I 2236 01:45:16,240 --> 01:45:17,760 THINK WE FIGURED THAT OUT BY NOW 2237 01:45:17,760 --> 01:45:19,960 AFTER ALL THE FUN TODAY. 2238 01:45:19,960 --> 01:45:22,840 FOR TECHNICAL ISSUES FORWARD 2239 01:45:22,840 --> 01:45:29,520 THOSE ISSUES TO THE DL 2240 01:45:29,520 --> 01:45:30,680 REPRESENTATIVES BRIAN GLEESON AT 2241 01:45:30,680 --> 01:45:36,840 REAL TIME TECH SUPPORT AND LAURA 2242 01:45:36,840 --> 01:45:37,680 SANG WILL PROVIDE BACK UP AND 2243 01:45:37,680 --> 01:45:40,240 YOU CAN PUT THAT IN THE CHAT AND 2244 01:45:40,240 --> 01:45:43,280 HOPEFULLY WE'LL GET GOING. 2245 01:45:43,280 --> 01:45:43,720 FIRST THING'S FIRST. 2246 01:45:43,720 --> 01:45:48,240 THE REFRESHER TRAINING. 2247 01:45:48,240 --> 01:45:56,240 BRIAN. 2248 01:45:56,240 --> 01:46:06,600 >>GOOD AFTERNOON. 2249 01:46:13,480 --> 01:46:15,480 I'M PAT QUIN. 2250 01:46:15,480 --> 01:46:17,960 WE HAD A CHANGE. 2251 01:46:17,960 --> 01:46:18,480 I'M REPLACING BRIAN. 2252 01:46:18,480 --> 01:46:20,240 THANK YOU FOR HAVING US SUPPORT 2253 01:46:20,240 --> 01:46:21,280 THE EVENT. 2254 01:46:21,280 --> 01:46:25,320 I'LL GIVE A BRIEF OVERVIEW OF 2255 01:46:25,320 --> 01:46:25,920 DECISION LENS. 2256 01:46:25,920 --> 01:46:28,920 THANKFULLY ALL OUR PANELISTS 2257 01:46:28,920 --> 01:46:31,080 HAVE USED IT BEFORE. 2258 01:46:31,080 --> 01:46:33,840 HERE AGAIN, TO GET STARTED 2259 01:46:33,840 --> 01:46:39,240 WITHIN THE LAST HOUR OR SO, YOU 2260 01:46:39,240 --> 01:46:41,040 SHOULD HAVE RECEIVED AN EMAIL, 2261 01:46:41,040 --> 01:46:44,240 TO RATE ALTERNATIVES AND SHOULD 2262 01:46:44,240 --> 01:46:45,920 COME FROM ADMINISTRATOR AT 2263 01:46:45,920 --> 01:46:46,760 DECISION LENS.com. 2264 01:46:46,760 --> 01:46:48,880 IF YOU OPEN THE E-MAIL AND CLICK 2265 01:46:48,880 --> 01:46:50,840 THE GET STARTED BUTTON IT THE 2266 01:46:50,840 --> 01:46:52,680 TAKE YOU TO DECISION LENS AND WE 2267 01:46:52,680 --> 01:46:54,560 CAN BEGIN THE VOTING THROUGH 2268 01:46:54,560 --> 01:47:04,680 THAT. 2269 01:47:05,080 --> 01:47:07,400 IF YOU LOGGED IN DIRECTLY YOU'LL 2270 01:47:07,400 --> 01:47:09,440 COME TO THE PAGE. 2271 01:47:09,440 --> 01:47:11,440 IF YOU LOG IN THROUGH THE LINK 2272 01:47:11,440 --> 01:47:14,680 SENT OUT YOU'LL COME IN HERE. 2273 01:47:14,680 --> 01:47:16,520 YOU CAN CLICK THAT ALTERNATIVES 2274 01:47:16,520 --> 01:47:19,760 TASK TO OPEN THIS UP. 2275 01:47:19,760 --> 01:47:21,680 IF YOU LOG IN YOU'LL SEE A FEW 2276 01:47:21,680 --> 01:47:22,040 THINGS. 2277 01:47:22,040 --> 01:47:23,480 THE BOTTOM HALF OF THE PAGE 2278 01:47:23,480 --> 01:47:25,760 YOU'LL SEE THE LIST OF THE 2279 01:47:25,760 --> 01:47:28,320 CONCEPTS BEING REVIEWED TODAY. 2280 01:47:28,320 --> 01:47:32,760 AND THEN UP HERE AT THE TOP 2281 01:47:32,760 --> 01:47:34,520 YOU'LL SEE THIS ORANGE ACTION 2282 01:47:34,520 --> 01:47:35,800 START READING ALTERNATIVES 2283 01:47:35,800 --> 01:47:36,080 BUTTON. 2284 01:47:36,080 --> 01:47:37,360 TO GET STARTED YOU CAN CLICK 2285 01:47:37,360 --> 01:47:37,640 THAT. 2286 01:47:37,640 --> 01:47:43,680 THIS IS GOING TO BRING YOU INTO 2287 01:47:43,680 --> 01:47:48,560 THE VOTING MODULE. 2288 01:47:48,560 --> 01:47:51,320 YOU HAVE THIS SELF-GUIDED TOUR. 2289 01:47:51,320 --> 01:47:52,280 YOU CAN READ IT OR CLOSE IT OUT. 2290 01:47:52,280 --> 01:48:02,240 IT'S UP TO YOU. 2291 01:48:02,240 --> 01:48:03,720 HERE YOU'LL SEE THE NAME OF THE 2292 01:48:03,720 --> 01:48:06,360 CONCEPT AND IF YOU CLICK ON THE 2293 01:48:06,360 --> 01:48:07,760 BLUE TEXT ON THE SIDE YOU'LL GET 2294 01:48:07,760 --> 01:48:08,840 MORE INFORMATION ON IT. 2295 01:48:08,840 --> 01:48:12,240 OBVIOUSLY THIS IS ALL GOING TO 2296 01:48:12,240 --> 01:48:14,600 BE BRIEF. 2297 01:48:14,600 --> 01:48:17,360 I DON'T THINK THIS IS ENTIRELY 2298 01:48:17,360 --> 01:48:18,200 NECESSARY FOR YOU BUT THERE IF 2299 01:48:18,200 --> 01:48:28,600 YOU NEED TO ACCESS IT. 2300 01:48:35,000 --> 01:48:37,400 AND BELOW THAT WE HAVE THE AREA 2301 01:48:37,400 --> 01:48:41,360 WHERE YOU MAKE THE RATING ON THE 2302 01:48:41,360 --> 01:48:41,760 CONCEPTS. 2303 01:48:41,760 --> 01:48:43,800 YOU'LL SEE IN THE PURPLE TEXT 2304 01:48:43,800 --> 01:48:44,960 THAT'S THE CRITERIA YOU'RE 2305 01:48:44,960 --> 01:48:48,200 EVALUATING THE CONTEXT AGAIN. 2306 01:48:48,200 --> 01:48:50,600 IN THIS CASE IT'S IMPORTANT FOR 2307 01:48:50,600 --> 01:48:52,400 THE ISSUE OR OPPORTUNITY AND 2308 01:48:52,400 --> 01:48:58,120 BELOW THAT IN THE BLACK REGULAR 2309 01:48:58,120 --> 01:49:00,080 TEXTUAL SEE A MORE DETAILED 2310 01:49:00,080 --> 01:49:01,760 DESCRIPTION SO IF YOU NEED MORE 2311 01:49:01,760 --> 01:49:05,760 CLARITY ON WHAT YOU ARE 2312 01:49:05,760 --> 01:49:07,560 EVALUATING THE CONCEPT AGAINST 2313 01:49:07,560 --> 01:49:08,920 YOU'LL SEE THAT AND SOMETIMES IF 2314 01:49:08,920 --> 01:49:10,280 IT'S A LONGER DESCRIPTION YOU'LL 2315 01:49:10,280 --> 01:49:12,240 CLICK MORE AND GET MORE 2316 01:49:12,240 --> 01:49:13,320 INFORMATION. 2317 01:49:13,320 --> 01:49:15,200 YOU CAN ALSO CLICK ON THE PURPLE 2318 01:49:15,200 --> 01:49:17,160 TEXT AND GET A MORE DETAILED 2319 01:49:17,160 --> 01:49:20,560 DESCRIPTION OF THE RATING SCALE. 2320 01:49:20,560 --> 01:49:24,200 WHAT IS MEANT BY IMPORTANT OR 2321 01:49:24,200 --> 01:49:25,240 MODERATELY IMPORTANT AS WELL AND 2322 01:49:25,240 --> 01:49:27,400 THAT'S ON THE PURPLE TEXT. 2323 01:49:27,400 --> 01:49:30,520 IN ORDER TO MAKE YOUR RATING, 2324 01:49:30,520 --> 01:49:36,240 SELECT THE ONE YOU BELIEVE BEST 2325 01:49:36,240 --> 01:49:41,760 FITS THE RESPONSE AND ONCE IT'S 2326 01:49:41,760 --> 01:49:43,640 HIGHLIGHTED IN GREEN YOU CAN 2327 01:49:43,640 --> 01:49:45,200 CLICK THAT AND NOW YOU'RE ON TO 2328 01:49:45,200 --> 01:49:46,600 THE NEXT CRITERIA. 2329 01:49:46,600 --> 01:49:48,200 YOU'RE STILL IN THE SAME 2330 01:49:48,200 --> 01:49:48,800 ALTERNATIVE UNTIL YOU'VE GOP 2331 01:49:48,800 --> 01:49:57,600 THROUGH ALL OF THEM. 2332 01:49:57,600 --> 01:49:59,800 YOU CAN USE MULE VIEW WHERE YOU 2333 01:49:59,800 --> 01:50:04,000 SEE THE ONE ALTERNATIVE AND ONE 2334 01:50:04,000 --> 01:50:05,040 CONCEPT AND ALL THE CRITERIA 2335 01:50:05,040 --> 01:50:06,560 YOU'RE EVALUATING IT AGAINST. 2336 01:50:06,560 --> 01:50:08,240 I'LL SWITCH THAT NOW AND YOU CAN 2337 01:50:08,240 --> 01:50:12,160 SEE WHAT THAT LOOKS LIKE AND I 2338 01:50:12,160 --> 01:50:13,720 RECOMMEND USING THAT FORMAT 2339 01:50:13,720 --> 01:50:14,400 INSTEAD. 2340 01:50:14,400 --> 01:50:15,920 YOU HAVE IN THE BLUE TEXT THE 2341 01:50:15,920 --> 01:50:17,880 CONTEXT YOU'RE EVALUATING AND 2342 01:50:17,880 --> 01:50:24,560 THEN NOW SINCE I'M DOING THIS IN 2343 01:50:24,560 --> 01:50:28,280 MULTIVIEW IT'S EASIER TO KEEP 2344 01:50:28,280 --> 01:50:28,800 TRAM OF WHAT YOU'RE DOING. 2345 01:50:28,800 --> 01:50:29,360 I'LL WALK THROUGH ALL THE 2346 01:50:29,360 --> 01:50:39,560 SELECTIONS. 2347 01:50:41,320 --> 01:50:43,480 AND FOR THE ORANGE NEXT BUTTON 2348 01:50:43,480 --> 01:50:45,360 IS NOW HIGHLIGHTED AND CLICK 2349 01:50:45,360 --> 01:50:46,640 NEXT AND NOW I'M ON THE SECOND 2350 01:50:46,640 --> 01:50:49,800 CONCEPT FOR THE DAY AND HAVE A 2351 01:50:49,800 --> 01:50:51,360 CLEAN SLATE ON ALL THOSE. 2352 01:50:51,360 --> 01:50:52,520 THAT'S AN OPTION TO GO AHEAD AND 2353 01:50:52,520 --> 01:50:53,240 USE THAT. 2354 01:50:53,240 --> 01:50:54,880 IF YOU WANT TO PROVIDE MORE 2355 01:50:54,880 --> 01:50:56,680 CONTEXT ON YOUR ANSWERS, I KNOW 2356 01:50:56,680 --> 01:50:58,960 WE LIKE TO MAKE USE OF THE 2357 01:50:58,960 --> 01:51:01,200 COMMENTS FEATURE, SO IF YOU WANT 2358 01:51:01,200 --> 01:51:03,440 TO MAKE A COMMENT IT'S ASSIGNED 2359 01:51:03,440 --> 01:51:09,840 FOR THE CONCEPT AND CRITERIA 2360 01:51:09,840 --> 01:51:10,120 LEVEL. 2361 01:51:10,120 --> 01:51:13,080 IF I WANTED TO LEAVE A COMMENT 2362 01:51:13,080 --> 01:51:15,000 ON 3891 I CAN MAKE A SELECTION 2363 01:51:15,000 --> 01:51:17,320 OR FOR MORE NUANCE I CAN GO TO 2364 01:51:17,320 --> 01:51:18,560 THE SPEECH BUBBLE TO GO TO VIEW 2365 01:51:18,560 --> 01:51:24,080 COMMENTS AND CLICK ON THAT AND 2366 01:51:24,080 --> 01:51:25,520 LEAVE MY COMMENT RIGHT THERE IN 2367 01:51:25,520 --> 01:51:28,280 A FREE-TEXT COMMENT AND ASSIGN 2368 01:51:28,280 --> 01:51:30,320 IT A CATEGORY OR INTENSITY 2369 01:51:30,320 --> 01:51:32,240 OPTION IF YOU HAVE ADDITIONAL 2370 01:51:32,240 --> 01:51:35,720 CATEGORIZATIONS YOU CAN DO THE 2371 01:51:35,720 --> 01:51:41,880 STRENGTH OR WEAKNESS OF IT OR 2372 01:51:41,880 --> 01:51:47,240 CHOOSE THE INTENSITY. 2373 01:51:47,240 --> 01:51:48,600 YOU'LL SEE IN THE UPPER RIGHT 2374 01:51:48,600 --> 01:51:51,040 HAND CORNER WE HAVE THE OVER ALL 2375 01:51:51,040 --> 01:51:51,480 PROGRESS. 2376 01:51:51,480 --> 01:51:56,440 IT WILL SHOW YOU EVERY CLICK YOU 2377 01:51:56,440 --> 01:51:59,200 HAVE TO MAKE. 2378 01:51:59,200 --> 01:52:02,960 THE SIXTH CRITERIA THE CONCEPTS 2379 01:52:02,960 --> 01:52:03,640 THROUGHOUT THE DAY. 2380 01:52:03,640 --> 01:52:06,160 EACH CLICK YOU MAKE YOU'LL SEE 2381 01:52:06,160 --> 01:52:08,040 IT INCREASES ALONG THE WAY. 2382 01:52:08,040 --> 01:52:09,280 THAT SHOULD LET YOU KNOW WHEN 2383 01:52:09,280 --> 01:52:16,000 YOU'RE 100% DONE AT THAT POINT. 2384 01:52:16,000 --> 01:52:18,880 ONCE YOU COMPLETED YOUR RATINGS 2385 01:52:18,880 --> 01:52:20,240 YOU'LL GET A POP UP THAT SAYS 2386 01:52:20,240 --> 01:52:22,480 YOU COMPLETED AND YOU CAN SEE 2387 01:52:22,480 --> 01:52:24,800 HOW YOU EVALUATE THE CONCEPTS. 2388 01:52:24,800 --> 01:52:27,040 THAT IS NOT THE FINAL RATING 2389 01:52:27,040 --> 01:52:28,280 JUST YOUR INDIVIDUAL ONES. 2390 01:52:28,280 --> 01:52:29,280 THE FINAL ONES ARE THE AGGREGATE 2391 01:52:29,280 --> 01:52:33,720 OF ALL THE VOTERS. 2392 01:52:33,720 --> 01:52:37,640 AND CLOSE OUT OF THE MODULE AT 2393 01:52:37,640 --> 01:52:40,800 THE TIME. 2394 01:52:40,800 --> 01:52:42,920 SO ANY PROGRESS YOU MAKE OR HAVE 2395 01:52:42,920 --> 01:52:46,280 AN INTERNET DISRUPTION THERE'S 2396 01:52:46,280 --> 01:52:53,280 IT'S ALL CAPTURED ALONG THE WAY. 2397 01:52:53,280 --> 01:52:55,600 WE'LL BE MONITORING PROGRESS AND 2398 01:52:55,600 --> 01:52:57,800 IF YOU EXCELLENTLY SKIP 2399 01:52:57,800 --> 01:52:58,800 SOMETHING WE'LL GO AHEAD AND TAP 2400 01:52:58,800 --> 01:53:00,800 YOU ON THE SHOULDER AND HELP YOU 2401 01:53:00,800 --> 01:53:04,960 WITH THAT AND FOR THOSE NOT IN 2402 01:53:04,960 --> 01:53:08,200 THE ROOM YOU CAN REACH US OVER 2403 01:53:08,200 --> 01:53:09,000 THE CHAT. 2404 01:53:09,000 --> 01:53:11,280 MY NAME IS PAT AND LAURA WILL 2405 01:53:11,280 --> 01:53:13,520 PUT OUR E-MAIL ADDRESSES IN 2406 01:53:13,520 --> 01:53:16,000 THERE IF SHE HAS NOT ALREADY. 2407 01:53:16,000 --> 01:53:17,280 BARRING ANY QUESTIONS, THAT'S 2408 01:53:17,280 --> 01:53:18,120 ALL I HAVE. 2409 01:53:18,120 --> 01:53:19,560 THANK YOU FOR HAVING US TODAY 2410 01:53:19,560 --> 01:53:21,040 AND IF YOU NEED ANYTHING WE'LL 2411 01:53:21,040 --> 01:53:31,520 BE IN THE BACK OF THE ROOM. 2412 01:54:02,840 --> 01:54:03,800 >>GOOD AFTERNOON, EVERYONE. 2413 01:54:03,800 --> 01:54:06,600 HAPPY IT SEE EVERYBODY. 2414 01:54:06,600 --> 01:54:12,280 -- HAPPY TO SEE EVERYBODY -- 2415 01:54:12,280 --> 01:54:22,440 [ECHOING] 2416 01:54:47,000 --> 01:54:49,040 >>THERE'S SOME GREMLIN IN THE 2417 01:54:49,040 --> 01:54:51,560 ROOM TODAY FOR ECHOING. 2418 01:54:51,560 --> 01:54:52,360 >>THAT'S ALWAYS LIVELY. 2419 01:54:52,360 --> 01:55:02,920 WE'LL GO AHEAD AND GET STARTED. 2420 01:55:07,400 --> 01:55:08,760 IF YOU HAVE A PROBLEM REACH OUT 2421 01:55:08,760 --> 01:55:10,480 TO BRIAN OR LAURA IN THE ROOM 2422 01:55:10,480 --> 01:55:11,920 AND PAT IS AVAILABLE ONLINE. 2423 01:55:11,920 --> 01:55:22,360 THOSE ARE YOUR CONTACTS. 2424 01:55:34,240 --> 01:55:37,240 >>TO CONFIRM -- YOU DON'T NEED 2425 01:55:37,240 --> 01:55:37,560 TO JOIN. 2426 01:55:37,560 --> 01:55:38,560 >>YOU DON'T NEED TO. 2427 01:55:38,560 --> 01:55:48,880 >>GOOD AFTERNOON. 2428 01:55:50,280 --> 01:55:51,960 THERE'S THREE INITIATIVES FOR 2429 01:55:51,960 --> 01:55:53,280 YOUR CONSIDERATION. 2430 01:55:53,280 --> 01:55:59,440 THE FIRST ONE IS CONCEPT NUMBER 2431 01:55:59,440 --> 01:56:00,280 3890. 2432 01:56:00,280 --> 01:56:03,280 THIS IS A SHORT TERM EDUCATION 2433 01:56:03,280 --> 01:56:07,040 PROGRAM TO ENHANCE DIVERSITY IN 2434 01:56:07,040 --> 01:56:11,000 HEALTH-RELATED RESEARCH. 2435 01:56:11,000 --> 01:56:18,640 A REISSUE OF THE HFRH1002 AND 2436 01:56:18,640 --> 01:56:20,200 ENHANCING DIFFERS IF I IN THE 2437 01:56:20,200 --> 01:56:22,640 WORKFORCE IS CRITICAL TO THE 2438 01:56:22,640 --> 01:56:24,920 SUCCESS OF OUR NHLBI MISSION. 2439 01:56:24,920 --> 01:56:26,320 THE PURPOSE OF THIS SPECIFIC 2440 01:56:26,320 --> 01:56:27,160 MISSION IS TO SUPPORT 2441 01:56:27,160 --> 01:56:30,560 EDUCATIONAL ACTIVITIES THAT 2442 01:56:30,560 --> 01:56:33,080 ENHANCE THE DIVERSITY OF THE 2443 01:56:33,080 --> 01:56:34,600 WORKFORCE PROVIDING RESEARCH 2444 01:56:34,600 --> 01:56:36,240 EXPERIENCES AND RELATED 2445 01:56:36,240 --> 01:56:37,720 OPPORTUNITIES THAT CAN ENRICH 2446 01:56:37,720 --> 01:56:40,680 THE POOL OF INDIVIDUALS FROM 2447 01:56:40,680 --> 01:56:45,960 DIVERSE BACKGROUNDS INCLUDING 2448 01:56:45,960 --> 01:56:48,280 NATIONALLY UNDER REPRESENTED 2449 01:56:48,280 --> 01:56:57,480 GROUPS FOR RESEARCH TURNS AND TO 2450 01:56:57,480 --> 01:56:59,240 ENCOURAGE UNDERGRADUATE AND 2451 01:56:59,240 --> 01:57:02,400 COLLEGE STUDENTS AND HIGH SCHOOL 2452 01:57:02,400 --> 01:57:05,440 STUDENTS IN BIO MEDICAL AND 2453 01:57:05,440 --> 01:57:07,160 BEHAVIORAL SCIENCE AND EXPOSE 2454 01:57:07,160 --> 01:57:08,120 THEM TO RESEARCH TRAINING 2455 01:57:08,120 --> 01:57:09,800 OPPORTUNITIES IN OUR MISSION 2456 01:57:09,800 --> 01:57:10,000 AREA. 2457 01:57:10,000 --> 01:57:15,320 IN PARTICULAR, EMPHASIS ON 2458 01:57:15,320 --> 01:57:19,080 PROVIDING HANDS-ON EXPOSURE TO 2459 01:57:19,080 --> 01:57:20,280 RESEARCH ENFORCE TO GRADUATE 2460 01:57:20,280 --> 01:57:22,320 WITH A SCIENCE DEGREE AND 2461 01:57:22,320 --> 01:57:23,960 PREPARE THEM FOR CAREERS IN 2462 01:57:23,960 --> 01:57:24,240 RESEARCH. 2463 01:57:24,240 --> 01:57:28,320 THIS FUNDING ANNOUNCEMENT WILL 2464 01:57:28,320 --> 01:57:30,760 BE AN R25 FUNDING MECHANISM AND 2465 01:57:30,760 --> 01:57:35,120 CLINICAL TRIALS ARE NOT ALLOWED 2466 01:57:35,120 --> 01:57:37,160 AND SUPPORT NINE MERITORIOUS 2467 01:57:37,160 --> 01:57:38,440 AWARDS EACH YEAR EACH LASTING 2468 01:57:38,440 --> 01:57:38,880 FIVE YEARS. 2469 01:57:38,880 --> 01:57:41,200 I'LL STOP HERE TO SEE IF THERE'S 2470 01:57:41,200 --> 01:57:42,920 COMMENTS, SUGGESTIONS OR 2471 01:57:42,920 --> 01:57:53,040 QUESTIONS. 2472 01:57:53,040 --> 01:58:03,560 IF NOT PLEASE CAST YOUR VOTE. 2473 01:58:45,440 --> 01:58:46,000 >>WE'RE JUST WAITING ON A FEW 2474 01:58:46,000 --> 01:58:56,120 MORE. 2475 01:59:13,320 --> 01:59:13,480 OKAY. 2476 01:59:13,480 --> 01:59:15,560 WE CAN MOVE ON TO THE NEXT 2477 01:59:15,560 --> 01:59:16,120 INITIATIVE. 2478 01:59:16,120 --> 01:59:17,320 >>THANK YOU. 2479 01:59:17,320 --> 01:59:22,040 THE SECOND INITIATIVE IS NUMBER 2480 01:59:22,040 --> 01:59:22,240 3891. 2481 01:59:22,240 --> 01:59:24,240 A SECOND IN MULTI-SECTORIAL 2482 01:59:24,240 --> 01:59:27,840 PREVENTION INTERVENTIONS THAT 2483 01:59:27,840 --> 01:59:28,480 ADDRESS SOCIAL DETERMINATES OF 2484 01:59:28,480 --> 01:59:29,720 HEALTH IN POPULATIONS THAT 2485 01:59:29,720 --> 01:59:32,240 EXPERIENCE HEALTH DISPARITIES. 2486 01:59:32,240 --> 01:59:32,480 IT USES THE 2487 01:59:35,040 --> 01:59:38,080 UG3, UH3 MECHANISM. 2488 01:59:38,080 --> 01:59:40,280 THE NHLBI-WIDE INITIATIVE PART 2489 01:59:40,280 --> 01:59:42,520 OF OUR NIH EFFORT LED BY THE NIH 2490 01:59:42,520 --> 01:59:45,320 OFFICE OF DISEASE PREVENTION, 2491 01:59:45,320 --> 01:59:47,880 ODP AS KNOWN AS ADVANCED AND 2492 01:59:47,880 --> 01:59:50,320 STANDS BY ADVANCING PREVENTION 2493 01:59:50,320 --> 01:59:52,240 RESEARCH FOR HEALTH EQUITY. 2494 01:59:52,240 --> 01:59:55,240 THE ORIGIN OF THIS INITIATIVE IS 2495 01:59:55,240 --> 01:59:57,040 AN NIH-WIDE PORTFOLIO ANALYSIS 2496 01:59:57,040 --> 01:59:59,640 CONDUCTED BY ODP THAT SHOWED 2497 01:59:59,640 --> 02:00:05,440 THAT LESS THAN 10% OF ALL FUNDED 2498 02:00:05,440 --> 02:00:07,280 PROJECTS FOCUSSED ON THE LEADING 2499 02:00:07,280 --> 02:00:09,720 RISK FACTORS OR CAUSES OF DEATH 2500 02:00:09,720 --> 02:00:11,200 AND DISABILITY. 2501 02:00:11,200 --> 02:00:14,360 MANY OF WHICH FALL IN THE NHLBI 2502 02:00:14,360 --> 02:00:15,120 MISSION AREAS. 2503 02:00:15,120 --> 02:00:22,440 BETWEEN 2012 AND 2020, ONLY 2504 02:00:22,440 --> 02:00:26,080 ABOUT 4% OF PROJECTS FOCUSSED ON 2505 02:00:26,080 --> 02:00:27,960 COMMUNITIES FACING HEALTH 2506 02:00:27,960 --> 02:00:31,280 DISPARITIES AND MORTALITY AND 2507 02:00:31,280 --> 02:00:33,960 THE EMPHASIS IS MOVING BEYOND 2508 02:00:33,960 --> 02:00:35,040 JUST ADDRESSING KNOWLEDGE 2509 02:00:35,040 --> 02:00:36,640 ATTITUDES, AWARENESS, BEHAVIORS 2510 02:00:36,640 --> 02:00:39,280 AND LIFE STYLES OF INDIVIDUALS 2511 02:00:39,280 --> 02:00:43,680 TO GO INTO SUPPORTING 2512 02:00:43,680 --> 02:00:45,400 INTERVENTION RESEARCH USING 2513 02:00:45,400 --> 02:00:47,560 MULTI-SECTORIAL COLLABORATIONS 2514 02:00:47,560 --> 02:00:49,560 THAT ENGAGE COMMUNITY-BASED 2515 02:00:49,560 --> 02:00:50,480 ORGANIZATIONS THAT HAVE THE 2516 02:00:50,480 --> 02:00:54,080 POTENTIAL TO DEVELOP, IMPLEMENT 2517 02:00:54,080 --> 02:00:55,520 AND TO SUSTAIN PREVENTION 2518 02:00:55,520 --> 02:00:57,960 INTERVENTIONS IN THEIR 2519 02:00:57,960 --> 02:00:58,880 COMMUNITIES AND ADDRESS RELEVANT 2520 02:00:58,880 --> 02:00:59,640 SOCIAL DETERMINATES OF HEALTH 2521 02:00:59,640 --> 02:01:01,800 AND PROMOTE HEALTH EQUITY. 2522 02:01:01,800 --> 02:01:05,240 THESE RESEARCH PROJECTS WILL BE 2523 02:01:05,240 --> 02:01:07,320 PART OF THE NIH MULTISECTORIAL 2524 02:01:07,320 --> 02:01:12,240 INTERVENTION, RESEARCH NETWORK. 2525 02:01:12,240 --> 02:01:15,640 RESPONSIVE APPLICATIONS 2526 02:01:15,640 --> 02:01:18,080 INCLUDING MULTI-SECTORIAL 2527 02:01:18,080 --> 02:01:19,560 PARTNERSHIPS AND BETTER HELP 2528 02:01:19,560 --> 02:01:22,720 UNDERSTAND THE INNOVATION 2529 02:01:22,720 --> 02:01:24,240 MECHANISMS AND CONTRIBUTE TO 2530 02:01:24,240 --> 02:01:26,320 HEALTH OUTCOMES AND IMPORTANTLY 2531 02:01:26,320 --> 02:01:28,840 THERE MUST BE A FOCUS ON HEALTH 2532 02:01:28,840 --> 02:01:30,640 EQUITY IN THE COMMUNITIES FACING 2533 02:01:30,640 --> 02:01:32,040 HEALTH DISPARITIES. 2534 02:01:32,040 --> 02:01:38,560 THIS FUNDING OPPORTUNITY 2535 02:01:38,560 --> 02:01:39,480 ANNOUNCEMENT COOPERATIVE 2536 02:01:39,480 --> 02:01:41,840 AGREEMENT MECHANISM. 2537 02:01:41,840 --> 02:01:43,800 IMPORTANTLY, EACH PARTICIPATING 2538 02:01:43,800 --> 02:01:45,840 I.C. WILL BE EXPECTED TO FUND AT 2539 02:01:45,840 --> 02:01:49,920 LEAST ONE MERITORIOUS AWARDTOWN 2540 02:01:49,920 --> 02:01:52,280 THE MISSION AREA AND USING THE 2541 02:01:52,280 --> 02:01:54,640 PAY LINE APPROACH AND MANAGED BY 2542 02:01:54,640 --> 02:01:57,000 A COORDINATING CENTER FULLY 2543 02:01:57,000 --> 02:02:00,280 FUNDED BY THE OFFICE OF DISEASE 2544 02:02:00,280 --> 02:02:02,360 PREVENTION AND MANAGED BY OTHER 2545 02:02:02,360 --> 02:02:02,560 I.C. 2546 02:02:02,560 --> 02:02:04,520 AT THE MOMENT THERE'S ABOUT 2547 02:02:04,520 --> 02:02:06,080 SEVEN I.C.s THAT SIGNED ON TO 2548 02:02:06,080 --> 02:02:06,440 PARTICIPATE. 2549 02:02:06,440 --> 02:02:07,800 I'LL PAUSE TO SEE IF YOU HAVE 2550 02:02:07,800 --> 02:02:11,720 ANY COMMENTS OR QUESTIONS. 2551 02:02:11,720 --> 02:02:16,240 >>QUICK QUESTION. 2552 02:02:16,240 --> 02:02:19,080 IS PCORI INVOLVED? 2553 02:02:19,080 --> 02:02:29,640 >>THE REAL DISTINCTION IS TO GO 2554 02:02:37,480 --> 02:02:40,240 BEYOND THAT AND ENGAGED 2555 02:02:40,240 --> 02:02:40,920 COMMUNITY-BASED ORGANIZATIONS SO 2556 02:02:40,920 --> 02:02:41,400 THERE'S FOCUS IN THE 2557 02:02:41,400 --> 02:02:41,720 COMMUNITIES. 2558 02:02:41,720 --> 02:02:51,880 >>THANKS. 2559 02:02:54,680 --> 02:02:59,800 IF THERE'S NO COMMENTS OR 2560 02:02:59,800 --> 02:03:00,480 SUGGESTIONS, YOU CAN GO AHEAD 2561 02:03:00,480 --> 02:03:10,960 AND CAST YOUR VOTE, PLEASE. 2562 02:03:53,560 --> 02:04:04,000 >>WE'RE JUST WAITING ON ONE. 2563 02:04:10,040 --> 02:04:12,800 >>WE'RE READY TO MOVE ON. 2564 02:04:12,800 --> 02:04:13,320 >>THANK YOU. 2565 02:04:13,320 --> 02:04:16,960 THE LAST INITIATIVE IS CONCEPT 2566 02:04:16,960 --> 02:04:18,440 NUMBER 3916. 2567 02:04:18,440 --> 02:04:22,480 THIS IS A SECONDARY 2568 02:04:22,480 --> 02:04:24,640 PARTICIPATION IN THE FOGARTY 2569 02:04:24,640 --> 02:04:27,400 INTERNATIONAL TRAINING PROGRAM 2570 02:04:27,400 --> 02:04:33,240 FOR LOW AND MIDDLE INCOME 2571 02:04:33,240 --> 02:04:33,520 PAR22-151. 2572 02:04:33,520 --> 02:04:36,680 THIS IS AN NHLBI WIDE INITIATIVE 2573 02:04:36,680 --> 02:04:39,800 AND SUPPORTS A BROAD RANGE OF 2574 02:04:39,800 --> 02:04:41,000 THEMES FROM BASIC BIOMEDICAL 2575 02:04:41,000 --> 02:04:42,800 RESEARCH TO IMPLEMENTATION 2576 02:04:42,800 --> 02:04:44,040 SCIENCE. 2577 02:04:44,040 --> 02:04:48,960 IMPORTANTLY, IT IS DESIGN TO 2578 02:04:48,960 --> 02:04:50,360 LEVERAGE THE HIV/AIDS INVESTMENT 2579 02:04:50,360 --> 02:04:54,360 AND CAPACITY BUILT BY OTHER 2580 02:04:54,360 --> 02:04:58,360 FUNDERS BY, FOR EXAMPLE, NIAID, 2581 02:04:58,360 --> 02:05:00,720 THE U.S. AID, PEP FAR AND OTHER 2582 02:05:00,720 --> 02:05:03,000 PROGRAMS AND TO LEVERAGE THE 2583 02:05:03,000 --> 02:05:05,440 CAPACITY AND INFRASTRUCTURES FOR 2584 02:05:05,440 --> 02:05:08,040 TRAINING IN-COUNTRY EXPERTS ON 2585 02:05:08,040 --> 02:05:10,240 THE SCIENCE OF HEART, LUNG, 2586 02:05:10,240 --> 02:05:12,360 BLOOD AND SLEEP COMORBIDITIES IN 2587 02:05:12,360 --> 02:05:15,120 PEOPLE LIVING WITH HIV. 2588 02:05:15,120 --> 02:05:18,640 THE PROGRAM AIMS TO STRENGTHEN 2589 02:05:18,640 --> 02:05:22,000 THE CAPACITY OF LOW AND 2590 02:05:22,000 --> 02:05:22,960 MIDDLE-INCOME COUNTRY 2591 02:05:22,960 --> 02:05:24,640 INSTITUTIONS FOR HEART, LUNG, 2592 02:05:24,640 --> 02:05:26,520 BLOOD AND SLEEP COMORBIDITIES IN 2593 02:05:26,520 --> 02:05:28,080 HOME COUNTRIES. 2594 02:05:28,080 --> 02:05:30,640 IT'S ESTIMATE THE 30 TO 40 2595 02:05:30,640 --> 02:05:33,200 MILLION PEOPLE LIVING WITH HIV 2596 02:05:33,200 --> 02:05:37,040 AID LIVING LONGER AND LIVING AND 2597 02:05:37,040 --> 02:05:40,240 ELEVATED RISK FOR BLOOD AND 2598 02:05:40,240 --> 02:05:40,600 COMORBIDITIES. 2599 02:05:40,600 --> 02:05:42,680 THE RESEARCH NHLBI HAS FUNDED 2600 02:05:42,680 --> 02:05:45,560 SUCH AS THE REPRIEVE TRIAL HAS 2601 02:05:45,560 --> 02:05:46,960 SHOWN PARTICIPANTS ASSIGNED A 2602 02:05:46,960 --> 02:05:50,360 STATIN HAVE A 35% REDUCED RISK 2603 02:05:50,360 --> 02:05:52,720 FOR MAJOR ADVERSE CARDIOVASCULAR 2604 02:05:52,720 --> 02:05:54,280 EVENTS COMPARED TO THOSE ON 2605 02:05:54,280 --> 02:05:54,800 PLACEBO. 2606 02:05:54,800 --> 02:05:58,560 THE TIME IS REALLY RIGHT TO 2607 02:05:58,560 --> 02:06:01,320 TRAIN AND GROW THE NEXT 2608 02:06:01,320 --> 02:06:02,960 GENERATION OF LOW AND MIDDLE 2609 02:06:02,960 --> 02:06:04,240 INCOME COUNTRIES TO ADVANCE 2610 02:06:04,240 --> 02:06:06,640 HEART, LUNG, BLOOD AND SLEEP 2611 02:06:06,640 --> 02:06:07,520 RESEARCH. 2612 02:06:07,520 --> 02:06:10,520 THIS USE THE D43 FUNDING 2613 02:06:10,520 --> 02:06:12,680 MECHANISM AND UP TO FIVE-YEAR 2614 02:06:12,680 --> 02:06:14,400 INTERNATIONAL TRAINING GRANT 2615 02:06:14,400 --> 02:06:18,320 SIMILAR TO THE U.S.-BASED T32 2616 02:06:18,320 --> 02:06:18,600 STRUCTURE. 2617 02:06:18,600 --> 02:06:22,480 IMPORTANTLY, APPLICATIONS CAN BE 2618 02:06:22,480 --> 02:06:30,120 SUBMITTED BY AN ELIGIBLE, LOW OR 2619 02:06:30,120 --> 02:06:32,960 MIDDLE INCOME INSTITUTION OR 2620 02:06:32,960 --> 02:06:36,240 DOMESTIC U.S. INSTITUTION THAT 2621 02:06:36,240 --> 02:06:45,600 DEMONSTRATE COLLABORATION WITH A 2622 02:06:45,600 --> 02:06:51,240 LOW OR MIDDLE-INCOME COUNTRY. 2623 02:06:51,240 --> 02:06:54,120 I'LL STOP AND TAKE QUESTIONS OR 2624 02:06:54,120 --> 02:06:54,400 COMMENTS. 2625 02:06:54,400 --> 02:06:54,960 PLEASE CONTINUE THE VOTES, 2626 02:06:54,960 --> 02:07:05,120 PLEASE. 2627 02:07:40,640 --> 02:07:41,120 >>I'LL GIVE ANOTHER FEW 2628 02:07:41,120 --> 02:07:45,120 SECONDS. 2629 02:07:45,120 --> 02:07:46,840 >>WE'RE READY TO MOVE ON. 2630 02:07:46,840 --> 02:07:47,600 >>THANK YOU VERY MUCH. 2631 02:07:47,600 --> 02:07:48,640 WE'RE DONE WITH OUR 2632 02:07:48,640 --> 02:07:51,360 PRESENTATIONS AND I'LL TURN IT 2633 02:07:51,360 --> 02:07:53,600 OVER TO DR. GOTH FROM THE 2634 02:07:53,600 --> 02:07:54,160 DIVISION OF CARDIOVASCULAR 2635 02:07:54,160 --> 02:07:54,400 SCIENCE. 2636 02:07:54,400 --> 02:08:04,520 DAVID. 2637 02:08:24,040 --> 02:08:30,120 >>THANK YOU ALL. 2638 02:08:30,120 --> 02:08:30,680 OKAY. 2639 02:08:30,680 --> 02:08:37,600 SO WITH HAVE EYE NUMBER OF 2640 02:08:37,600 --> 02:08:39,720 CONCEPT TO BRING TO YOUR 2641 02:08:39,720 --> 02:08:42,040 ATTENTION, IDEAS NUMBERS 3872 2642 02:08:42,040 --> 02:08:43,320 AND 3873. 2643 02:08:43,320 --> 02:08:45,080 I'LL PRESENT THEM TOGETHER BUT 2644 02:08:45,080 --> 02:08:46,160 YOU WILL NEED TO RATE THEM 2645 02:08:46,160 --> 02:08:51,520 INDIVIDUALLY IN THE SYSTEM. 2646 02:08:51,520 --> 02:08:54,720 THESE ARE A DATA COORDINATING 2647 02:08:54,720 --> 02:08:56,800 CENTER AND CLINICAL TRIAL 2648 02:08:56,800 --> 02:08:59,000 CENTERS FOR CARDIOVASCULAR RISK 2649 02:08:59,000 --> 02:09:05,880 REDUCTION IN TYPE 1 DIABETES 2650 02:09:05,880 --> 02:09:06,440 CLINICAL TRIALS REQUIRED. 2651 02:09:06,440 --> 02:09:09,320 THE LEAD AUTHOR IS NICOLE REDMAN 2652 02:09:09,320 --> 02:09:13,320 I HOPE IS IN ZOOM LAND IN CASE 2653 02:09:13,320 --> 02:09:14,080 QUESTIONS COME UP. 2654 02:09:14,080 --> 02:09:16,840 NIDDK IS THE LEAD INSTITUTE FOR 2655 02:09:16,840 --> 02:09:19,720 THE SPECIAL STATUTORY FUNDING 2656 02:09:19,720 --> 02:09:23,880 PROGRAM FOR TYPE 1 DIABETES 2657 02:09:23,880 --> 02:09:25,000 RESEARCH PREFERRED TO AS SPECIAL 2658 02:09:25,000 --> 02:09:26,240 DIABETES PROGRAM A SPECIAL 2659 02:09:26,240 --> 02:09:27,840 APPROPRIATION FOR RESEARCH ON 2660 02:09:27,840 --> 02:09:31,160 THE PREVENTION AND CURE OF TYPE 2661 02:09:31,160 --> 02:09:32,240 1 DIABETES AND ITS 2662 02:09:32,240 --> 02:09:36,920 COMPLICATIONS. 2663 02:09:36,920 --> 02:09:45,800 AS YOU ALL KNOW, THERE'S RISK 2664 02:09:45,800 --> 02:09:47,560 FACTORS SUCH AS OBESITY OR 2665 02:09:47,560 --> 02:09:50,160 INFLAMMATION IN ADOLESCENTS AND 2666 02:09:50,160 --> 02:09:53,960 YOUNG ADULTHOOD. 2667 02:09:53,960 --> 02:09:56,800 THE EVENT RATES APPROXIMATE THE 2668 02:09:56,800 --> 02:09:57,680 EVENT RATES FOR CARDIOVASCULAR 2669 02:09:57,680 --> 02:10:01,680 DISEASE FOR ADULTS WITHOUT TYPE 2670 02:10:01,680 --> 02:10:03,800 1 DIABETES WHO ARE 10 TO 20 2671 02:10:03,800 --> 02:10:04,920 YEARS OLDER. 2672 02:10:04,920 --> 02:10:07,360 DESPITE THE HIGH RISK STATUS 2673 02:10:07,360 --> 02:10:08,280 THERE'S SIGNIFICANT EVIDENCE 2674 02:10:08,280 --> 02:10:10,640 GAPS THE OBSTACLES TO THE 2675 02:10:10,640 --> 02:10:12,280 DEVELOPMENT AND IMPLEMENTATION 2676 02:10:12,280 --> 02:10:16,280 OF GUIDELINE RECOMMENDATIONS FOR 2677 02:10:16,280 --> 02:10:18,000 INITIATION FOR PHARMACO THERAPY 2678 02:10:18,000 --> 02:10:20,120 AND RISK FACTORS IN PEDIATRIC 2679 02:10:20,120 --> 02:10:23,600 AND YOUNG ADULT TYPE 1 DIABETES 2680 02:10:23,600 --> 02:10:23,920 POPULATIONS. 2681 02:10:23,920 --> 02:10:26,720 SO IN AN EFFORT TO ADDRESS THIS 2682 02:10:26,720 --> 02:10:27,960 EVIDENCE GAP, THIS INITIATIVE 2683 02:10:27,960 --> 02:10:30,280 WOULD USE A PHASED AWARD 2684 02:10:30,280 --> 02:10:33,400 MECHANISM TO TEST APPROACHES TO 2685 02:10:33,400 --> 02:10:36,240 REDUCE CARDIOVASCULAR RISK IN 2686 02:10:36,240 --> 02:10:38,040 TYPE 1 DIABETES. 2687 02:10:38,040 --> 02:10:40,640 THE APPROACH OF USING THE PHASED 2688 02:10:40,640 --> 02:10:42,080 AWARD MECHANISM ALLOWS 2689 02:10:42,080 --> 02:10:43,080 FLEXIBILITIES TO MAKE DECISIONS 2690 02:10:43,080 --> 02:10:45,160 NOT TO TRANSITION TO THE SECOND 2691 02:10:45,160 --> 02:10:48,680 PHASE OF AWARD IF AN AWARD 2692 02:10:48,680 --> 02:10:49,720 DEMONSTRATES IT CANNOT 2693 02:10:49,720 --> 02:10:50,720 SUCCESSFULLY RECRUIT 2694 02:10:50,720 --> 02:10:53,160 PARTICIPANTS OR MEET OTHER 2695 02:10:53,160 --> 02:10:55,640 STUDIES THUS REDUCING THE OVER 2696 02:10:55,640 --> 02:10:57,840 ALL RISK TO THE INSTITUTE. 2697 02:10:57,840 --> 02:10:59,400 THIS INITIATIVE WOULD SIGNAL TO 2698 02:10:59,400 --> 02:11:00,160 THE EXTRAMURAL COMMUNITY THE 2699 02:11:00,160 --> 02:11:03,280 IMPORTANCE OF THE AREA OF 2700 02:11:03,280 --> 02:11:05,240 RESEARCH AND MAY STIMULATE 2701 02:11:05,240 --> 02:11:06,400 ADDITIONAL RESEARCH INCLUDING 2702 02:11:06,400 --> 02:11:08,840 RO1 STUDIES AND CAREER 2703 02:11:08,840 --> 02:11:10,040 DEVELOPMENT TRAINING AWARDS 2704 02:11:10,040 --> 02:11:10,640 INCLUDING SUPPLEMENT. 2705 02:11:10,640 --> 02:11:13,240 WE ANTICIPATE THE OPPORTUNITY 2706 02:11:13,240 --> 02:11:16,280 WILL CONTINUE OUR PARTNERSHIP 2707 02:11:16,280 --> 02:11:20,920 WITH NIDDK AND EXPAND THE 2708 02:11:20,920 --> 02:11:22,000 PORTFOLIO IN CARDIOVASCULAR 2709 02:11:22,000 --> 02:11:22,240 DISEASE. 2710 02:11:22,240 --> 02:11:23,800 I'LL BE HAPPY TO STOP AND 2711 02:11:23,800 --> 02:11:25,800 ENTERTAIN QUESTIONS ABOUT THE 2712 02:11:25,800 --> 02:11:26,360 TWO RELATED CONCEPTS OR 2713 02:11:26,360 --> 02:11:36,600 INITIATIVES. 2714 02:11:41,080 --> 02:11:51,480 WE CAN MOVE ON TO RATING. 2715 02:12:16,200 --> 02:12:18,640 >>JUST A REMINDER, YOU'RE GOING 2716 02:12:18,640 --> 02:12:21,240 TO BE VOTING ON 3872 AS WELL AS 2717 02:12:21,240 --> 02:12:31,480 3873, PLEASE. 2718 02:13:33,160 --> 02:13:35,240 >>WE CAN MOVE ON TO THE NEXT 2719 02:13:35,240 --> 02:13:35,520 CONCEPT. 2720 02:13:35,520 --> 02:13:36,680 >>THANK YOU. 2721 02:13:36,680 --> 02:13:39,920 THE NEXT CONCEPT IS NUMBER 3893. 2722 02:13:39,920 --> 02:13:44,720 THIS IS A RENEWAL BY CONTRACT OF 2723 02:13:44,720 --> 02:13:50,400 THE MULTIETHNIC STUDY OF 2724 02:13:50,400 --> 02:13:52,760 ATHEROSCLEROSIS AND THE AUTHOR 2725 02:13:52,760 --> 02:13:54,840 IS IN THE ROOM IN CASE THERE'S 2726 02:13:54,840 --> 02:13:55,080 QUESTIONS. 2727 02:13:55,080 --> 02:13:59,040 I PROPOSES RENEWAL OF THE FOLLOW 2728 02:13:59,040 --> 02:14:02,800 COMPONENT AND INFRASTRUCTURE OF 2729 02:14:02,800 --> 02:14:04,280 THE STUDY COHORT. 2730 02:14:04,280 --> 02:14:08,160 THE ORIGINAL COHORT CONSISTED OF 2731 02:14:08,160 --> 02:14:10,920 6,814 MEN AND WOMEN AGES 45 TO 2732 02:14:10,920 --> 02:14:13,800 84 AT BASELINE FROM FOUR ETHNIC 2733 02:14:13,800 --> 02:14:16,160 GROUPS, WHITES, BLACKS, 2734 02:14:16,160 --> 02:14:17,680 HISPANICS AND CHINESE AMERICANS 2735 02:14:17,680 --> 02:14:20,000 FREE OF CLINICAL CARDIOVASCULAR 2736 02:14:20,000 --> 02:14:20,760 DISEASE AT BASELINE. 2737 02:14:20,760 --> 02:14:22,640 SIX FIELD CENTERS ENROLLED 2738 02:14:22,640 --> 02:14:26,000 PARTICIPANTS AND NOW CONDUCTED A 2739 02:14:26,000 --> 02:14:29,360 SERIES OF LONGITUDINAL EXAMS 2740 02:14:29,360 --> 02:14:30,800 FOCUSSING ON HEALTH OUTCOMES 2741 02:14:30,800 --> 02:14:31,600 BEYOND CARDIOVASCULAR DISEASE. 2742 02:14:31,600 --> 02:14:34,000 THE RENEWAL OF CONTRACT SUPPORT 2743 02:14:34,000 --> 02:14:36,040 WOULD ALLOW THE STUDY TO 2744 02:14:36,040 --> 02:14:39,200 CONTINUE TO MAINTAIN REGULAR 2745 02:14:39,200 --> 02:14:42,160 CONTACT WITH STUDY PARTICIPANT 2746 02:14:42,160 --> 02:14:44,280 TO IDENTIFY AND ADJUDICATE 2747 02:14:44,280 --> 02:14:47,120 EVENTS AND MANAGE, STORE 2748 02:14:47,120 --> 02:14:48,920 BIOLOGIC DATA SPECIMENS TO SERVE 2749 02:14:48,920 --> 02:14:54,680 AS A PLATFORM FOR STUDIES AND 2750 02:14:54,680 --> 02:15:05,160 PROVIDE SUPPORT FOR A CORE 2751 02:15:11,000 --> 02:15:12,640 EXAMINATION COMPONENTS AND ALLOW 2752 02:15:12,640 --> 02:15:16,280 FOLLOW-UP AS THEY APPROACH A 2753 02:15:16,280 --> 02:15:18,720 PERIOD IN OLDER ADULTHOODS WHERE 2754 02:15:18,720 --> 02:15:24,240 CLINICAL EVENTS WILL ALMOST MORE 2755 02:15:24,240 --> 02:15:28,280 COMMON AND STUDY SUCCESSFUL 2756 02:15:28,280 --> 02:15:33,440 PULMONARY AGING AND STUDY HEART, 2757 02:15:33,440 --> 02:15:37,480 LUNG AND BLOOD AND SLEEPING 2758 02:15:37,480 --> 02:15:41,960 PROGRESSION AND DISCOVERY 2759 02:15:41,960 --> 02:15:43,400 SCIENCE AND ADDRESS QUESTIONS 2760 02:15:43,400 --> 02:15:44,280 AND BETTER UNDERSTAND THE 2761 02:15:44,280 --> 02:15:48,120 REASONS FOR RACIAL DISPARITIES 2762 02:15:48,120 --> 02:15:48,560 ACROSS THESE GROUPS. 2763 02:15:48,560 --> 02:15:52,280 HAPPY IT TAKE QUESTIONS AT THIS 2764 02:15:52,280 --> 02:16:00,960 POINT. 2765 02:16:00,960 --> 02:16:02,360 I DON'T SEE HANDS UP. 2766 02:16:02,360 --> 02:16:05,080 DO YOU SEE ANYTHING IN THE ZOOM 2767 02:16:05,080 --> 02:16:05,680 ROOM? 2768 02:16:05,680 --> 02:16:08,840 >>NOTHING'S CHANGED IN THE CHAT 2769 02:16:08,840 --> 02:16:09,720 SO WE LOOK GOOD. 2770 02:16:09,720 --> 02:16:10,280 >>THANK YOU. 2771 02:16:10,280 --> 02:16:20,800 I THINK WE CAN GO TO RATINGS. 2772 02:16:27,960 --> 02:16:32,000 THERE'S ONE OF KEY 13 NHLBI 2773 02:16:32,000 --> 02:16:42,560 STUDIES ADVANCING LUNG RESEARCH. 2774 02:16:59,320 --> 02:17:01,400 >>WE'RE READY TO MOVE ON. 2775 02:17:01,400 --> 02:17:02,000 >>ALL RIGHT. 2776 02:17:02,000 --> 02:17:02,960 THANK YOU. 2777 02:17:02,960 --> 02:17:07,560 THE NEXT CONCEPT IS IDS NUMBER 2778 02:17:07,560 --> 02:17:09,400 3902 UNDERSTANDING CHRONIC 2779 02:17:09,400 --> 02:17:11,800 CONDITIONS UNDER STUDIED AMONG 2780 02:17:11,800 --> 02:17:14,400 WOMEN R01 MECHANISM, CLINICAL 2781 02:17:14,400 --> 02:17:15,320 TRIAL OPTIONAL. 2782 02:17:15,320 --> 02:17:16,800 WE WOULD BE SECONDARY 2783 02:17:16,800 --> 02:17:17,440 PARTICIPANTS IN THE FUNDING 2784 02:17:17,440 --> 02:17:19,400 OPPORTUNITY LED BY THE OFFICE OF 2785 02:17:19,400 --> 02:17:23,280 RESEARCH ON WOMEN'S HEALTH AND 2786 02:17:23,280 --> 02:17:25,320 YES, THE LEAD AUTHOR IS IN THE 2787 02:17:25,320 --> 02:17:25,800 ZOOM ROOM. 2788 02:17:25,800 --> 02:17:28,320 THE OVERARCHING GOAL OF THIS 2789 02:17:28,320 --> 02:17:30,720 FUNDING OPPORTUNITY IS TO USE 2790 02:17:30,720 --> 02:17:33,120 RO1 MECHANISM TO STIMULATE 2791 02:17:33,120 --> 02:17:34,720 RESEARCH ADDRESSING RISING RATES 2792 02:17:34,720 --> 02:17:36,280 OF CHRONIC DEBILITATING 2793 02:17:36,280 --> 02:17:37,880 CONDITIONS IN WOMEN AND 2794 02:17:37,880 --> 02:17:41,200 OPPORTUNITIES IDENTIFIED AT THE 2795 02:17:41,200 --> 02:17:44,200 CONGRESSIONALLY REQUESTED 2796 02:17:44,200 --> 02:17:45,840 FUNDING ADVANCE ON WOMEN'S 2797 02:17:45,840 --> 02:17:47,200 HEALTH A 2021 CONFERENCE. 2798 02:17:47,200 --> 02:17:49,960 COMPARED TO MEN, WOMEN HAVE 2799 02:17:49,960 --> 02:17:51,040 HIGHER PREFERENCE OF CHRONIC 2800 02:17:51,040 --> 02:17:52,960 CONDITIONS OFTEN PRESENT WITH 2801 02:17:52,960 --> 02:17:56,080 DIFFERENT SYMPTOMS LIKE 2802 02:17:56,080 --> 02:17:57,840 DIZZINESS, CHEST PAIN WITH 2803 02:17:57,840 --> 02:18:00,320 CARDIOVASCULAR DISEASE ARE 2804 02:18:00,320 --> 02:18:04,240 AFFECTED BY DIFFERENT CHRONIC 2805 02:18:04,240 --> 02:18:07,160 CONDITIONS AND AUTOIMMUNITY 2806 02:18:07,160 --> 02:18:08,600 DISEASE AND MULTI-MORBIDITY AT 2807 02:18:08,600 --> 02:18:09,800 DIFFERENT LIFE COURSE TIME 2808 02:18:09,800 --> 02:18:11,080 POINTS. 2809 02:18:11,080 --> 02:18:11,880 PARTICIPA 2810 02:18:11,880 --> 02:18:14,160 PARTICIPATION IN THIS RFA WOULD 2811 02:18:14,160 --> 02:18:15,720 ADDRESS THE SIGNIFICANT IMPACT 2812 02:18:15,720 --> 02:18:18,200 OF HEART, LUNG, BLOOD AND SLEEP 2813 02:18:18,200 --> 02:18:19,040 RELATED DISEASES ON WOMEN'S 2814 02:18:19,040 --> 02:18:21,680 HEALTH ACROSS THE LIFE SPAN AND 2815 02:18:21,680 --> 02:18:26,360 FACILITATE DEVELOPMENT OF 2816 02:18:26,360 --> 02:18:27,120 RELEVANT PREVENTIVE DIAGNOSTIC 2817 02:18:27,120 --> 02:18:29,360 AND THERAPEUTIC APPROACHES AND 2818 02:18:29,360 --> 02:18:31,280 THERE'S HIGHER PREVALENCE OF 2819 02:18:31,280 --> 02:18:32,280 DISEASES OF WOMEN HISTORICALLY 2820 02:18:32,280 --> 02:18:35,800 UNDER STUDIED AND UNDER 2821 02:18:35,800 --> 02:18:36,920 REPRESENTED IN BIOMEDICAL 2822 02:18:36,920 --> 02:18:39,280 RESEARCH AND PARTICIPATION 2823 02:18:39,280 --> 02:18:40,640 ALIGNS WITH THE ONGOING 2824 02:18:40,640 --> 02:18:42,000 COMMITMENT TO ADDRESS THE 2825 02:18:42,000 --> 02:18:45,680 DISPARITIES AND IMPROVE OUTCOMES 2826 02:18:45,680 --> 02:18:48,160 FOR HEART, LUNG, BLOOD AND SLEEP 2827 02:18:48,160 --> 02:18:48,640 DISORDERS IN ALL WOMEN. 2828 02:18:48,640 --> 02:18:52,240 I'D BE HAPPY TO TAKE QUESTIONS 2829 02:18:52,240 --> 02:18:57,240 AT THIS POINT. 2830 02:18:57,240 --> 02:19:07,640 THIS IS INITIATIVE 3902. 2831 02:19:15,040 --> 02:19:25,360 YOU CAN GO TO RATING. 2832 02:19:41,720 --> 02:19:43,520 >>YOU CAN MOVE ON TO THE NEXT 2833 02:19:43,520 --> 02:19:44,240 CONCEPT. 2834 02:19:44,240 --> 02:19:44,560 >>ALL RIGHT. 2835 02:19:44,560 --> 02:19:46,400 BEFORE I GET INTO THE NEXT ONE I 2836 02:19:46,400 --> 02:19:47,920 WANT TO MENTION THE NEXT TWO 2837 02:19:47,920 --> 02:19:52,240 CONCEPTS ARE RELATED TO THE 2838 02:19:52,240 --> 02:19:53,920 RESOURCES WE PROVIDE TO SUPPORT 2839 02:19:53,920 --> 02:19:55,400 RESEARCH-RELATED TO GENE THERAPY 2840 02:19:55,400 --> 02:19:56,360 AND WHILE WE'RE GOING TO BE 2841 02:19:56,360 --> 02:19:59,600 ASKING TO YOU COMMENT ON EACH OF 2842 02:19:59,600 --> 02:20:01,440 THESE SEPARATELY, WE'D ALSO BE 2843 02:20:01,440 --> 02:20:03,800 INTERESTED IN ANYTHING YOU MIGHT 2844 02:20:03,800 --> 02:20:05,920 HAVE TO SHARE WITH US ABOUT THE 2845 02:20:05,920 --> 02:20:09,680 WAY WE SUPPORT GENETIC THERAPY 2846 02:20:09,680 --> 02:20:10,640 RESEARCH IN GENERAL BEYOND 2847 02:20:10,640 --> 02:20:14,160 WHAT'S IN THESE PROPOSALS AND 2848 02:20:14,160 --> 02:20:16,320 PERHAPS AFTER WE DISCUSS EACH OF 2849 02:20:16,320 --> 02:20:18,320 THESE WE MAY HAVE A LITTLE BIT 2850 02:20:18,320 --> 02:20:21,520 OF OPEN TIME TO DISCUSS GENE 2851 02:20:21,520 --> 02:20:23,040 THERAPY SUPPORT MORE BROADLY. 2852 02:20:23,040 --> 02:20:29,320 THE FIRST ONE IS IDS NUMBER 389 2853 02:20:29,320 --> 02:20:32,000 THE NATIONAL GENE VECTOR BIO 2854 02:20:32,000 --> 02:20:35,600 REPOSITORY CONTRACT RENEWAL. 2855 02:20:35,600 --> 02:20:40,240 THE AUTHOR IS RAY EBERT AND 2856 02:20:40,240 --> 02:20:43,360 SEEKS RENEWAL FOR THE REPOSITORY 2857 02:20:43,360 --> 02:20:45,760 KNOWN AS THE HCBB AND ORIGINS 2858 02:20:45,760 --> 02:20:48,720 CAN BE TRACED IN THE 1990s AND 2859 02:20:48,720 --> 02:20:52,280 THE FIRST FDA APPROVED GENE 2860 02:20:52,280 --> 02:20:53,640 THERAPY TRIAL BY INTRAMURAL 2861 02:20:53,640 --> 02:20:58,680 INVESTIGATORS FROM NHLBI AND NCI 2862 02:20:58,680 --> 02:21:02,640 TO TREAT ADA SKID AND THEY HAVE 2863 02:21:02,640 --> 02:21:04,040 CLINICAL INVESTIGATORS IN FIVE 2864 02:21:04,040 --> 02:21:04,240 AREAS. 2865 02:21:04,240 --> 02:21:06,640 FIRST, BY MAKING AVAILABLE OVER 2866 02:21:06,640 --> 02:21:12,240 70 RE-AGENTS, PLASMIDS, 2867 02:21:12,240 --> 02:21:16,280 RETROVIRAL PACKAGING FOR 2868 02:21:16,280 --> 02:21:19,640 CONSTRUCTING GENE-THERAPY 2869 02:21:19,640 --> 02:21:21,440 VECTORS AND PROVIDING STORING OF 2870 02:21:21,440 --> 02:21:22,640 SAMPLES. 2871 02:21:22,640 --> 02:21:25,600 THIRD, BY PERFORMING REPLICATION 2872 02:21:25,600 --> 02:21:30,160 COMPETENCY ASSAYS AND ANALYSIS 2873 02:21:30,160 --> 02:21:30,960 FOR PARTICIPANTS SICKLE CELL AND 2874 02:21:30,960 --> 02:21:35,040 OTHER STUDIES AND FIFTH BY 2875 02:21:35,040 --> 02:21:36,720 DEVELOPING NEW INTEGRATION 2876 02:21:36,720 --> 02:21:40,640 CYTOANALYSIS METHODS EXPECTED TO 2877 02:21:40,640 --> 02:21:42,000 BE NIGEEDED IN THE FUTURE. 2878 02:21:42,000 --> 02:21:44,840 A WELL ESTABLISHED FUTURE IS THE 2879 02:21:44,840 --> 02:21:47,080 PROGRAM'S TRACK RECORD OF 2880 02:21:47,080 --> 02:21:48,120 PROACTIVELY ANTICIPATING THE 2881 02:21:48,120 --> 02:21:50,560 NEEDS OF INVESTIGATORS OVER THE 2882 02:21:50,560 --> 02:21:51,400 PAST 15 YEARS. 2883 02:21:51,400 --> 02:21:54,440 A FEATURE THAT LEAD TO TIMELY 2884 02:21:54,440 --> 02:21:55,880 DELIVERY OF TOOLS AND 2885 02:21:55,880 --> 02:22:00,280 CAPABILITIES TO THE GENE THERAPY 2886 02:22:00,280 --> 02:22:03,640 INVESTIGATIVE COMMUNITY. 2887 02:22:03,640 --> 02:22:06,360 APPROVAL WOULD ENABLE MGBB TO 2888 02:22:06,360 --> 02:22:07,760 CONTINUE OPERATING AS A 2889 02:22:07,760 --> 02:22:09,600 COST-EFFECTIVE CENTER OF GENE 2890 02:22:09,600 --> 02:22:11,560 THERAPY EXCELLENCE FOR OUR 2891 02:22:11,560 --> 02:22:11,800 INSTITUTE. 2892 02:22:11,800 --> 02:22:12,800 HAPPY TO ENTERTAIN QUESTIONS AND 2893 02:22:12,800 --> 02:22:20,120 COMMENTS AT THIS TIME. 2894 02:22:20,120 --> 02:22:23,400 IS IT INSTITUTE SPECIFIC OR MORE 2895 02:22:23,400 --> 02:22:23,640 BROADLY? 2896 02:22:23,640 --> 02:22:25,480 >>IT'S USED MORE BROADLY. 2897 02:22:25,480 --> 02:22:28,880 RAY, IF YOU'RE OUT THERE AND 2898 02:22:28,880 --> 02:22:31,280 HAVE STATS IN YOUR BACK POCKET 2899 02:22:31,280 --> 02:22:33,040 THAT'D BE GREAT BUT MY 2900 02:22:33,040 --> 02:22:34,720 UNDERSTANDING IS IT'S USED MORE 2901 02:22:34,720 --> 02:22:35,280 BROADLY THAN NHLBI. 2902 02:22:35,280 --> 02:22:38,560 >>YES, THIS IS RAY. 2903 02:22:38,560 --> 02:22:41,160 THE VAST MAJORITY OF 2904 02:22:41,160 --> 02:22:47,880 BENEFICIARIES ARE NHLBI-FUNDED. 2905 02:22:47,880 --> 02:22:49,600 BUT IT IS AVAILABLE TO OTHER 2906 02:22:49,600 --> 02:22:50,040 INSTITUTES ON REQUEST. 2907 02:22:50,040 --> 02:22:52,240 WE CAN USUALLY WORK OUT 2908 02:22:52,240 --> 02:22:54,240 ARRANGEMENTS. 2909 02:22:54,240 --> 02:22:57,520 WE HAVE CLOSE COLLABORATION WITH 2910 02:22:57,520 --> 02:23:03,080 NCI AND THEY FUNDED THE WORK OB 2911 02:23:03,080 --> 02:23:05,840 THEIR OWN. 2912 02:23:05,840 --> 02:23:06,440 IT'S GENERALLY INSTITUTE WIDE. 2913 02:23:06,440 --> 02:23:13,440 THANK YOU FOR THE QUESTION. 2914 02:23:13,440 --> 02:23:16,120 >>OTHER QUESTIONS, COMMENTS? 2915 02:23:16,120 --> 02:23:17,080 NOT SEEING ANY I THINKS WE CAN 2916 02:23:17,080 --> 02:23:27,360 MOVE TO RATING. 2917 02:23:51,480 --> 02:24:01,920 >>JUST ANOTHER MOMENT OR TWO. 2918 02:24:22,120 --> 02:24:24,000 OKAY THE NEXT CONCEPT. 2919 02:24:24,000 --> 02:24:26,960 >>IT'S IDS NUMBER 3915. 2920 02:24:26,960 --> 02:24:28,280 THE GENE THERAPY RESOURCE 2921 02:24:28,280 --> 02:24:28,640 PROGRAM. 2922 02:24:28,640 --> 02:24:34,080 THIS IS A CONTRACT RENEWAL LEAD 2923 02:24:34,080 --> 02:24:37,480 AUTHOR IS CHERYL McDONALD IN THE 2924 02:24:37,480 --> 02:24:38,400 ROOM. 2925 02:24:38,400 --> 02:24:40,880 IT CALLED FOR NEWLY OF GTRP. 2926 02:24:40,880 --> 02:24:42,760 A CONTRACT PROGRAM FIRST 2927 02:24:42,760 --> 02:24:44,480 LAUNCHED IN 2007 AND WAS DESIGN 2928 02:24:44,480 --> 02:24:48,240 TO PROVIDE RESOURCES AT NO-COST 2929 02:24:48,240 --> 02:24:49,560 TO INVESTIGATORS TO FACILITATE 2930 02:24:49,560 --> 02:24:52,240 THE GENE THERAPY DISCOVERIES 2931 02:24:52,240 --> 02:24:57,040 INTO CLINICAL VANCE -- 2932 02:24:57,040 --> 02:24:59,600 ADVANCEMENTS AND THERE'S THREE 2933 02:24:59,600 --> 02:25:00,440 CORES. 2934 02:25:00,440 --> 02:25:04,200 A CLINICAL COORDINATING CORE, 2935 02:25:04,200 --> 02:25:07,600 PRE-CLINICAL VECTOR CORE AND THE 2936 02:25:07,600 --> 02:25:08,240 PHARMACOLOGY TOXICOLOGY CORE AND 2937 02:25:08,240 --> 02:25:11,040 THE PLAN IS TO KEEP THE SAME 2938 02:25:11,040 --> 02:25:12,760 THREE CORES AND ADD RE-AGENT 2939 02:25:12,760 --> 02:25:14,880 CORE THAT HAS THE FLEXIBILITY TO 2940 02:25:14,880 --> 02:25:16,280 PROVIDE A BROADER RANGE OF 2941 02:25:16,280 --> 02:25:18,000 RESOURCES TO ADDRESS THE NEEDS 2942 02:25:18,000 --> 02:25:18,840 OF RESEARCHERS IN A MORE 2943 02:25:18,840 --> 02:25:22,160 INDIVIDUALIZED MANNER. 2944 02:25:22,160 --> 02:25:25,800 THROUGH JANUARY 2023, THE GTRP 2945 02:25:25,800 --> 02:25:28,400 HAS HAD 171 INVESTIGATORS 2946 02:25:28,400 --> 02:25:30,800 REPRESENTING 79 INSTITUTIONS IN 2947 02:25:30,800 --> 02:25:32,920 THE U.S. REGISTERED WITH THE 2948 02:25:32,920 --> 02:25:33,320 GTRP. 2949 02:25:33,320 --> 02:25:35,120 THE PROGRAM SERVICES ARE SECURED 2950 02:25:35,120 --> 02:25:38,600 BY REQUEST FOR SERVICE 2951 02:25:38,600 --> 02:25:41,520 APPLICATION OR RSA AND A TOTAL 2952 02:25:41,520 --> 02:25:45,240 OF 2005RSA'S HAVE BEEN FULFILLED 2953 02:25:45,240 --> 02:25:47,960 WITH 124 DIRECTLY SUPPORTING A 2954 02:25:47,960 --> 02:25:48,720 CURRENT GRANT. 2955 02:25:48,720 --> 02:25:51,160 OF THOSE GRANTS ABOUT 2956 02:25:51,160 --> 02:25:54,760 THREE-QUARTERS ARE R01s AND OF 2957 02:25:54,760 --> 02:25:56,960 THE REMAINING QUARTER PRIMARILY 2958 02:25:56,960 --> 02:25:57,360 PROGRAM PROJECTS. 2959 02:25:57,360 --> 02:26:02,800 THE GTRP HAS ENABLED 16 INDs FOR 2960 02:26:02,800 --> 02:26:04,600 CLINICAL TRIALS AND THE OTHER IS 2961 02:26:04,600 --> 02:26:06,800 CURRENTLY UNDERGOING ADDITIONAL 2962 02:26:06,800 --> 02:26:09,480 TESTING PRIOR TO LAUNCHING THE 2963 02:26:09,480 --> 02:26:09,840 CLINICAL TRIAL. 2964 02:26:09,840 --> 02:26:15,160 THEY ENABLED TWO AWARDING PATENT 2965 02:26:15,160 --> 02:26:17,720 AND ONE PATENT APPLICATION AND 2966 02:26:17,720 --> 02:26:19,520 THE PROGRAMS WERE PICKED UP BY 2967 02:26:19,520 --> 02:26:22,280 INDUSTRY ON ANEMIA AND ONE ON 2968 02:26:22,280 --> 02:26:24,280 SICKLE CELL DISEASE AND ANOTHER 2969 02:26:24,280 --> 02:26:28,320 ON CONGESTIVE HEART FAILURE SO 2970 02:26:28,320 --> 02:26:30,280 IT WOULD CONTINUE TO FOSTER 2971 02:26:30,280 --> 02:26:32,920 RESEARCH AND PLAY A ROLE IN THE 2972 02:26:32,920 --> 02:26:34,640 EVOLUTION OF GENE THERAPIES AND 2973 02:26:34,640 --> 02:26:36,240 THE IMPACT THAT WILL HAVE ON 2974 02:26:36,240 --> 02:26:37,400 MEDICINE. 2975 02:26:37,400 --> 02:26:39,600 SO HAPPY TO ANSWER QUESTIONS AT 2976 02:26:39,600 --> 02:26:44,240 THIS POINT. 2977 02:26:44,240 --> 02:26:46,440 ARE THERE ANY OUT THERE? 2978 02:26:46,440 --> 02:26:54,960 WE CAN MOVE ON TO RATING. 2979 02:26:54,960 --> 02:27:05,400 >>I SEE A COUPLE THINGS. 2980 02:27:10,520 --> 02:27:12,120 >>WE HAD SOMEONE ABOUT WHAT 2981 02:27:12,120 --> 02:27:13,160 CONCEPT WE WERE ON BUT DON'T 2982 02:27:13,160 --> 02:27:16,240 WORRY ABOUT IT. 2983 02:27:16,240 --> 02:27:17,560 >>THANK YOU. 2984 02:27:17,560 --> 02:27:19,040 >>SO WE'RE MAKE GOING PROGRESS. 2985 02:27:19,040 --> 02:27:29,520 JUST ANOTHER MOMENT OR TWO. 2986 02:27:58,360 --> 02:28:00,760 >>WE CAN GO TO THE NEXT 2987 02:28:00,760 --> 02:28:01,320 CONCEPT. 2988 02:28:01,320 --> 02:28:04,200 >>I KNOW WE'RE RUNNING A LITTLE 2989 02:28:04,200 --> 02:28:05,840 BIT BEHIND BUT THERE'S AN 2990 02:28:05,840 --> 02:28:06,640 OPPORTUNITY FOR COUNCIL MEMBER 2991 02:28:06,640 --> 02:28:11,120 TO GIVE US INPUT AS TO WHETHER 2992 02:28:11,120 --> 02:28:15,480 THERE ARE IMPORTANT GAPS IN WHAT 2993 02:28:15,480 --> 02:28:17,960 WE'RE DOING TO PROVIDE FOR THE 2994 02:28:17,960 --> 02:28:19,000 GENE RESEARCH COMMUNITY OR 2995 02:28:19,000 --> 02:28:20,400 THINGS WE'RE PROPOSING GOING 2996 02:28:20,400 --> 02:28:23,640 FORWARD WE SHOULD STOP OR DO 2997 02:28:23,640 --> 02:28:24,240 DIFFERENTLY. 2998 02:28:24,240 --> 02:28:27,080 IF YOU CAN GIVE US THAT FEEDBACK 2999 02:28:27,080 --> 02:28:28,240 NOW DURING THE DISCUSSION OR 3000 02:28:28,240 --> 02:28:30,080 LATER IF YOU'D LIKE TO GIVE MORE 3001 02:28:30,080 --> 02:28:31,760 THOUGHT TO THAT AND SEND ME AN 3002 02:28:31,760 --> 02:28:37,440 E-MAIL OR GIVE ME A CALL. 3003 02:28:37,440 --> 02:28:39,480 >>A LISTENER HAS HER HAND UP. 3004 02:28:39,480 --> 02:28:44,960 >>PLEASE COME OFF MUTE. 3005 02:28:44,960 --> 02:28:47,560 >>THANK YOU SO MUCH. 3006 02:28:47,560 --> 02:28:48,680 THERE SEEMS TO BE A LOT OF AREAS 3007 02:28:48,680 --> 02:28:54,080 OF OVERLAP BETWEEN THE LAST TWO 3008 02:28:54,080 --> 02:28:54,400 INITIATIVES. 3009 02:28:54,400 --> 02:28:55,120 THE GENE THERAPY RESEARCH 3010 02:28:55,120 --> 02:28:58,560 PROGRAM AND THE RENEWAL OF THE 3011 02:28:58,560 --> 02:29:04,040 GENE VICTORY BIO REPOSITORY 3012 02:29:04,040 --> 02:29:04,800 CONTRACT. 3013 02:29:04,800 --> 02:29:10,240 I'M WONDERING IF THERE'S A 3014 02:29:10,240 --> 02:29:15,600 POSSIBILITY TO ANALYZE AND THE 3015 02:29:15,600 --> 02:29:16,200 REAGENTS CORE HAVE POTENTIAL 3016 02:29:16,200 --> 02:29:22,720 AREAS OF OVERLAP. 3017 02:29:22,720 --> 02:29:25,880 >>WE APPRECIATE THAT AND WOULD 3018 02:29:25,880 --> 02:29:28,640 WORK TO MAKE SURE THERE'S NO 3019 02:29:28,640 --> 02:29:29,000 OVERLAP. 3020 02:29:29,000 --> 02:29:30,760 WE HAD SOME DISCUSSIONS 3021 02:29:30,760 --> 02:29:31,520 INTERNALLY WHETHER IT WOULD MAKE 3022 02:29:31,520 --> 02:29:35,600 SENSE TO BRING THESE TWO 3023 02:29:35,600 --> 02:29:36,760 PROGRAMS UNDER A LARGER 3024 02:29:36,760 --> 02:29:40,280 UMBRELLA. 3025 02:29:40,280 --> 02:29:44,240 PERHAPS WITH SUB AWARDS BUT 3026 02:29:44,240 --> 02:29:48,120 THERE AREN'T MANY PLACE QUALIFY 3027 02:29:48,120 --> 02:29:49,520 SERVE IN THE CAPACITY OF THE 3028 02:29:49,520 --> 02:29:52,280 NGBB BUT THE SUB AWARDS IS ONE 3029 02:29:52,280 --> 02:29:54,760 POSSIBILITY. 3030 02:29:54,760 --> 02:29:59,120 >>JUST TO CLARIFY. 3031 02:29:59,120 --> 02:30:01,600 >>TO BRING THEM UNDER THE 3032 02:30:01,600 --> 02:30:01,920 UMBRELLA. 3033 02:30:01,920 --> 02:30:08,720 >>AND REDUCE THE POSSIBILITY OF 3034 02:30:08,720 --> 02:30:09,440 REDUNDANCY. 3035 02:30:09,440 --> 02:30:15,320 OTHER COMMENTS? 3036 02:30:15,320 --> 02:30:18,280 >>SOME OF IT IS VERY ORGAN 3037 02:30:18,280 --> 02:30:18,680 SPECIFIC. 3038 02:30:18,680 --> 02:30:21,120 I WAS TRYING TO THINK ABOUT 3039 02:30:21,120 --> 02:30:24,760 ECONOMIES OF SCALE FOR THE MORE 3040 02:30:24,760 --> 02:30:28,280 UNIVERSAL COMPONENTS. 3041 02:30:28,280 --> 02:30:33,880 >>THANK YOU. 3042 02:30:33,880 --> 02:30:34,520 >>GARY? 3043 02:30:34,520 --> 02:30:35,840 >>MAYBE ALONG THE LINES OF THE 3044 02:30:35,840 --> 02:30:38,680 TWO COMMENTS AS WE LOOK AT THE 3045 02:30:38,680 --> 02:30:39,920 PROGRAMS THAT HAVE BEEN AROUND 3046 02:30:39,920 --> 02:30:50,280 15 YEARS OR SO, SOME OF THEM 3047 02:30:50,280 --> 02:30:54,760 ENGENDERED WITH FIRST IN HUMAN 3048 02:30:54,760 --> 02:30:57,360 STUDIES IN THAT ERA. 3049 02:30:57,360 --> 02:30:59,600 ONE THING IS FOR THE INSTITUTE 3050 02:30:59,600 --> 02:31:01,840 TO REMAIN ADAPTIVE AND NOT 3051 02:31:01,840 --> 02:31:02,800 FIGHTING THE NEXT WAR BUT 3052 02:31:02,800 --> 02:31:04,240 FINDING OUT WHAT THE COMMUNITY 3053 02:31:04,240 --> 02:31:06,800 NEEDS AND WHAT SUPPORTS THE 3054 02:31:06,800 --> 02:31:11,640 COMMUNITY NEEDS IN THE NEXT FIVE 3055 02:31:11,640 --> 02:31:12,600 TO 10 YEARS. 3056 02:31:12,600 --> 02:31:16,160 WE WANT TO BE SURE AND STAY 3057 02:31:16,160 --> 02:31:16,520 NIMBLE. 3058 02:31:16,520 --> 02:31:19,920 TOWARD THAT END, I'M GENERALLY 3059 02:31:19,920 --> 02:31:22,880 AWARE THERE'S A LOT OF CORES AND 3060 02:31:22,880 --> 02:31:26,120 VENDORS NOW AND BIO 3061 02:31:26,120 --> 02:31:27,640 MANUFACTURERS WE'VE HAD VACCINES 3062 02:31:27,640 --> 02:31:31,400 THAT ARE ABLE TO MAKE AB, ADENO 3063 02:31:31,400 --> 02:31:32,720 VIRAL VECTORS. 3064 02:31:32,720 --> 02:31:35,680 IT'S NOT AS CLEAR TO ME 15 YEARS 3065 02:31:35,680 --> 02:31:38,600 IN IT'S AS BIG OF A CHALLENGE TO 3066 02:31:38,600 --> 02:31:43,080 THE BASIC STUFF FOR MANY 3067 02:31:43,080 --> 02:31:44,800 LABORATORIES OR EVEN A MOUSE 3068 02:31:44,800 --> 02:31:47,160 COLONY TO GET ENOUGH VIRUS TO DO 3069 02:31:47,160 --> 02:31:49,320 AN EXPERIMENT RELATIVELY 3070 02:31:49,320 --> 02:31:49,760 CHEAPER. 3071 02:31:49,760 --> 02:31:53,160 I DON'T KNOW THE INSTITUTE HAS 3072 02:31:53,160 --> 02:31:56,240 TO DO QUITE AS MUCH AS IT DID 15 3073 02:31:56,240 --> 02:32:00,240 YEARS AGO OR NEED TO DO 3074 02:32:00,240 --> 02:32:02,440 SOMETHING DIFFERENT. 3075 02:32:02,440 --> 02:32:08,160 IT'S HEALTHY TO STEP BACK AND 3076 02:32:08,160 --> 02:32:10,600 SEE WHAT IS NECESSARY FOR THE 3077 02:32:10,600 --> 02:32:11,080 NEXT SPOT. 3078 02:32:11,080 --> 02:32:16,240 >>I WAS THINKING OF 3079 02:32:16,240 --> 02:32:20,840 CELL-SPECIFIC TARGETING. 3080 02:32:20,840 --> 02:32:22,200 ANY OTHER COMMENTS ON THIS 3081 02:32:22,200 --> 02:32:23,400 BEFORE I PASS THE BATON? 3082 02:32:23,400 --> 02:32:25,480 I APPRECIATE YOU ALLOWING A FEW 3083 02:32:25,480 --> 02:32:26,680 MORE MINUTES TO DISCUSS THIS 3084 02:32:26,680 --> 02:32:26,880 ISSUE. 3085 02:32:26,880 --> 02:32:29,600 IT'S REALLY IMPORTANT TO US AS 3086 02:32:29,600 --> 02:32:31,440 WE FIGURE OUT HOW TO MOVE 3087 02:32:31,440 --> 02:32:32,240 FORWARD TO SUPPORT THE IMPORTANT 3088 02:32:32,240 --> 02:32:42,560 AREA OF RESEARCH. 3089 02:32:45,280 --> 02:32:46,120 >>DR. KILEY. 3090 02:32:46,120 --> 02:32:48,240 >>OKAY. 3091 02:32:48,240 --> 02:32:50,560 PRESENT. 3092 02:32:50,560 --> 02:32:51,640 >>THANKS, DAVID. 3093 02:32:51,640 --> 02:32:53,480 WE'RE GOING TO MOVE ON AND TALK 3094 02:32:53,480 --> 02:32:55,960 ABOUT THE ONES LED BY THE 3095 02:32:55,960 --> 02:32:57,480 DIVISION OF LUNG DISEASES. 3096 02:32:57,480 --> 02:33:00,280 WE HAVE SIX INITIATIVES ALL 3097 02:33:00,280 --> 02:33:04,680 EXCEPT FOR MAYBE ONE ARE EITHER 3098 02:33:04,680 --> 02:33:07,960 HL WIDE OR NLH WIDE STARTING 3099 02:33:07,960 --> 02:33:10,680 WITH INITIATIVE 3897. 3100 02:33:10,680 --> 02:33:16,200 THE NATIONAL FERRET RESOURCE AND 3101 02:33:16,200 --> 02:33:20,680 RESEARCH CENTER LED BY THE LUNGS 3102 02:33:20,680 --> 02:33:21,000 DIVISION. 3103 02:33:21,000 --> 02:33:25,080 THIS PROGRAM STARTED BACK IN 3104 02:33:25,080 --> 02:33:27,640 2014 AS AN INVESTIGATOR 3105 02:33:27,640 --> 02:33:29,680 INITIATED R24 PROGRAM AND THEN 3106 02:33:29,680 --> 02:33:32,280 CONVERTED IN 2020 TO CONTRACT 3107 02:33:32,280 --> 02:33:33,120 PROGRAM. 3108 02:33:33,120 --> 02:33:34,920 SOMEWHAT SIMILAR TO THE RESOURCE 3109 02:33:34,920 --> 02:33:36,280 PROGRAM THAT DAVID JUST 3110 02:33:36,280 --> 02:33:40,640 MENTIONED FOR GENE THERAPY. 3111 02:33:40,640 --> 02:33:41,720 THE MAJOR GOALS FOR THIS 3112 02:33:41,720 --> 02:33:43,680 RESOURCE ARE TO CREATE AND 3113 02:33:43,680 --> 02:33:46,640 DISTRIBUTE GENETICALLY MODIFIED 3114 02:33:46,640 --> 02:33:48,960 FERRET MODELS RELEVANT TO HEART, 3115 02:33:48,960 --> 02:33:51,080 LUNG, BLOOD, SLEEP DISEASE AND 3116 02:33:51,080 --> 02:33:53,920 FACILITATING OUR USAGE AMONG THE 3117 02:33:53,920 --> 02:33:56,240 RESEARCH COMMUNITY AND SERVE AS 3118 02:33:56,240 --> 02:33:58,080 A CENTRALIZED RESOURCE FOR 3119 02:33:58,080 --> 02:34:00,120 HUSBANDRY AND TRAINING AND STUDY 3120 02:34:00,120 --> 02:34:01,840 DESIGN FOR FERRET RECEIVER. 3121 02:34:01,840 --> 02:34:06,800 THE RESOURCE ITSELF HAS BEEN 3122 02:34:06,800 --> 02:34:08,880 INSTRUMENTAL IN IMPROVING 3123 02:34:08,880 --> 02:34:11,040 PROCESS AND MOLECULAR BASIS OF 3124 02:34:11,040 --> 02:34:13,440 LUNG DISEASES WHILE ADVANCING 3125 02:34:13,440 --> 02:34:14,520 PRECLINICAL STUDIES TO MOVE 3126 02:34:14,520 --> 02:34:16,560 TREATMENT TO CLINIC. 3127 02:34:16,560 --> 02:34:18,160 ONE OF THE MAIN AREAS THAT WAS 3128 02:34:18,160 --> 02:34:21,720 SET UP FOR IN THE EARLY DAYS WAS 3129 02:34:21,720 --> 02:34:24,480 TO REALLY STUDY CYSTIC FIBROSIS. 3130 02:34:24,480 --> 02:34:27,200 THIS WAS THE FIRST ANIMAL MODEL 3131 02:34:27,200 --> 02:34:31,640 OF THE ET WHERE THEY -- FERRET 3132 02:34:31,640 --> 02:34:33,800 WHERE THEY WERE ABLE TO KNOCKOUT 3133 02:34:33,800 --> 02:34:37,840 THE GENE RESPONSIBLE AND THERE'S 3134 02:34:37,840 --> 02:34:40,280 BEEN STRIDES IN CF THERAPY DUE 3135 02:34:40,280 --> 02:34:42,720 TO USING THE ANIMAL MODEL. 3136 02:34:42,720 --> 02:34:45,840 ONE THING I THINK IS UNIQUE HERE 3137 02:34:45,840 --> 02:34:48,240 IS THAT THERE'S A LOT OF 3138 02:34:48,240 --> 02:34:51,760 SIMILARITIES WITH THE HUMAN 3139 02:34:51,760 --> 02:34:52,360 PULMONARY SYSTEM INCLUDING 3140 02:34:52,360 --> 02:34:56,840 COMMON ANATOMICAL STRUCTURE AND 3141 02:34:56,840 --> 02:34:59,840 THE AIRWAY IS SIMILAR TO 3142 02:34:59,840 --> 02:35:00,720 RESPIRATORY BRONCHIOLES. 3143 02:35:00,720 --> 02:35:02,200 THERE'S SHARED IMMUNOLOGICAL 3144 02:35:02,200 --> 02:35:04,040 RESPONSES AND THE ABILITY TO 3145 02:35:04,040 --> 02:35:04,680 COUGH. 3146 02:35:04,680 --> 02:35:08,240 FERRETS REALLY ARE A GOOD MODEL 3147 02:35:08,240 --> 02:35:12,280 FOR RESPIRATORY DISEASE AND 3148 02:35:12,280 --> 02:35:13,120 PARTICULARLY RESPIRATORY 3149 02:35:13,120 --> 02:35:15,680 INFECTION AND WHEN YOU COMPARE 3150 02:35:15,680 --> 02:35:20,720 IT TO THE MOUSE MODEL THEY CAN'T 3151 02:35:20,720 --> 02:35:22,680 RECAPITULATE AND WHEN YOU RAMP 3152 02:35:22,680 --> 02:35:29,720 UP TO PIGS, SHEEP AND NON HUMAN 3153 02:35:29,720 --> 02:35:31,440 PRIMATES IT GETS COSTLY. 3154 02:35:31,440 --> 02:35:32,800 THIS IS A CONTRACT RENEWAL FOR 3155 02:35:32,800 --> 02:35:35,200 THE FERRET RESOURCE AND THINK 3156 02:35:35,200 --> 02:35:36,640 IT'S BEEN A PRODUCTIVE RESOURCE 3157 02:35:36,640 --> 02:35:37,560 OVER THE YEARS. 3158 02:35:37,560 --> 02:35:41,120 AS MENTIONED, IT WAS FIRST USED 3159 02:35:41,120 --> 02:35:45,880 FOR THE CFTR GENE AND THEN AFTER 3160 02:35:45,880 --> 02:35:47,600 A BIT IT BECAME CLEAR IT COULD 3161 02:35:47,600 --> 02:35:52,840 BE ADAPTED TO STUDY OTHER LUNG 3162 02:35:52,840 --> 02:35:56,320 DISEASES SUCH AS DEFICIENCIES, 3163 02:35:56,320 --> 02:35:58,160 PULMONARY FIBROSIS AND COPD AND 3164 02:35:58,160 --> 02:35:59,880 THERE'S BEEN INNOVATIVE WORK 3165 02:35:59,880 --> 02:36:01,560 DONE NOT ONLY USING THE RESOURCE 3166 02:36:01,560 --> 02:36:03,560 ITSELF BUT PROVIDING THE ANIMALS 3167 02:36:03,560 --> 02:36:06,160 TO THE COMMUNITY AS A WHOLE. 3168 02:36:06,160 --> 02:36:09,400 IN FACT EVEN DURING THE COVID 3169 02:36:09,400 --> 02:36:11,320 ERA IT WAS UTILIZED FOR 3170 02:36:11,320 --> 02:36:15,560 RESPIRATORY TRACT INFECTIONS FOR 3171 02:36:15,560 --> 02:36:15,840 SARS COV2. 3172 02:36:15,840 --> 02:36:17,480 THEY WERE ADAPTIVE IN THE LAST 3173 02:36:17,480 --> 02:36:18,280 FEW YEARS. 3174 02:36:18,280 --> 02:36:19,080 HAVE BEEN HIGHLY PRODUCTIVE. 3175 02:36:19,080 --> 02:36:21,640 I WON'T TELL YOU ALL THE 3176 02:36:21,640 --> 02:36:21,880 DETAILS. 3177 02:36:21,880 --> 02:36:24,240 IT'S IN THE WRITE-UP BUT IT'S 3178 02:36:24,240 --> 02:36:30,440 BEEN A USEFUL RESOURCE FOR THE 3179 02:36:30,440 --> 02:36:35,200 PULMONARY COMMUNITY AND WE WOULD 3180 02:36:35,200 --> 02:36:37,120 LIKE TO CONSIDER RENEWING THIS. 3181 02:36:37,120 --> 02:36:38,400 LOTS OF STATISTICS BECAUSE 3182 02:36:38,400 --> 02:36:43,880 THEY'VE BEEN PRODUCTIVE ALL 3183 02:36:43,880 --> 02:36:44,160 AROUND. 3184 02:36:44,160 --> 02:36:45,640 ONE THING IN THE INSTITUTE WE'RE 3185 02:36:45,640 --> 02:36:48,200 EXCITE ABOUT IS THE POSSIBILITY 3186 02:36:48,200 --> 02:36:52,280 OF USING THE ANIMAL MODEL MORE 3187 02:36:52,280 --> 02:36:56,120 THAN JUST FOR LUNG DISEASE AND 3188 02:36:56,120 --> 02:36:56,880 CARDIOVASCULAR DISEASE AND OTHER 3189 02:36:56,880 --> 02:37:00,240 AREAS WITHIN NHLBI THE MODEL 3190 02:37:00,240 --> 02:37:06,080 COULD EXPAND TO. 3191 02:37:06,080 --> 02:37:09,080 AND IT'S BEEN VERY ADAPTIVE AND 3192 02:37:09,080 --> 02:37:09,360 MODIFIED. 3193 02:37:09,360 --> 02:37:12,160 IT'S OVER ALL PROCESSES AND 3194 02:37:12,160 --> 02:37:14,600 LEVERAGED AN AMAZING AMOUNT OF 3195 02:37:14,600 --> 02:37:16,240 RESOURCES LOCALLY AND ACROSS NIH 3196 02:37:16,240 --> 02:37:18,600 TO MAINTAIN THE COLONY AND THE 3197 02:37:18,600 --> 02:37:23,080 RESOURCE TO PROVIDE THESE 3198 02:37:23,080 --> 02:37:24,560 ANIMALS AND VARIOUS MATERIALS TO 3199 02:37:24,560 --> 02:37:26,520 THE INVESTIGATIVE COMMUNITY. 3200 02:37:26,520 --> 02:37:31,680 I'LL STOP THERE AND TAKE ANY 3201 02:37:31,680 --> 02:37:33,120 QUESTI 3202 02:37:33,120 --> 02:37:36,240 QUESTIONS AND GET YOUR FEEDBACK 3203 02:37:36,240 --> 02:37:46,440 ON THIS ONE. 3204 02:37:56,760 --> 02:37:57,800 >>NOT SEEING MUCH YOU CAN RATE 3205 02:37:57,800 --> 02:38:03,200 THIS ONE. 3206 02:38:03,200 --> 02:38:13,360 >>3897. 3207 02:38:37,400 --> 02:38:39,160 >>WE CAN MOVE ON TO THE NEXT 3208 02:38:39,160 --> 02:38:40,120 CONCEPT. 3209 02:38:40,120 --> 02:38:41,120 >>THANK YOU. 3210 02:38:41,120 --> 02:38:43,960 THE NEXT CONCEPT THIS IS A 3211 02:38:43,960 --> 02:38:46,680 PACKAGE LIKE YOU SAW FOR I THINK 3212 02:38:46,680 --> 02:38:46,960 MESA. 3213 02:38:46,960 --> 02:38:53,120 THIS ONE IS 3900 AND 3901 I'LL 3214 02:38:53,120 --> 02:38:54,360 PRESENT TOGETHER BECAUSE THEY'RE 3215 02:38:54,360 --> 02:38:56,880 THE SAME JUST USING TWO FUNDING 3216 02:38:56,880 --> 02:39:00,240 MECHANISMS THE UL1 AND U24. 3217 02:39:00,240 --> 02:39:03,880 YOU'LL NEED TO RATE THEM 3218 02:39:03,880 --> 02:39:05,120 INDIVIDUALLY BUT IT'S 3219 02:39:05,120 --> 02:39:06,200 ESSENTIALLY THE SAME INITIATIVE. 3220 02:39:06,200 --> 02:39:08,240 ENTITLE OF ENTITLED ADVANCING 3221 02:39:08,240 --> 02:39:12,280 METHODS FOR 24-HOUR BEHAVIORAL 3222 02:39:12,280 --> 02:39:16,240 PATTERNS AND DIET ACTIVITY AND 3223 02:39:16,240 --> 02:39:25,760 SLEEP AND UL 1, U24 RFA AND 3224 02:39:25,760 --> 02:39:32,520 WE'RE A SECONDARY SIGN-ON. 3225 02:39:32,520 --> 02:39:34,920 AND THE HEART DIVISION HAS BEEN 3226 02:39:34,920 --> 02:39:37,640 INVOLVED AND THERE'S A TEAM OF 3227 02:39:37,640 --> 02:39:38,880 NHLBI INSTRUMENTAL IN MOVING 3228 02:39:38,880 --> 02:39:40,040 THIS FORWARD. 3229 02:39:40,040 --> 02:39:42,160 THIS CONCEPT IS FOCUSSED ON 3230 02:39:42,160 --> 02:39:46,080 LEVERAGING EXISTING DATA TO 3231 02:39:46,080 --> 02:39:47,760 INTEGRATE AND EXAMINE BEHAVIORAL 3232 02:39:47,760 --> 02:39:50,040 PATTERNS OF DIET, PHYSICAL 3233 02:39:50,040 --> 02:39:52,160 ACTIVITY AND SLEEP LOOKING AT 3234 02:39:52,160 --> 02:39:53,440 HEART DISEASES AND DISORDERS. 3235 02:39:53,440 --> 02:39:57,720 AS A BACKGROUND IN SEPTEMBER OF 3236 02:39:57,720 --> 02:39:58,480 '22 THE WHITE HOUSE CONFERENCE 3237 02:39:58,480 --> 02:40:01,680 ON HUNGER, NUTRITION AND HEALTH 3238 02:40:01,680 --> 02:40:04,240 CALLED FOR HHS AND NIH TO 3239 02:40:04,240 --> 02:40:06,840 EXPLORE DEVELOPING VALIDATED 3240 02:40:06,840 --> 02:40:11,920 MEASUREMENTS TO ASSESS 24-HOUR 3241 02:40:11,920 --> 02:40:13,240 PATTERNS OF DIET, PHYSICAL 3242 02:40:13,240 --> 02:40:13,680 ACTIVITY AND SLEEP. 3243 02:40:13,680 --> 02:40:15,680 THIS ATTEMPTS TO ANSWER THE CALL 3244 02:40:15,680 --> 02:40:17,160 USING THE TWO FUNDING MECHANISMS 3245 02:40:17,160 --> 02:40:22,120 AND IT WOULD BE JOINTLY 3246 02:40:22,120 --> 02:40:26,280 SUPPORTED BY NHLBI, NCI AND THE 3247 02:40:26,280 --> 02:40:27,080 DIABETES DISEASE AND BEHAVIORAL 3248 02:40:27,080 --> 02:40:28,960 AND SOCIAL SCIENCES GROUP. 3249 02:40:28,960 --> 02:40:31,880 SO I THINK ALL OF YOU KNOW DIET, 3250 02:40:31,880 --> 02:40:36,840 PHYSICAL ACTIVITY SLEEP ALL 3251 02:40:36,840 --> 02:40:38,680 MODIFIABLE LIFE RISK FACTORS AND 3252 02:40:38,680 --> 02:40:40,240 STUDIES HAVE COLLECTED DATA ON 3253 02:40:40,240 --> 02:40:42,920 ALL THESE BEHAVIORS BUT FEW HAVE 3254 02:40:42,920 --> 02:40:44,920 EXAMINED HOW THEY COMBINED TO 3255 02:40:44,920 --> 02:40:47,280 EFFECT HEALTH AND DISEASE. 3256 02:40:47,280 --> 02:40:49,040 ACCORDINGLY, SIGNIFICANT GAPS 3257 02:40:49,040 --> 02:40:49,560 REMAIN ALONG THE RESEARCH 3258 02:40:49,560 --> 02:40:51,080 CONTINUUM. 3259 02:40:51,080 --> 02:40:53,840 SO WE'RE LOOKING TO FACILITATE 3260 02:40:53,840 --> 02:40:55,960 COLLABORATIVE EFFORTS TO ADVANCE 3261 02:40:55,960 --> 02:41:00,240 OUR UNDERSTANDING OF THESE 3262 02:41:00,240 --> 02:41:04,000 INTERRELATIONSHIPS IN TIME IN 3263 02:41:04,000 --> 02:41:05,160 TEMPORAL MANNER AND IN TERM OF 3264 02:41:05,160 --> 02:41:07,800 INTEGRATING THEM TOGETHER. 3265 02:41:07,800 --> 02:41:10,280 SO THE INITIATIVE WILL SOLICIT 3266 02:41:10,280 --> 02:41:12,840 PROPOSALS THAT LEVERAGE EXISTING 3267 02:41:12,840 --> 02:41:14,640 DATA AMONG DIVERSE POPULATIONS 3268 02:41:14,640 --> 02:41:17,960 TO INVESTIGATE HOW THE TIMING OF 3269 02:41:17,960 --> 02:41:22,320 DIET, PHYSICAL ACTIVITY AND 3270 02:41:22,320 --> 02:41:23,640 SLEEP SYNERGISTICALLY ADDRESS 3271 02:41:23,640 --> 02:41:24,640 CARDIO METABOLIC OUTCOMES 3272 02:41:24,640 --> 02:41:27,120 THROUGH THE DEVELOPMENT OF 3273 02:41:27,120 --> 02:41:28,640 ROBUST ANALYTICAL APPROACHES. 3274 02:41:28,640 --> 02:41:31,560 THIS CONCEPT HAS SIGNIFICANT 3275 02:41:31,560 --> 02:41:33,240 PUBLIC HEALTH AND IMPLICATIONS 3276 02:41:33,240 --> 02:41:33,960 AND WILL EXPAND OUR 3277 02:41:33,960 --> 02:41:36,240 UNDERSTANDING OF HOW THE TIMING 3278 02:41:36,240 --> 02:41:38,400 OF BEHAVIORAL PATTERNS MAY BE 3279 02:41:38,400 --> 02:41:40,320 LEVERAGED AND IMPLEMENTED INTO 3280 02:41:40,320 --> 02:41:42,240 TARGETED INTERVENTIONS AND 3281 02:41:42,240 --> 02:41:42,680 PRECISION MEDICINE. 3282 02:41:42,680 --> 02:41:45,640 THE KEY IN CASE I DIDN'T MAKE IT 3283 02:41:45,640 --> 02:41:48,160 CLEAR, THESE HAVE BEEN LOOKED AT 3284 02:41:48,160 --> 02:41:49,480 INDIVIDUALLY AND IN ISOLATION. 3285 02:41:49,480 --> 02:41:51,760 THIS IS AN ATTEMPT TO BRING IT 3286 02:41:51,760 --> 02:41:53,640 ALL TOGETHER AS BEST WE CAN AND 3287 02:41:53,640 --> 02:41:57,280 LOOK AT IT IN A HOLISTIC MANNER. 3288 02:41:57,280 --> 02:41:58,560 THAT'S THE THRUST OF THE TWO 3289 02:41:58,560 --> 02:41:59,520 INITIATIVES. 3290 02:41:59,520 --> 02:42:01,200 I'M HAPPY TO TRY TO TAKE 3291 02:42:01,200 --> 02:42:01,840 QUESTIONS ON THESE IF THERE ARE 3292 02:42:01,840 --> 02:42:11,920 ANY. 3293 02:42:25,800 --> 02:42:27,720 GO AHEAD AND RATE THESE AS WELL, 3294 02:42:27,720 --> 02:42:38,160 PLEASE, THE TWO OF THEM. 3295 02:43:00,280 --> 02:43:04,280 A QUICK REMINDER, THAT'S 3900 3296 02:43:04,280 --> 02:43:14,440 AND 3901. 3297 02:43:19,520 --> 02:43:20,640 WE CAN MOVE ON. 3298 02:43:20,640 --> 02:43:22,560 >>OKAY. 3299 02:43:22,560 --> 02:43:26,560 THE THIRD ONE IN THIS GROUPING 3300 02:43:26,560 --> 02:43:27,880 IS 3914. 3301 02:43:27,880 --> 02:43:29,680 THIS IS THE NHLBI PROGRAM 3302 02:43:29,680 --> 02:43:33,840 PROJECT APPLICATIONS. 3303 02:43:33,840 --> 02:43:40,240 THIS INITIATIVE HAS BEEN LED BY 3304 02:43:40,240 --> 02:43:42,360 DR. LISA POSTOE IN THE LUNG 3305 02:43:42,360 --> 02:43:42,640 DIVISION. 3306 02:43:42,640 --> 02:43:47,520 THIS IS A PROPOSAL TO RENEW THE 3307 02:43:47,520 --> 02:43:50,440 EXISTING PAR WITH REVIEW THAT 3308 02:43:50,440 --> 02:43:51,320 SUPPORTS PROGRAM PROJECT GRANTS 3309 02:43:51,320 --> 02:43:53,400 OR THE PL1s. 3310 02:43:53,400 --> 02:43:54,720 THIS WAS LAST PRESENTED ABOUT 3311 02:43:54,720 --> 02:43:59,040 THREE YEARS AGO SO IT'S TIME TO 3312 02:43:59,040 --> 02:44:01,600 RENEW THIS INITIATIVE. 3313 02:44:01,600 --> 02:44:04,680 IT WILL CONTINUE TO REQUEST 3314 02:44:04,680 --> 02:44:06,840 INVESTIGATOR-INITIATED PROGRAM 3315 02:44:06,840 --> 02:44:09,520 PROJECT APPLICATIONS THAT 3316 02:44:09,520 --> 02:44:11,160 INVESTIGATE FUNDAMENTAL 3317 02:44:11,160 --> 02:44:14,600 PROCESSES AND DISEASE IN HEART, 3318 02:44:14,600 --> 02:44:15,160 LUNG, BLOOD AND SLEEP. 3319 02:44:15,160 --> 02:44:17,520 MANY OF THE PO1 GRANTS WE HAVE 3320 02:44:17,520 --> 02:44:18,840 SUPPORTED AND WHAT COMES IN THE 3321 02:44:18,840 --> 02:44:21,360 DOOR FOCUS ON MECHANISTIC 3322 02:44:21,360 --> 02:44:23,560 RESEARCH. 3323 02:44:23,560 --> 02:44:25,920 ONE OF THE THINGS LIKE TO 3324 02:44:25,920 --> 02:44:27,200 ENCOURAGE AND HOPEFULLY SEE 3325 02:44:27,200 --> 02:44:31,960 DEVELOP IN THIS RENEWAL IS A 3326 02:44:31,960 --> 02:44:33,440 LITTLE BIT MORE IN THE WAY OF 3327 02:44:33,440 --> 02:44:35,800 TRANSLATIONAL AND IMPLEMENTATION 3328 02:44:35,800 --> 02:44:36,040 RESEARCH. 3329 02:44:36,040 --> 02:44:38,200 THOSE ARE TWO AREAS ENCOURAGED 3330 02:44:38,200 --> 02:44:40,320 AS WE PUT THIS BACK OUT ON THE 3331 02:44:40,320 --> 02:44:40,840 STREET. 3332 02:44:40,840 --> 02:44:43,920 AS MOST OF YOU KNOW, PPG NEEDS A 3333 02:44:43,920 --> 02:44:45,880 MINIMUM OF THREE INTERRELATED 3334 02:44:45,880 --> 02:44:46,520 PROJECTS. 3335 02:44:46,520 --> 02:44:48,720 THEY ALL HAVE TO BE AROUND A 3336 02:44:48,720 --> 02:44:49,400 COMMON THEME. 3337 02:44:49,400 --> 02:44:53,720 THEY INCLUDE SCIENTIFIC AND 3338 02:44:53,720 --> 02:44:55,760 ADMINISTRATIVE CORPS, FOSTERING 3339 02:44:55,760 --> 02:44:59,000 COLLABORATION WITH 3340 02:44:59,000 --> 02:45:00,680 INTERDISCIPLINARY RESEARCH FOR A 3341 02:45:00,680 --> 02:45:04,240 MAXIMUM SO YEARS AND MAXIMUM 3342 02:45:04,240 --> 02:45:09,800 BUDGET OF $5.51 MILLION AND NEW 3343 02:45:09,800 --> 02:45:12,240 INVESTIGATOR -- FIVE YEARS. 3344 02:45:12,240 --> 02:45:16,240 AND USED TO ENCOURAGE THE 3345 02:45:16,240 --> 02:45:21,040 CAREERS OF JUNIOR INVESTIGATORS 3346 02:45:21,040 --> 02:45:21,800 IN THE COLLABORATIVE ENVIRONMENT 3347 02:45:21,800 --> 02:45:23,960 IF THE PROJECT IS LED BY AN 3348 02:45:23,960 --> 02:45:27,080 EARLY STAGE INVESTIGATOR THE 3349 02:45:27,080 --> 02:45:30,200 REQUEST CAN BE UP TO $1.765 3350 02:45:30,200 --> 02:45:32,240 MILLION PER YEAR. 3351 02:45:32,240 --> 02:45:36,840 WE HOPE THE P.A.R. WILL CONTINUE 3352 02:45:36,840 --> 02:45:42,280 ALONG OVER A 10-YEAR PERIOD AND 3353 02:45:42,280 --> 02:45:44,760 PLAN TO AWARD 14 TO 15 A YEAR 3354 02:45:44,760 --> 02:45:48,000 AND HAVE A SET ASIDE FOR THE 3355 02:45:48,000 --> 02:45:51,080 P.P.G. MECHANISM. 3356 02:45:51,080 --> 02:45:52,600 IT'S AN IMPORTANT 3357 02:45:52,600 --> 02:45:53,640 INVESTIGATOR-INITIATED MECHANISM 3358 02:45:53,640 --> 02:46:00,560 AND HISTORICALLY PPG GRANTS 3359 02:46:00,560 --> 02:46:02,320 FUNDED IN THE GRANT PORTFOLIO 3360 02:46:02,320 --> 02:46:04,880 AND I POINT TO CYSTIC FIBE ROYCE 3361 02:46:04,880 --> 02:46:11,840 WHERE WE HAD LONG-STANDING PPGs 3362 02:46:11,840 --> 02:46:22,400 AND RELATIONSHIPS BETWEEN THEM. 3363 02:47:00,920 --> 02:47:11,320 GO AHEAD AND RATE THIS ONE. 3364 02:47:22,440 --> 02:47:24,240 >>WE CAN MOVE ON TO THE NEXT 3365 02:47:24,240 --> 02:47:25,880 CONCEPT. 3366 02:47:25,880 --> 02:47:26,520 >>THANK YOU. 3367 02:47:26,520 --> 02:47:30,840 WE'RE ON THE FOURTH IS NUMBER 3368 02:47:30,840 --> 02:47:31,800 3924, 3924. 3369 02:47:31,800 --> 02:47:35,760 THE NHLBI CLINICAL TRIAL PILOT 3370 02:47:35,760 --> 02:47:36,000 STUDIES. 3371 02:47:36,000 --> 02:47:38,360 THIS IS THE R34 CLINICAL TRIAL 3372 02:47:38,360 --> 02:47:40,120 OPTIONAL MECHANISM. 3373 02:47:40,120 --> 02:47:42,800 THIS ONE IS LED BY DR. MICHELLE 3374 02:47:42,800 --> 02:47:44,240 KRAMER IN THE LUNG DIVISION. 3375 02:47:44,240 --> 02:47:50,400 THIS HAS A NUMBER OF ADDITIONAL 3376 02:47:50,400 --> 02:47:52,240 STAFF 3377 02:47:52,240 --> 02:48:00,640 [LISTING NAMES] 3378 02:48:00,640 --> 02:48:03,640 ALL FROM HEART, LUNG, BLOOD AND 3379 02:48:03,640 --> 02:48:03,920 CONTRIBUTED. 3380 02:48:03,920 --> 02:48:05,240 THIS SHOULD BE FAIRLY FAMILIAR 3381 02:48:05,240 --> 02:48:07,560 BECAUSE YOU'VE SEEN THIS BEFORE. 3382 02:48:07,560 --> 02:48:11,160 THE PURPOSE OF THE R 34 IS TO 3383 02:48:11,160 --> 02:48:13,120 SUPPORT INVESTIGATORS IN 3384 02:48:13,120 --> 02:48:13,920 OBTAINING INFORMATION REQUIRED 3385 02:48:13,920 --> 02:48:16,240 TO COMPLETE THE DESIGN AND 3386 02:48:16,240 --> 02:48:21,360 PROTOCOL FOR A PHASE 2 CLINICAL 3387 02:48:21,360 --> 02:48:22,200 TRIAL AND OTHER CLINICAL TRIAL 3388 02:48:22,200 --> 02:48:23,280 OPPORTUNITIES BY ALLOWING 3389 02:48:23,280 --> 02:48:24,840 INVESTIGATORS TO ADDRESS 3390 02:48:24,840 --> 02:48:27,240 CRITICAL QUESTIONS PRIOR TO 3391 02:48:27,240 --> 02:48:29,280 SUBMISSION OF AN APPLICATION TO 3392 02:48:29,280 --> 02:48:31,520 SUPPORT THE PLANNED LARGER 3393 02:48:31,520 --> 02:48:31,920 TRIAL. 3394 02:48:31,920 --> 02:48:35,840 THE NHLBI IS USED THE R34 SINCE 3395 02:48:35,840 --> 02:48:36,240 2010. 3396 02:48:36,240 --> 02:48:37,880 WE PRESENTED THIS LAST IN 3397 02:48:37,880 --> 02:48:41,760 JANUARY OF 2018 TO ALL OF YOU. 3398 02:48:41,760 --> 02:48:45,800 AT THE TIME OF IT'S INCEPTION 3399 02:48:45,800 --> 02:48:48,120 STAFF RECOGNIZED THE MECHANISM 3400 02:48:48,120 --> 02:48:48,960 WHICH ALLOWS UP TO THREE YEARS 3401 02:48:48,960 --> 02:48:52,080 OF FUNDING WITH A TOTAL BUDGET 3402 02:48:52,080 --> 02:48:56,360 OF $450,000 IN DIRECT COST TO 3403 02:48:56,360 --> 02:49:03,080 IMPROVE THE CONDUCT OR OBTAIN 3404 02:49:03,080 --> 02:49:03,880 ADDITIONAL INFORMATION THAT MAY 3405 02:49:03,880 --> 02:49:11,240 BE REQUIRED TO DO THE MORE 3406 02:49:11,240 --> 02:49:12,240 INTENSE CLINICAL TRIAL AND 3407 02:49:12,240 --> 02:49:15,320 BELIEVE IT SERVES THE 3408 02:49:15,320 --> 02:49:16,080 INVESTIGATIVE COMMUNITY. 3409 02:49:16,080 --> 02:49:18,840 RIGHT NOW WE FUND APPROXIMATELY 3410 02:49:18,840 --> 02:49:21,680 20 TO 25 OF THESE PER YEAR. 3411 02:49:21,680 --> 02:49:24,520 THESE R34 APPLICATIONS. 3412 02:49:24,520 --> 02:49:28,200 AND THERE IS A RELATIVELY ROBUST 3413 02:49:28,200 --> 02:49:29,920 RESPONSE FROM THE INVESTIGATIVE 3414 02:49:29,920 --> 02:49:31,040 COMMUNITY THIS IS A VERY 3415 02:49:31,040 --> 02:49:33,440 IMPORTANT AND NEEDED MECHANISM. 3416 02:49:33,440 --> 02:49:35,640 RENEWAL OF THE PROGRAM WILL 3417 02:49:35,640 --> 02:49:38,040 CONTINUE TO SERVE THE 3418 02:49:38,040 --> 02:49:38,720 INVESTIGATOR COMMUNITY ACROSS 3419 02:49:38,720 --> 02:49:41,320 NHLBI AND WE WILL MAKE SURE THAT 3420 02:49:41,320 --> 02:49:44,240 LANGUAGE IS INCLUDED IN THE 3421 02:49:44,240 --> 02:49:46,200 ANNOUNCEMENT TO ENCOURAGE 3422 02:49:46,200 --> 02:49:47,320 DIVERSITY, EQUITY, INCLUSION AND 3423 02:49:47,320 --> 02:49:47,920 ACCESSIBILITY IN RESEARCH. 3424 02:49:47,920 --> 02:49:50,680 THIS IS ONE AREA YOU HEARD FROM 3425 02:49:50,680 --> 02:49:52,000 DR. GIBBONS WE'RE TRYING TO 3426 02:49:52,000 --> 02:49:52,720 STRATEGICALLY ADVANCE AND THIS 3427 02:49:52,720 --> 02:49:56,240 IS A MECHANISM THAT ALLOWS TO DO 3428 02:49:56,240 --> 02:49:58,520 THAT. 3429 02:49:58,520 --> 02:49:59,840 OTHERWISE, NOT VERY MANY CHANGES 3430 02:49:59,840 --> 02:50:01,800 TO THE FUNDING OPPORTUNITY 3431 02:50:01,800 --> 02:50:03,200 ANNOUNCEMENT ARE ANTICIPATED. 3432 02:50:03,200 --> 02:50:05,040 THIS IS PRETTY MUCH A RENEWAL OF 3433 02:50:05,040 --> 02:50:05,840 WHAT'S ON THE STREET. 3434 02:50:05,840 --> 02:50:06,960 I'LL STOP THERE AND TRY TO TAKE 3435 02:50:06,960 --> 02:50:17,120 QUESTIONS. 3436 02:50:25,720 --> 02:50:28,280 HOPEFULLY YOU CAN RATE THIS ONE 3437 02:50:28,280 --> 02:50:38,440 AS WELL. 3438 02:50:56,080 --> 02:51:01,760 >>THIS LAST ONE IS 3927. 3439 02:51:01,760 --> 02:51:06,800 IT'S SUB POPULATIONS AND 3440 02:51:06,800 --> 02:51:11,040 INTERMEDIATE OUTCOME STUDIES IN 3441 02:51:11,040 --> 02:51:21,480 COPD KNOWN AS SPIROMIC TO 3442 02:51:22,960 --> 02:51:26,840 IDENTIFY DIFFERENT INDIVIDUALS 3443 02:51:26,840 --> 02:51:28,600 WITH COPD AND DEFINE SPECIFIC 3444 02:51:28,600 --> 02:51:34,160 INTERVENTIONS. 3445 02:51:34,160 --> 02:51:36,040 THE GOAL IS BEING ACCOMPLISHED 3446 02:51:36,040 --> 02:51:37,560 BY INTENSIVE PHENOTYPING OF A 3447 02:51:37,560 --> 02:51:39,200 COHORT WITH A HISTORY OF SMOKING 3448 02:51:39,200 --> 02:51:42,800 WITH AND WITHOUT COPD AND 3449 02:51:42,800 --> 02:51:45,040 CONTROL PARTICIPANTS WITHOUT 3450 02:51:45,040 --> 02:51:45,560 COPD. 3451 02:51:45,560 --> 02:51:48,880 THIS IS A LIMITED COMPETITION 3452 02:51:48,880 --> 02:51:49,720 RENEWAL. 3453 02:51:49,720 --> 02:51:54,840 IN THE NEXT CYCLE OF SPIROMICS 3454 02:51:54,840 --> 02:51:55,720 THE INVESTIGATORS WILL BE 3455 02:51:55,720 --> 02:51:58,240 CHARGED OR CHALLENGED TO OBTAIN 3456 02:51:58,240 --> 02:51:59,320 ADDITIONAL LONGITUDINAL DATA 3457 02:51:59,320 --> 02:52:02,520 FROM THE COHORT AND THEY'LL 3458 02:52:02,520 --> 02:52:06,760 ADDRESS THREE CRITICAL TOPICS 3459 02:52:06,760 --> 02:52:11,680 THAT HAVE BEEN PROMPTED BY 3460 02:52:11,680 --> 02:52:14,280 RECENT FINDINGS WHETHER 3461 02:52:14,280 --> 02:52:15,440 NON-OBSTRUCTIVE AIRWAY DISEASE 3462 02:52:15,440 --> 02:52:18,520 IS SIMILAR TO COPD AND REPRESENT 3463 02:52:18,520 --> 02:52:20,920 AS A PRECURSOR CONDITION THAT 3464 02:52:20,920 --> 02:52:21,880 CAN PROGRESS TO COPD. 3465 02:52:21,880 --> 02:52:24,840 THE SECOND IS TO EXPLORE THE USE 3466 02:52:24,840 --> 02:52:30,840 OF NOVEL CT MEASURES TO IDENTIFY 3467 02:52:30,840 --> 02:52:35,960 EMP 3468 02:52:35,960 --> 02:52:37,600 EMPHYSEMA SUB TYPES AND TRACK 3469 02:52:37,600 --> 02:52:40,280 PROGRESSION OF THE ABNORMALITIES 3470 02:52:40,280 --> 02:52:42,200 AND CHARACTERIZE ENVIRONMENTAL 3471 02:52:42,200 --> 02:52:43,120 EXPOSURES AND SOCIAL 3472 02:52:43,120 --> 02:52:45,240 DETERMINATES OF HEALTH IN 3473 02:52:45,240 --> 02:52:47,440 POPULATIONS TO RELATE RISK 3474 02:52:47,440 --> 02:52:50,400 FACTORS TO PARTICULAR COPD SUB 3475 02:52:50,400 --> 02:52:55,080 TYPES AND RELATE THAT BACK TO 3476 02:52:55,080 --> 02:53:00,840 PATHOBIOLOGICAL MECHANISMS. 3477 02:53:00,840 --> 02:53:02,840 IT'S BEEN DRIVING UNDERSTANDING 3478 02:53:02,840 --> 02:53:03,880 ABNORMALITIES IN COPD. 3479 02:53:03,880 --> 02:53:08,120 IT'S HAD A PRODUCTIVE HISTORY. 3480 02:53:08,120 --> 02:53:11,320 IT COMPLEMENTS OUR OTHER 3481 02:53:11,320 --> 02:53:11,760 LONGITUDINAL STUDY. 3482 02:53:11,760 --> 02:53:14,000 IN LUNG WE HAVE TWO THAT RELATE 3483 02:53:14,000 --> 02:53:16,240 TO COPD GENE STUDY LOOKING AT 3484 02:53:16,240 --> 02:53:18,440 GENETICS AND NATURAL HISTORY AND 3485 02:53:18,440 --> 02:53:22,240 THIS LOOKS AT BIOMARKERS AND 3486 02:53:22,240 --> 02:53:25,440 DOES MORE INTENSE PHENOTYPING. 3487 02:53:25,440 --> 02:53:28,280 THE OTHER ELEMENT OF THIS 3488 02:53:28,280 --> 02:53:34,360 RENEWAL IS TO ROLL INTO 3489 02:53:34,360 --> 02:53:38,920 SPIROMICS YOUNGER SMOKERS CALLED 3490 02:53:38,920 --> 02:53:42,120 SOURCE BY BE AN INVESTIGATOR 3491 02:53:42,120 --> 02:53:43,160 INITIATED GRANT USING THE SAME 3492 02:53:43,160 --> 02:53:44,520 PLATFORM AND IT'S BEEN ACTIVE 3493 02:53:44,520 --> 02:53:47,560 ONLY A COUPLE YEARS AND IT'S 3494 02:53:47,560 --> 02:53:49,680 CURRENTLY ENROLLING IN 3495 02:53:49,680 --> 02:53:51,640 CHARACTERIZING THE YOUNGER 3496 02:53:51,640 --> 02:53:57,040 INDIVIDUALS USING THE SPIROMICS 3497 02:53:57,040 --> 02:53:59,520 PROTOCOL AND PROPOSE TO BRING 3498 02:53:59,520 --> 02:54:03,360 THEM IN DURING THE SECOND HALF 3499 02:54:03,360 --> 02:54:04,080 OF THE CONTRACT PERIOD. 3500 02:54:04,080 --> 02:54:07,160 ADDING SOURCE WILL INCREASE THE 3501 02:54:07,160 --> 02:54:12,240 SIZE OF THE COHORT AND IMPROVE 3502 02:54:12,240 --> 02:54:15,960 THE USEFULNESS IN STUDYING COPD. 3503 02:54:15,960 --> 02:54:17,320 THAT'S THAT PROGRAM AND HAPPY TO 3504 02:54:17,320 --> 02:54:18,840 TAKE QUESTIONS ON THAT OR TO 3505 02:54:18,840 --> 02:54:28,960 INPUT. 3506 02:54:31,320 --> 02:54:32,440 >>NOT SEEING ANY. 3507 02:54:32,440 --> 02:54:36,240 >>OKAY. 3508 02:54:36,240 --> 02:54:46,640 RATE THIS ONE AS WELL. 3509 02:54:58,200 --> 02:54:59,560 >>WE'RE READY TO MOVE ON. 3510 02:54:59,560 --> 02:55:00,960 >>THANK YOU VERY MUCH. 3511 02:55:00,960 --> 02:55:05,440 WE'LL MOVE ON TO THE BLOOD, 3512 02:55:05,440 --> 02:55:05,680 VISION. 3513 02:55:05,680 --> 02:55:06,560 >>THE DIVISION OF BLOOD DISEASE 3514 02:55:06,560 --> 02:55:09,480 OF DISEASES AND RESOURCES WILL 3515 02:55:09,480 --> 02:55:11,200 PRESENT ONE CONCEPT NUMBER 3922. 3516 02:55:11,200 --> 02:55:12,840 A REQUEST TO RENEW THE 3517 02:55:12,840 --> 02:55:18,800 MAINTENANCE OF MODELS OF HUMAN 3518 02:55:18,800 --> 02:55:24,240 BLEEDING DISORDERS RESOURCE LED 3519 02:55:24,240 --> 02:55:26,360 BY DR. GILLESPIE HERE. 3520 02:55:26,360 --> 02:55:28,280 THE RESOURCE HAS BEEN IN 3521 02:55:28,280 --> 02:55:30,880 EXISTENCE SINCE 1947 AND 3522 02:55:30,880 --> 02:55:36,240 CONTINUOUSLY NHLBI FUNDED BY A 3523 02:55:36,240 --> 02:55:40,600 FUNDING MECHANISM AND WE'RE 3524 02:55:40,600 --> 02:55:42,840 REQUESTING A RENEWAL OF FIVE 3525 02:55:42,840 --> 02:55:47,680 YEARS. 3526 02:55:47,680 --> 02:55:49,080 THE SCIENTIFIC PURPOSE IS TO 3527 02:55:49,080 --> 02:55:53,200 CONTINUE DOG MODELS OF BLEEDING 3528 02:55:53,200 --> 02:55:55,760 DISORDERS AND FACTOR 7 3529 02:55:55,760 --> 02:55:56,600 DEFICIENCY AND OTHERS. 3530 02:55:56,600 --> 02:56:00,000 SPECIFIC OBJECTIVES INCLUDE TO 3531 02:56:00,000 --> 02:56:05,120 MAINTAIN A BREEDING COLONY WITH 3532 02:56:05,120 --> 02:56:06,040 INHERITED BLEEDING DISORDER FOR 3533 02:56:06,040 --> 02:56:07,800 A COST-EFFECTIVE MANNER. 3534 02:56:07,800 --> 02:56:10,120 IN ADDITION TO PROVIDE 3535 02:56:10,120 --> 02:56:11,640 SPECIALIZED SUPPORT SERVICES FOR 3536 02:56:11,640 --> 02:56:13,360 THE VETERINARY CARE OF THE 3537 02:56:13,360 --> 02:56:15,040 ANIMALS THROUGHOUT THEIR LIFE 3538 02:56:15,040 --> 02:56:17,920 TIME BY INCLUDING CANINE BLOOD 3539 02:56:17,920 --> 02:56:20,480 BANKING AND COAGULATION MALL SIS 3540 02:56:20,480 --> 02:56:22,600 AND OTHER PROCEDURES FOR THEIR 3541 02:56:22,600 --> 02:56:25,680 CARE AND MAINTENANCE TO PRODUCE 3542 02:56:25,680 --> 02:56:27,000 PURPOSE-BRED RESEARCH ANIMALS TO 3543 02:56:27,000 --> 02:56:31,680 SERVE AS BLOOD DONORS FOR 3544 02:56:31,680 --> 02:56:32,720 HEMOPHILIA DOGS IN THE COLONY 3545 02:56:32,720 --> 02:56:35,160 AND SERVE AS CONTROL AND TO 3546 02:56:35,160 --> 02:56:36,560 ACQUIRE AND CHARACTERIZE NEW 3547 02:56:36,560 --> 02:56:38,200 MODELS OF INHERITED BLEEDING 3548 02:56:38,200 --> 02:56:42,200 DISORDER TO STUDY FOR HEME 3549 02:56:42,200 --> 02:56:43,200 ATOLOGICAL DISORDERS AND 3550 02:56:43,200 --> 02:56:45,640 FACILITATE NEW HUMAN THERAPIES. 3551 02:56:45,640 --> 02:56:47,480 RESEARCH USING THE CANINE COLONY 3552 02:56:47,480 --> 02:56:49,560 HAS MORE THAN DOUBLED DURING THE 3553 02:56:49,560 --> 02:56:52,240 PAST 20 YEARS AND WITH THE 3554 02:56:52,240 --> 02:56:53,480 CONTINUED FACILITATION OF THE 3555 02:56:53,480 --> 02:56:54,920 SCIENCES AND ACCELERATION OF THE 3556 02:56:54,920 --> 02:56:57,520 TRANSLATION OF DISCOVERIES INTO 3557 02:56:57,520 --> 02:56:57,840 THERAPEUTICS. 3558 02:56:57,840 --> 02:57:02,600 TO NOTE A FEW OF MANY NOTABLE 3559 02:57:02,600 --> 02:57:05,000 ACCOMPLISHMENTS FROM THE CANINE 3560 02:57:05,000 --> 02:57:06,600 RESOURCE INCLUDE FIRST 3561 02:57:06,600 --> 02:57:08,640 LABORATORY TEST TO IDENTIFY 3562 02:57:08,640 --> 02:57:13,520 HEMOPHILIA A IN HUMANS AND THE 3563 02:57:13,520 --> 02:57:16,240 DECLINING FACTOR OF A FACTOR 8 3564 02:57:16,240 --> 02:57:19,480 CONCENTRATE AND GENE THERAPY IN 3565 02:57:19,480 --> 02:57:22,400 HEMOPHILIA A AND B LEADING TO 3566 02:57:22,400 --> 02:57:23,920 RECENT FDA APPROVAL FOR 3567 02:57:23,920 --> 02:57:25,280 HEMOPHILIA B PRODUCTS. 3568 02:57:25,280 --> 02:57:29,800 IN SUMMARY THIS IS A UNIQUE 3569 02:57:29,800 --> 02:57:30,840 RESOURCE FOR INVESTIGATORS AND 3570 02:57:30,840 --> 02:57:32,240 NHLBI CONTRIBUTION IN THE 3571 02:57:32,240 --> 02:57:33,120 SUCCESS OF THE RESOURCE 3572 02:57:33,120 --> 02:57:34,320 INCLUDING SUPPORT OF 3573 02:57:34,320 --> 02:57:37,000 GROUND-BREAKING DISCOVERIES THAT 3574 02:57:37,000 --> 02:57:38,320 ADVANCE THE DIAGNOSIS AND 3575 02:57:38,320 --> 02:57:40,240 TREATMENT OF HEMOPHILIA AND 3576 02:57:40,240 --> 02:57:42,840 OTHER BLEEDING DISORDERS AND 3577 02:57:42,840 --> 02:57:43,800 IMPROVING AND SAVING LIVES. 3578 02:57:43,800 --> 02:57:44,440 I'M HAPPY TO DISCUSS AND TAKE 3579 02:57:44,440 --> 02:57:54,680 ANY QUESTIONS. 3580 02:58:01,680 --> 02:58:02,880 >>I DON'T SEE ANYTHING IN THE 3581 02:58:02,880 --> 02:58:03,080 CHAT. 3582 02:58:03,080 --> 02:58:03,400 >>ALL RIGHT. 3583 02:58:03,400 --> 02:58:13,560 THANK YOU. 3584 02:58:33,280 --> 02:58:35,280 >>CONGRATULATIONS I THINK WE'RE 3585 02:58:35,280 --> 02:58:36,120 DONE. 3586 02:58:36,120 --> 02:58:43,920 >>ARE THERE QUESTIONS? 3587 02:58:43,920 --> 02:58:45,360 YES, DAVID. 3588 02:58:45,360 --> 02:58:47,160 >>UNRELATED QUESTION. 3589 02:58:47,160 --> 02:58:52,240 >>JUST TO MAKE SURE NOBODY HAS 3590 02:58:52,240 --> 02:59:02,680 A RELATED QUESTION FIRST. 3591 02:59:03,120 --> 02:59:04,480 GO AHEAD AND ASKED YOUR 3592 02:59:04,480 --> 02:59:04,880 UNRELATED QUESTION. 3593 02:59:04,880 --> 02:59:09,240 >>I'M SEEING MORE AND MORE 3594 02:59:09,240 --> 02:59:10,800 DIVERSITY-RELATED RO1 OFFERINGS 3595 02:59:10,800 --> 02:59:12,840 FROM OTHER INSTITUTES. 3596 02:59:12,840 --> 02:59:14,520 I THINK THERE'S THE CANCER MOON 3597 02:59:14,520 --> 02:59:17,080 SHOT AND THE REWARDS PROGRAM AND 3598 02:59:17,080 --> 02:59:18,040 AT-RISK INVESTIGATORS PROGRAM. 3599 02:59:18,040 --> 02:59:19,520 AS WE'RE TALKING ABOUT NEW 3600 02:59:19,520 --> 02:59:22,480 CONCEPTS AND NEW PLACES TO PUT 3601 02:59:22,480 --> 02:59:26,400 MONEY I DIDN'T KNOW IF NHLBI WAS 3602 02:59:26,400 --> 02:59:27,800 THINKING ABOUT THAT. 3603 02:59:27,800 --> 02:59:30,600 >>WE PARTICIPATED IN A NUMBER 3604 02:59:30,600 --> 02:59:31,640 THINGS OFFERED BY OTHER 3605 02:59:31,640 --> 02:59:33,200 INSTITUTES AND THE UNITE PROGRAM 3606 02:59:33,200 --> 02:59:39,120 AND I THINK WE'RE CONTINUING TO 3607 02:59:39,120 --> 02:59:43,920 DEVELOP NEW POTENTIAL OFFERINGS 3608 02:59:43,920 --> 02:59:46,320 AND NOT SURE IF IT'S THE RIGHT 3609 02:59:46,320 --> 02:59:48,600 PLACE TO PUT OUR MONEY AND SOME 3610 02:59:48,600 --> 02:59:49,920 WE'D LIKE TO SEE IN AND OUT 3611 02:59:49,920 --> 02:59:51,880 BEFORE WE MAKE A DECISION ON 3612 02:59:51,880 --> 02:59:54,960 WHAT TO DO NEXT IN TERMS OF 3613 02:59:54,960 --> 02:59:55,360 INTERRELATEDNESS. 3614 02:59:55,360 --> 02:59:57,520 >>I DON'T KNOW THE 3615 02:59:57,520 --> 02:59:59,760 EFFECTIVENESS OF THOSE PROGRAMS 3616 02:59:59,760 --> 03:00:01,320 IS IT'S REALLY AN IGNORANCE 3617 03:00:01,320 --> 03:00:02,360 PROGRAM. 3618 03:00:02,360 --> 03:00:03,680 >>IT'S A GOOD QUESTION AND ONE 3619 03:00:03,680 --> 03:00:06,280 WE'RE ALL WONDERING ABOUT. 3620 03:00:06,280 --> 03:00:11,440 >>GARY. 3621 03:00:11,440 --> 03:00:14,480 >>WE'RE OPEN TO IDEAS AN 3622 03:00:14,480 --> 03:00:16,080 CONCEPTS IN THE SPACE. 3623 03:00:16,080 --> 03:00:20,240 FRANKLY, ACADEMIA, MANY 3624 03:00:20,240 --> 03:00:21,080 INSTITUTIONS HAVE BEEN AHEAD OF 3625 03:00:21,080 --> 03:00:24,720 THE CURVE IN THE SPACE. 3626 03:00:24,720 --> 03:00:26,840 IF THERE'S THINGS EVEN SHARING 3627 03:00:26,840 --> 03:00:27,680 BEST PRACTICES OR STRATEGIES, 3628 03:00:27,680 --> 03:00:38,040 THAT WOULD BE HELPFUL. 3629 03:00:42,560 --> 03:00:45,240 AND THE WAY THE PROGRAMS ARE 3630 03:00:45,240 --> 03:00:46,320 EXECUTED IS KEY. 3631 03:00:46,320 --> 03:00:48,240 THAT INVOLVES A LOT OF 3632 03:00:48,240 --> 03:00:51,360 CONSULTATION FRANKLY WITH OUR 3633 03:00:51,360 --> 03:00:57,840 OFFICE OF LEGAL COUNSEL TO MAKE 3634 03:00:57,840 --> 03:01:03,320 SURE WE'RE ALIGNED OF BEING 3635 03:01:03,320 --> 03:01:04,240 INCLUSIVE WITHOUT ANY 3636 03:01:04,240 --> 03:01:06,800 DISCRIMINATION AND THAT'S PART 3637 03:01:06,800 --> 03:01:08,080 OF THE PRINCIPLE. 3638 03:01:08,080 --> 03:01:12,240 SOME OF THAT IS ON THE SUPREME 3639 03:01:12,240 --> 03:01:22,680 COURT DOCKET AS WE SPEAK. 3640 03:01:25,600 --> 03:01:27,560 WE WANT TO DO THIS IN A SMART 3641 03:01:27,560 --> 03:01:28,160 WAY. 3642 03:01:28,160 --> 03:01:31,320 THAT'S WHERE YOU'RE SEEING A LOT 3643 03:01:31,320 --> 03:01:33,200 OF EXPERIMENTS AND WE'RE 3644 03:01:33,200 --> 03:01:36,840 TRACKING THEM AND AS LAURA'S 3645 03:01:36,840 --> 03:01:38,720 POINTING OUT TRYING TO BE 3646 03:01:38,720 --> 03:01:39,600 JUDICIOUS IN HOW WE GO. 3647 03:01:39,600 --> 03:01:43,400 TO BE FRANK, I THINK THE NHLBI 3648 03:01:43,400 --> 03:01:45,880 HAS A PRETTY ROBUST PORTFOLIO 3649 03:01:45,880 --> 03:01:52,240 WHEN IT COMES TO DIVERSITY PAYS 3650 03:01:52,240 --> 03:02:00,240 AND I THINK WE'VE BEEN AT THAT 3651 03:02:00,240 --> 03:02:10,960 VANGUARD AS LAURA WAS SAYING AND 3652 03:02:10,960 --> 03:02:12,280 SEEING WHERE THE EXPERIMENTS 3653 03:02:12,280 --> 03:02:14,400 HAVE BEEN DEVELOPED UP ADDITION 3654 03:02:14,400 --> 03:02:16,920 TO THE COSWIT WE'RE LINKED TO. 3655 03:02:16,920 --> 03:02:19,560 IT'S AN ACTIVE AREA AND STAY 3656 03:02:19,560 --> 03:02:20,960 TUNED ONE WHERE I THINK IT'S 3657 03:02:20,960 --> 03:02:23,240 GOOD FOR ACADEMIA AND DIALOGUE. 3658 03:02:23,240 --> 03:02:28,680 IT'S A COLLABORATION TO MAKE 3659 03:02:28,680 --> 03:02:34,640 THIS WORK SINCE AND TRYING TO 3660 03:02:34,640 --> 03:02:37,120 MAKE THEM CONDUCIVE. 3661 03:02:37,120 --> 03:02:40,240 >>WE'RE HAVING A CONVERSATION 3662 03:02:40,240 --> 03:02:44,240 IN THE CLOSED SESSION ABOUT 3663 03:02:44,240 --> 03:02:50,600 PROGRAMMATICALLY APPOINTED AND 3664 03:02:50,600 --> 03:02:59,480 WE LOST SOMEONE WHO WENT ON TO 3665 03:02:59,480 --> 03:03:02,080 BIGGER AND GREATER THINGS SO. 3666 03:03:02,080 --> 03:03:07,200 >>ONE THING WE REPORTED BEFORE 3667 03:03:07,200 --> 03:03:11,040 WAS THE DIVERSITY OF OUR Rs, Ts, 3668 03:03:11,040 --> 03:03:12,840 Ks, WHAT HAVE YOU AND ONE THING 3669 03:03:12,840 --> 03:03:15,680 WE'RE LOOKING AT IS OUR Ts. 3670 03:03:15,680 --> 03:03:18,880 IT'S AN AREA WHERE COUNCIL WILL 3671 03:03:18,880 --> 03:03:21,720 BE HELPFUL IN TERMS OF YOUR 3672 03:03:21,720 --> 03:03:22,000 EXPERIENCE. 3673 03:03:22,000 --> 03:03:22,600 IT'S FOR THE TRAINING 3674 03:03:22,600 --> 03:03:24,200 ENVIRONMENTS WE HAVE TO WORK 3675 03:03:24,200 --> 03:03:27,160 THROUGH HOW WE DO THAT AND HOW 3676 03:03:27,160 --> 03:03:28,680 WE THINK ABOUT BEING INCLUSIVE 3677 03:03:28,680 --> 03:03:32,480 AND INCLUSIVE AS YOU KNOW NOT 3678 03:03:32,480 --> 03:03:34,800 JUST IN TERMS OF SEX, GENDER, 3679 03:03:34,800 --> 03:03:38,720 RACE AND ETHNICITY BUT AS WE'VE 3680 03:03:38,720 --> 03:03:40,240 DISCUSSED ALL DAY DISCIPLINES 3681 03:03:40,240 --> 03:03:41,760 NOT ONLY IN HEART, LUNG, BLOOD 3682 03:03:41,760 --> 03:03:46,760 AND SLEEP BUT A VARIETY OF 3683 03:03:46,760 --> 03:03:47,920 PERSPECTIVE, DATA SCIENCE AND 3684 03:03:47,920 --> 03:03:51,680 OTHER ENGINEERING. 3685 03:03:51,680 --> 03:03:52,360 ALL THOSE WILL BE IMPORTANT FOR 3686 03:03:52,360 --> 03:03:52,800 OUR TRAINING PROGRAM. 3687 03:03:52,800 --> 03:04:03,000 I'LL STOP. 3688 03:04:03,880 --> 03:04:05,480 >>I THOUGHT I'D BRING SOMETHING 3689 03:04:05,480 --> 03:04:12,240 PARALLEL TO WHAT YOU DID. 3690 03:04:12,240 --> 03:04:22,760 WE'RE EXPERIENCE THE WORKFORCE 3691 03:04:25,800 --> 03:04:29,560 AND WHILE WE GROW INCLUSIVE 3692 03:04:29,560 --> 03:04:31,840 EXCELLENCE AND THE METRICS OF 3693 03:04:31,840 --> 03:04:34,800 HOW WE DO IN CLOSING DISPARITIES 3694 03:04:34,800 --> 03:04:36,240 IS HORRIBLE IN MULTIPLE 3695 03:04:36,240 --> 03:04:38,320 INSTANCES OVER THE PAST 20 3696 03:04:38,320 --> 03:04:38,520 YEARS. 3697 03:04:38,520 --> 03:04:40,280 WE HAVEN'T DEMONSTRATED UP 3698 03:04:40,280 --> 03:04:41,920 IMPROVEMENT IN THOSE SCIENCE 3699 03:04:41,920 --> 03:04:42,920 DISPARITIES WORK THAT CAN HELP 3700 03:04:42,920 --> 03:04:47,720 CLOSE THE GAP. 3701 03:04:47,720 --> 03:04:51,960 IT'S NOT ENTIRELY RELATED TO THE 3702 03:04:51,960 --> 03:04:54,280 WORKFORCE BUT ADDRESSING HEALTH 3703 03:04:54,280 --> 03:04:54,840 EQUITY. 3704 03:04:54,840 --> 03:05:00,600 SOME GUIDANCES TO WHAT WE CAN DO 3705 03:05:00,600 --> 03:05:03,920 DIFFERENTLY AS A NATION AND NOT 3706 03:05:03,920 --> 03:05:05,640 JUST OUR INSTITUTE. 3707 03:05:05,640 --> 03:05:07,240 NO MATTER WHAT YOU LOOK THE 3708 03:05:07,240 --> 03:05:09,240 MAJOR DRIVERS WE'RE NOT CLOSING 3709 03:05:09,240 --> 03:05:11,240 THE GAPS AND COULD USE YOUR 3710 03:05:11,240 --> 03:05:11,840 ADVICE. 3711 03:05:11,840 --> 03:05:13,560 >>MARTHA HAS HER HAND UP BEFORE 3712 03:05:13,560 --> 03:05:15,920 I LET YOU ANSWER, MARTHA, I WANT 3713 03:05:15,920 --> 03:05:17,920 TO POINT OUT GEORGE IS RIGHT ON 3714 03:05:17,920 --> 03:05:20,200 AND GIVEN ME AN OPPORTUNITY TO 3715 03:05:20,200 --> 03:05:21,120 PLUG THE SEPTEMBER MEETING WE'RE 3716 03:05:21,120 --> 03:05:22,880 ALL GOING TO HAVE AN OPPORTUNITY 3717 03:05:22,880 --> 03:05:25,480 TO GO TO THE BOARD OF EXTERNAL 3718 03:05:25,480 --> 03:05:28,280 EXPERTS TO WEIGH IN ON TOPICS 3719 03:05:28,280 --> 03:05:29,320 THAT HAVE BEEN VERY IMPORTANT TO 3720 03:05:29,320 --> 03:05:30,080 THE INSTITUTE. 3721 03:05:30,080 --> 03:05:32,160 SOME OF WHICH WE DISCUSSED 3722 03:05:32,160 --> 03:05:33,440 BEFORE AND SOME OF WHICH WE'LL 3723 03:05:33,440 --> 03:05:35,880 DISCUSS AGAIN IN TERMS OF OUR 3724 03:05:35,880 --> 03:05:37,200 EVER GREENING MISSION FOR THE 3725 03:05:37,200 --> 03:05:39,360 STRATEGIC VISION BUT THIS TIME 3726 03:05:39,360 --> 03:05:40,240 REALLY LOOKING AT A REFRESH 3727 03:05:40,240 --> 03:05:42,320 WHERE TO GO FOR THE NEXT FIVE 3728 03:05:42,320 --> 03:05:43,000 YEARS AND VERY MUCH INTERESTED 3729 03:05:43,000 --> 03:05:46,400 IN WHAT WE HEAR FROM ALL OF YOU. 3730 03:05:46,400 --> 03:05:48,560 WITH RESPECT TO WHAT GEORGE IS 3731 03:05:48,560 --> 03:05:52,240 TALKING ABOUT, THERE'S A 3732 03:05:52,240 --> 03:05:53,120 DISCONNECT BETWEEN WHAT WE'RE 3733 03:05:53,120 --> 03:05:54,760 DOING AND WHAT WE THINK SHOULD 3734 03:05:54,760 --> 03:05:55,120 HAPPEN. 3735 03:05:55,120 --> 03:05:57,200 IT'S NOT REALLY AS DISCONNECTED 3736 03:05:57,200 --> 03:05:59,560 AS YOU THINK IT IS. 3737 03:05:59,560 --> 03:06:07,480 WE TRY TO DIVIDE THINGS UP 3738 03:06:07,480 --> 03:06:09,400 DISCREETLY AND REALLY IF YOU 3739 03:06:09,400 --> 03:06:11,080 THINK ABOUT IT IF WE'RE NOT 3740 03:06:11,080 --> 03:06:12,600 MAKING ADVANCES IN A PARTICULAR 3741 03:06:12,600 --> 03:06:13,800 FIELD OR SUPPORTING RESEARCH IN 3742 03:06:13,800 --> 03:06:15,840 A PARTICULAR FIELD, THEN THE 3743 03:06:15,840 --> 03:06:17,160 PEOPLE THAT WE'RE RECRUITING WHO 3744 03:06:17,160 --> 03:06:18,720 HAVE AN INTEREST IN THE AREA WE 3745 03:06:18,720 --> 03:06:20,080 WANT TO ADDRESS AREN'T GOING TO 3746 03:06:20,080 --> 03:06:20,280 STAY. 3747 03:06:20,280 --> 03:06:22,240 IT'S ALL CONNECTED. 3748 03:06:22,240 --> 03:06:32,680 MARTHA, GO AHEAD, PLEASE. 3749 03:06:38,000 --> 03:06:41,160 >>WE NEED TO IMPROVE AND LOOK 3750 03:06:41,160 --> 03:06:42,800 BETTER AT ADDRESSING THE VERY 3751 03:06:42,800 --> 03:06:53,520 BIG GAP BUT AS A NATION THERE'S 3752 03:06:53,520 --> 03:06:55,080 SO MANY ISSUES BEYOND OUR 3753 03:06:55,080 --> 03:06:56,680 CONTROL THAT ARE KEY 3754 03:06:56,680 --> 03:06:57,040 DETERMINATES. 3755 03:06:57,040 --> 03:06:59,200 I DON'T KNOW WE CAN ADDRESS OR 3756 03:06:59,200 --> 03:07:03,920 HAVE POWER TO ADDRESS. 3757 03:07:03,920 --> 03:07:09,800 I THINK IT'S A CEILING TO HOW 3758 03:07:09,800 --> 03:07:17,400 MUCH WE CAN ACCOMPLISH AND I DO 3759 03:07:17,400 --> 03:07:24,200 THINK THE MAJOR DETERMIN DETERME 3760 03:07:24,200 --> 03:07:25,280 OUT OF SIGHT AND MAYBE I'M ALONE 3761 03:07:25,280 --> 03:07:26,640 BUT I'M THINKING THAT WAY. 3762 03:07:26,640 --> 03:07:28,120 >>I DON'T THINK YOU'RE ALONE. 3763 03:07:28,120 --> 03:07:31,400 ANYBODY ELSE WITH ANY COMMENTS? 3764 03:07:31,400 --> 03:07:32,800 ANYTHING ELSE ANYBODY WANT TO 3765 03:07:32,800 --> 03:07:34,800 BRING UP IN ADDITION TO WHAT 3766 03:07:34,800 --> 03:07:36,240 WE'VE BEEN CHATTING ABOUT. 3767 03:07:36,240 --> 03:07:37,840 IF NOT, DR. GIBBONS I BELIEVE 3768 03:07:37,840 --> 03:07:44,280 YOU CAN ADJOURN THE MEETING. 3769 03:07:44,280 --> 03:07:46,640 >>IN ORDER FOR YOU ALL TO MAKE 3770 03:07:46,640 --> 03:07:48,600 YOUR FLIGHTS, WE STAND 3771 03:07:48,600 --> 03:07:48,840 ADJOURNED. 3772 03:07:48,840 --> 00:00:00,000 >>THANK YOU FOR YOUR ATTENDANCE